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ABSTRACT 
Cerebral vasospasm, a grave sequel to subarachnoid hemorrhage (SAH), is 
characterized by prolonged severe constriction of arteries in the base of the brain, 
including the basilar artery. Spasmogens (serotonin, endothelin and vasopressin), 
elevated in response to SAH, induce persistent depolarization of the myocytes in the 
artery wall, leading to continuous influx of calcium (Ca2+) through voltage-sensitive Ca2+ 
channels (VSCC) resulting in hyperconstriction (spasm). The spasm of the arteries 
restricts blood flow to the brain, inducing ischemic neurological deficits and 
consequential high morbidity and mortality. The cellular pathogenesis of cerebral 
vasospasm is poorly understood and the therapeutic options are limited.  
Kv7 (KCNQ) potassium channels are reported to be critical determinants of 
resting membrane voltage in several excitable cells including neurons and vascular 
myocytes. Recent findings from our laboratory suggested that arginine8-vasopressin 
exerts its vasoconstrictor effects on mesenteric arteries via suppression of Kv7 currents. 
Hence, we hypothesized that suppression of Kv7 currents by spasmogens is a central 
phenomenon in the pathogenesis of cerebral vasospasm and that Kv7 channel openers 
would be effective therapeutic agents to treat the vasospasm.  
Expression of Kv7 channels evaluated by reverse transcriptase polymerase chain 
reaction revealed the presence of all five mammalian KCNQ channel subtypes (KCNQ1-
5) in freshly isolated rat basilar artery myocytes. Kv currents recorded using the whole-
xix 
cell patch-clamp techniques were attributed to Kv7 channel activity based on their 
voltage dependence of activation, lack of inactivation, enhancement by flupirtine, 
retigabine (selective Kv7 channel activators), and inhibition by XE991 (a selective Kv7 
channel blocker). XE991 depolarized the myocytes indicating that Kv7 channels are 
principal determinants of resting membrane voltage. Spasmogens suppressed Kv7 
currents and depolarized the myocytes. The effects of spasmogens were significantly 
attenuated in the presence of retigabine. Celecoxib, a clinically used anti-inflammatory 
drug, not only enhanced Kv7 currents but also inhibited voltage-sensitive Ca2+ currents. 
Functional responses to Kv7 channel modulators were studied in intact basilar 
artery segments using pressure myography. XE991 constricted basilar artery segments 
indicating that Kv7 channels are important determinants of contractile status. In the 
presence of XE991, spasmogens did not produce additive constrictor responses, 
suggesting that suppression of Kv7 currents is the predominant mechanism for 
spasmogen-induced membrane depolarization and constriction of basilar arteries. Kv7 
channel activators dilated basilar artery segments pre-constricted with spasmogens, and 
were more effective than nimodipine, an L-type Ca2+ channel blocker used as standard 
care to relieve cerebral vasospasm in patients with SAH. Intraperitoneal administration of 
Kv7 channel openers, retigabine or celecoxib, significantly attenuated basilar artery 
spasm in rats with experimentally induced SAH. Both the Kv7 channel openers induced a 
transient drop in mean arterial pressure (MAP) generally lasting 30-60 min after 
administration, but mean 24h BP measured using radio-telemetry in normal rats was not 
altered. 
     
xx 
In conclusion, Kv7 channels are expressed in basilar artery myocytes and function 
to maintain resting membrane voltage in basilar artery myocytes and hence oppose the 
constriction of the arteries. Suppression of Kv7 currents in myocytes is a mechanism by 
which spasmogens induce basilar artery constriction. Targeting vascular Kv7 channels 
using retigabine or celecoxib could provide a novel strategy to relieve basilar artery 
spasm without inducing hypotension. 
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 CHAPTER 1 
INTRODUCTION 
Aneurysms are abnormal ballooning or outpouching of arteries at sites of 
weakness in the blood vessel wall. Arteries in the base of the brain are common 
predilection sites for aneurysms because of the vascular remodeling associated with 
hemodynamic stress induced by blood flow and the anatomy of the arterial system in the 
base of the brain. These intracranial aneurysms are very common, with a prevalence of up 
to 6% in the adult population. Rarely, rupture of the aneurysms occurs, which forces 
blood into the subarachnoid space resulting in hemorrhagic stroke. Aneurysmal 
subarachnoid hemorrhage (SAH) affects 30,000 Americans yearly and accounts for about 
5% of all strokes (Bederson et al. 2009). The most common complication of SAH is 
cerebral vasospasm. As the name indicates, cerebral vasospasm is the intense constriction 
of cerebral arteries, mainly the large conduit arteries (basilar artery and arteries of the 
Circle of Willis) near the site of a ruptured aneurysm. Vasospasm is not usually detected 
until at least 48 hours after rupture of an aneurysm, but may be pronounced after 3 days 
of SAH and lasts up to 2 weeks after SAH. The consequent decrease in cerebral perfusion 
frequently results in stroke and death or prolonged disability in the SAH patients. Though 
considerable progress has been made in understanding the pathogenesis of cerebral 
vasospasm, the cellular events that lead to the delayed vasospasm and subsequent 
ischemic events remain poorly understood.  
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This basic science project aims to study the involvement of vascular Kv7 
potassium channels in the pathogenesis of basilar artery vasospasm and to test the utility 
of selective Kv7 channel activators to treat cerebral vasospasm. The study utilizes 
laboratory rats as a model system to examine the presence and function of the channel. 
During the course of the project, we discovered that celecoxib, a clinically used drug, was 
a Kv7 channel activator. The scope of my dissertation project was therefore expanded to 
test celecoxib as a possible therapeutic agent to treat cerebral vasospasm. Finally, my 
dissertation work also attempted to provide insights in to the mechanism by which 
celecoxib modulates Kv7 channels. 
Chapter 2 of the document provides a review of the literature as background 
information for the proposed project. Chapter 3 states the hypotheses and research 
objectives of the project; scientific rationale for the stated objectives is also provided. 
Chapter 4 describes the methods used to test my hypotheses. Chapter 5 presents the 
detailed results of the experiments that were performed. Chapter 6 discusses the results, 
describes how the novelty of the findings fit with the existing broad range of literature, 
and states the advancements made with this study. Chapter 7 states the salient 
conclusions derived from the project. Chapter 8 documents potential future directions for 
the project.  
 3 
CHAPTER 2 
REVIEW OF LITERATURE 
 
Arterial constriction and cerebral blood flow  
Anatomy of the cerebral vasculature 
The human brain is supplied with blood almost exclusively via two paired 
arteries- the left and right internal carotid and the left and right vertebral arteries. Three-
fourths of the total blood supply is provided by the internal carotid artery and one-fourth 
by the vertebral artery (Scheel et al. 2000). The blood flowing through these four arteries 
join in an equalizing manifold of arteries called the Circle of Willis (Kramer 1912). The 
internal carotid artery is a branch of the common carotid artery that arises from the aortic 
arch. Branches of the internal carotid artery supply most of the cerebrum and terminally 
branch to the anterior and middle cerebral arteries, which form part of the Circle of 
Willis. The vertebral arteries supply the hindbrain including the cerebellum and brain 
stem, and portions of the cerebrum before coming together to form the basilar artery that 
anestamoses into the Circle of Willis.  
 
Cerebral blood flow 
Blood flow to the brain is regulated by multifarious overlapping mechanisms, 
which perhaps represent a natural adaptation to protect the brain from ischemia. Apart 
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from several humoral factors, cerebral blood flow is regulated by specialized structural 
and  functional components that include myogenic arterial responses (cerebral blood 
pressure autoregulation), flow-metabolism coupling and the neurovascular unit 
comprised of endothelial cells, perivascular nerves and astrocytes (Peterson et al. 2011). 
The mechanisms that underlie the ability of the cerebral vasculature to maintain a 
constant blood flow despite variable mean arterial pressure (MAP), while rapidly 
adjusting the flow to meet the metabolic requirements of the brain, remain poorly 
understood.  
All the aforementioned factors however modulate blood flow primarily by 
constriction/dilation of the arteries through which the blood flows. Arterial constriction is 
a function of the contractile state of the smooth muscle cells within the artery wall, which 
is in turn governed by intricate actions of various ion channels and the signaling cascades 
that affect the sensitivity of the contractile apparatus in the smooth muscle cells.   
 
Regulation of arterial constriction 
Vascular tone is primarily under the control of cytosolic free calcium ([Ca2+]c) 
concentration in the vascular smooth muscle cells (VSMCs). A rise in [Ca2+]c causes 
VSMC contraction by activating actin-myosin cross bridge formation. Activation of cell 
surface receptors by vasoconstrictor agonists or mechanical force due to flow of blood 
results in elevation of cytosolic calcium [Ca2+]c. Elevation of [Ca2+]c above resting levels 
of around 100 nM leads to binding of free Ca2+ to an ubiquitous Ca2+ binding protein 
called calmodulin and resulting in its activation (Akata 2007b). The [Ca2+]c concentration 
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for half-activation of calmodulin is around 400 nM (Stull et al. 1998). The 
conformational change of calmodulin induced by Ca2+ binding enables its binding to a 
serine-threonine protein kinase called myosin light chain kinase (MLCK), resulting in 
autophosphorylation and activation of the kinase. The active Ca2+-calmodulin-MLCK 
complex catalyses the phosphorylation of serine-19 of the two 20-kDa light chains of 
myosin, triggering cross-bridge cycling and contraction of the VSMCs. Relaxation is 
induced by restoration of Ca2+ levels and dissociation of calmodulin from MLCK, 
accompanied by reversal of the downstream events- dephosphorylation of myosin by 
phosphatases and detachment of myosin from actin (Somlyo and Somlyo 2003). The 
force of contraction: [Ca2+]c ratio or the myosin light chain phosphorylation: [Ca2+]c ratio 
is not linear. This suggests secondary regulation of contractile responses by several other 
factors that include RhoA/Rho kinase, protein kinase C and cyclic nucleotides (Somlyo 
and Somlyo 2003; Akata 2007a; Hirano et al. 2004; Hirano et al. 2003; Rembold 1992; 
Stull et al. 1991). These factors can modulate the sensitivity of the contractile apparatus, 
but elevation of [Ca2+]c is the primary determinant of the contractile status of the artery. 
 
Regulation of cytosolic calcium concentrations in VSMCs 
An increase in [Ca2+]c  in cerebral artery myocytes, or in VSMCs in general, is 
brought about by either release of Ca2+ from the sarcoplasmic reticulum (the central 
reservoir of Ca2+ within the cell), or by increased influx of Ca2+ from the extracellular 
space.  
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Ca2+ release mechanisms 
Ca2+ release from the sacroplasmic reticulum is mediated through several 
channels, predominated by inositol 1,4,5-triphosphate receptor (IP3R) and ryanodine 
receptors (RyR) (Berridge et al. 2000). Activation of Gq-coupled seven transmembrane 
receptors leads to phospholipase C-mediated cleavage of the membrane-bound 
phosphatidylinositol 4,5-biphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3), a soluble 
second messenger, and diacylglycerol (DAG) (Berridge and Galione 1988). IP3 binds to 
its receptors on the sarcoplasmic reticulum to release Ca2+ from the stores. The Ca2+ 
released through IP3 receptors induces a bimodal modulation of IP3R activity, with a low 
concentration (<1 μM) stimulating further release and a higher concentration (>1-10 μM) 
inhibiting it (Bootman and Lipp 1999). A continuous release of Ca2+ through IP3 
receptors and reuptake into the sarcoplasmic reticulum, independent of Ca2+ entry, have 
been reported to give rise to “Ca2+ waves” in some VSMCs (Foskett et al. 2007). These 
Ca2+ waves that normally occur physiologically as discrete events within the cell however 
may occasionally get synchronized to initiate vasomotion (Mufti et al. 2010; Peng et al. 
2001). The Ca2+ waves have been reported to promote both depolarization, by activating 
Ca2+-activated Cl- channels (ClCa channels), and hyperpolarization, by activating large-
conductance Ca2+-activated K+ channels (BK channels) (Young et al. 2001), leading to 
enhanced or reduced Ca2+ entry through voltage-sensitive Ca2+ channels (VSCC) 
respectively. Activation of Gq-coupled receptors with uridine triphosphate (UTP) or 
norepinephrine have been shown to induce Ca2+ waves in VSMCs (Jaggar and Nelson 
2000; Ruehlmann et al. 2000). However, physiological concentrations of Gq-coupled 
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vasoconstrictor agonists like vasopressin do not induce appreciable IP3-mediated Ca2+ 
release, implying minimal contribution of these events to global elevation of Ca2+ (Byron 
and Taylor 1995). Therefore, the physiological significance of these waves remains 
uncertain (Hill-Eubanks et al. 2011). 
Cytosolic Ca2+ itself is the principal activator of RyR receptors in the 
sacroplasmic reticulum to release Ca2+ by a process called Ca2+-induced Ca2+ release 
(CICR). While CICR is a predominant mechanism in cardiac myocytes, the amount of 
Ca2+ required to induce CICR may be higher than what is achieved within smooth muscle 
cells during peak excitability, limiting the contribution of the RyR-mediated Ca2+ release 
to vascular contractility (Sanders 2001). Quantal local release of Ca2+ due to the opening 
of four to six RyR receptors, referred to as “Ca2+ sparks”, activates closely juxtaposed 
large-conductance Ca2+-activated K+ channels (BK channels) increasing their open 
probability and producing hyperpolarization (Cheng and Lederer 2008; Jaggar et al. 
2000). Ca2+ overload increases the spark frequency, probably acting as a feedback 
mechanism to limit membrane depolarization and Ca2+ influx through VSCC (Jaggar et 
al. 2000; Perez et al. 1999). Thus, RyR activation under physiological conditions seems 
to induce VSMC relaxation, opposite of the effect of IP3 receptor activation, which is 
most commonly associated with VSMC contraction. 
 
Ca2+ entry mechanisms 
Ca2+ entry into the cell across the plasma membrane principally occurs through 
three different types of channels defined by their mechanism of activation as (i) receptor-
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operated Ca2+ channels, (ii) store-operated Ca2+ channels and (iii) voltage-sensitive Ca2+ 
channels.  
(i) Receptor-operated Ca2+ entry: The transient receptor potential “canonical” 
(TRPC) superfamily of non-selective cation channels are the predominant receptor-
operated channels through which Ca2+ enters in to VSMCs (Dietrich et al. 2010). These 
channels are not activated directly by receptor ligands, but through signal transduction 
events activated by Gq-coupled receptor stimulation. The functional channels are 
constituted by homo- or hetero- tetramers of the family members. Of the seven family 
members (TRPC1-7), TRPC3/6/7 are well characterized as receptor-operated channels 
(Maruyama et al. 2006). The channels formed by the TRPC3/6/7 subgroup are directly 
activated by diacylglycerol, a signal transduction intermediate in the Gq-PLC-pathway 
(Dietrich et al. 2005). These channels primarily conduct Na+ ions rather than Ca2+ ions. 
Influx of cations through these channels has been proposed as an important mechanism of 
membrane depolarization by vasoconstrictor agonists (Maruyama et al. 2006; Soboloff et 
al. 2005; Onohara et al. 2006).  
The ATP-gated P2X receptor is the only direct receptor-operated cation channel 
that induces identifiable Ca2+ influx in VSMCs (Hill-Eubanks et al. 2011). These non-
selective receptor-operated channels predominantly conduct Na+ ions, but also allow 
substantial influx of Ca2+ in VSMCs upon binding of ATP (Lamont and Wier 2002).  
(ii) Store-operated Ca2+ channels: Store-operated Ca2+ entry (SOCE) is the influx 
of Ca2+ in response to depletion of intracellular stores. The Ca2+ release-activated Ca2+ 
influx through SOCE serves as a mechanism to replenish Ca2+ stores. The molecular 
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identity of these channels in VSMCs remains controversial (Leung et al. 2008). TRPC 
channels, particularly TRPC1, have been identified as store-operated Ca2+ channels, 
accounting for at least part of the SOCE (Xu and Beech 2001; Sweeney et al. 2002; 
Brueggemann et al. 2006). Recent evidence, however, points to STIM1 as the 
transmembrane endoplasmic reticulum Ca2+ sensor that activates a cell surface channel of 
the Orai family to mediate the SOCE (Varnai et al. 2009). A recent study also suggested 
STIM1 and TRPC1 as components of SOCE (Takahashi et al. 2007). The role of SOCE 
in the regulation of vascular contractile status is minor under physiological conditions. 
SOCE however likely plays an important role in VSMC proliferation and remodeling 
under certain pathological conditions (Leung et al. 2008). 
(iii)Voltage-sensitive Ca2+ channels: Calcium entry through voltage-sensitive 
Ca2+ channels (VSCC) is the primary contributor to global increase in [Ca2+]c in VSMCs. 
These channels open in response to membrane depolarization induced by a variety of 
humoral, chemical, or mechanical stimuli. The voltage-sensitive Ca2+ currents also 
inactivate rapidly in response to membrane depolarization. The inactivation is both 
voltage- and Ca2+-dependent. The activation and inactivation characteristics of VSCC are 
such that in a range of membrane voltage (around -60 to -20 mV) in which activation 
occurs, inactivation of the currents is incomplete. The remaining current is termed 
window current (Sanders 2001; Fleischmann et al. 1994). Though the magnitude of the 
sustained Ca2+ current within this “window” is small, the amount of Ca2+ influx driven by 
the steep difference in the concentration gradient is significant relative to the cell volume 
(Sanders 2001). Membrane depolarization of smooth muscles by about 15 mV from the 
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resting voltage (about -50 to -40 mV) activates VSCC and stimulates  Ca2+ influx enough 
to elevate global [Ca2+]c to ~300-400 nM (Hill-Eubanks et al. 2011). VSCCs are 
composed of a pore-forming α1 subunit and regulatory subunits β, α2δ and γ (Catterall 
2000). The channels are classified based on the α1 subunits that encompass the pore, 
selectivity filter and the voltage-sensor. They are referred to as Cav1.1, Cav1.2, Cav1.3, 
Cav1.4 (L-type VSCC), Cav2.1 (P/Q-type VSCC), Cav2.2 (N-type VSCC), Cav2.3 (R-type 
VSCC), Cav3.1, Cav3.2, Cav3.3  (T-type VSCC) (Lacinova 2005). T-type channels 
activate at a more negative membrane voltage (around -60 mV, and hence are called low 
voltage-activated channels), while other types of channels activate at more positive 
voltages (around -40 mV, and hence are called high voltage-activated channels) (Perez-
Reyes 2003). L-type and T-type Ca2+ channels are the most abundantly expressed 
subtypes in VSMCs. L-type Ca2+ channels inactivate relatively slowly, whereas T-type 
channels inactivate fast and have low unitary conductance, providing only a transient 
Ca2+ conductance. Though it is widely believed that L-type channels are the predominant 
Ca2+ channels in VSMCs, recent reports suggest that multiple types of Ca2+ channels are 
expressed in VSMCs derived from basilar artery (Nikitina et al. 2010; Navarro-Gonzalez 
et al. 2009).  
The contribution of Ca2+ influx through each subtype of Ca2+ channel is difficult 
to ascertain because of several limitations, including lack of specific antagonists for 
certain subtypes, difficulty in knocking down a specific channel subtype without altering 
the expression profile of other channels, difficulty in electrophysiological isolation of 
currents through each subtype of Ca2+ channels (even though there are subtle differences 
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in their biophysical characteristics) and heterogeneity of expression of Ca2+ channel 
subtypes between myocytes in the same artery.  
Calcium influx is mediated by multiple types of VSCC, with L-type and T-type 
being the predominant functional channels expressed in basilar artery myocytes (Nikitina 
et al. 2010; Navarro-Gonzalez et al. 2009; Nikitina et al. 2007). Calcium channel 
blockers selectively targeting L-type Ca2+ channels are used clinically to treat several 
cardiovascular disorders including hypertension, cerebral vasospasm, and angina 
(Kochegarov 2003).  
 
Electrical properties of membrane and membrane potential 
Ions are unequally distributed across the cell membrane, which acts as a charge 
storage device or capacitator. The electrical field or potential created by the charge 
separation across the membrane is given as V= Q/C, where V=voltage, Q=charge and C= 
capacitance. Membrane potential (Vm; also called membrane voltage) is the potential on 
the inside of the cell, equal to the difference between V inside the cell and V outside the 
cell. The normal resting membrane potential of most excitable cells is between -70 mV 
and -40 mV. Change in the membrane potential towards more negative voltages is termed 
hyperpolarization and a change towards more positive voltages is called depolarization.  
Changes to the membrane voltage are governed by the simple laws of physics. As 
per Ohm’s law, voltage (V) = Current (I) * Resistance (R). The input resistance of 
excitable cells (with particular reference to VSMCs) is high, in the order of 5-15 GΩ, 
implying that even a small change in current will induce a significant change in voltage at 
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resting levels. At resting levels, Vm is close to the reversal potential (a potential at which 
the current reverses direction of flow) of potassium ions (K+) (EK = -85 mV), indicating 
that under these conditions, the membrane voltage is predominantly controlled by K+ 
current. The Cl- current, non-selective cation currents and voltage-sensitive Ca2+ currents 
make only minor contributions (Nelson et al. 1990). Hence, at near resting conditions, 
modulation of very few K+ channels would induce a significant change in membrane 
voltage.  
 
Potassium channels 
Potassium channel activity largely determines the resting membrane voltage, and 
thereby controls the activity of VSCCs, which conduct Ca2+ into the cells to activate the 
contractile apparatus. Despite their importance as determinants of arterial smooth muscle 
contractility, K+ channels, which constitute the largest class of ion channels, have 
surprisingly not emerged as clinically favored targets to modulate blood flow and blood 
pressure.  
Four types of K+ channels have been described in cerebral arteries; ATP-sensitive 
(KATP), inwardly rectifying (KIR) K+ channels, large conductance Ca2+-activated (BKCa), 
and voltage-dependent (delayed rectifier) K+ channels (Faraci and Sobey 1998; Wellman 
2006).   
(i) ATP-sensitive K+ channels: ATP-sensitive K+ (KATP) channels in smooth 
muscle cells are formed by a 4:4 octomeric complex of pore forming Kir6.2 subunits, a 
member of the inward rectifier K+ channel family, and SUR2B regulatory sulfonylurea 
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receptors (Aguilar-Bryan et al. 1998). These channels are not voltage-dependent, but 
couple electrical activity of the cell to its metabolic status by activating in response to a 
decrease in [ATP]i (Quayle et al. 1997). In VSMCs, KATP channels open in response to 
hypoxic conditions, limiting the contractile force to conserve ATP (Daut et al. 1990). 
Vasodilators that activate protein kinase A (PKA) increase the open probability of KATP 
channels and vasoconstrictors that activate protein kinase C (PKC) inhibit these channels 
(Quayle et al. 1997; Zhang et al. 1994; Brayden 2002; Quayle et al. 1994). The channels 
are also activated by synthetic compounds such as levcromakalin, pinacidil, nicorandil, 
and diazoxide, and inhibited by sulphonylureas like glibenclamide (Quayle et al. 1997). 
Pharmacological evidence supports a role of KATP channels in the regulation of cerebral 
blood flow (Hong et al. 1994; Rosenblum 2003). These channels may be more abundant 
in smaller cerebral arteries than in larger arteries like the basilar artery (Rosenblum 
2003). KATP channels were implicated in vasoconstrictor responses when VSMCs were 
dialyzed in 0.1 mM ATP (Bonev and Nelson 1996). Whether these channels are active 
under physiological conditions in VSMCs, however remains controversial, as 
physiological concentrations (1.5 – 3 mM) of [ATP]i  reduce the open probability of the 
channels (Nelson and Quayle 1995).   
(ii) Inwardly rectifying KIR channels: Inwardly rectifying K+ (KIR) channels are 
tetramers of two membrane-spanning pore-forming domains encoded by KIR2.1 in 
cerebrovascular smooth muscle cells (Zaritsky et al. 2000). Under voltage-clamp 
conditions, inwardly rectifying K+ channels predominantly conduct inward currents rather 
than outward currents like other K+ channels (Nelson and Quayle 1995). The voltage at 
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which these channels open is dependent on extracellular K+ concentrations. The 
sensitivity of KIR channels to extracellular K+ is observed experimentally by dilation of 
the cerebral arteries in response to a modest elevation of extracellular K+ concentration 
(Edwards et al. 1988). The rectification is due to block of the outward conductance by 
binding of cytosolic positively charged polyvalent ions, such as Mg2+ and polyamines, to 
the channel (Lopatin et al. 1994). Hence, membrane depolarization from resting 
membrane voltages results in small outward K+ currents, whereas hyperpolarization 
elicits large inward currents in VSMCs (Edwards et al. 1988). Enhanced neuronal activity 
increases extracellular K+ concentrations activating KIR channels expressed in cerebral 
artery myocytes, resulting in vasodilation and increased blood flow to meet the metabolic 
requirements for the enhanced neuronal activity (Dunn and Nelson 2010). Apart from the 
regulation of vascular tone to meet the metabolic needs of neurons, the physiological 
significance of KIR channels still remains poorly understood. Unlike most other K+ 
channels in the cerebral vasculature, activity of KIR was not regulated by protein kinases 
like, PKA, PKC, and PKG (Wellman 2006).  
(iii) Voltage-dependent K+ channels: Voltage-dependent K+ channels are 
tetramers of identical or closely related pore forming six transmembrane α subunits that 
may be associated with 1 to 4 accessory β subunits (Cox 2005). Their versatile capacity 
for heteromeric assembly along with the influence of accessory subunits results in 
channels with diverse biophysical properties. However, most voltage-dependent K+ 
channels have similar pharmacological properties, making it difficult to determine which 
channels are functional in a given cell. Genes encoding voltage-dependent K+ channel 
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superfamily members constitute the largest of any ion channel family, with more than 70 
genes identified in the human genome (Coetzee et al. 1999). The phylogenetic 
superfamily includes 8 subfamilies of Kv (Kv1-Kv6 and Kv8-Kv9), KCNQ (Kv7), and 
EAG (Kv10-12) subfamilies (Coetzee et al. 1999). The most commonly expressed Kv 
channel subunits in VSMCs are Kv1.1, Kv1.2, Kv1.4-1.6, Kv2.1, Kv9.3 (Standen and 
Quayle 1998). In dog basilar artery myocytes, messenger RNA (mRNA) for Kv1.2, 
Kv1.5, Kv2.2, Kv3.1, Kv3.4 and Kv4.3 were identified with expression of Kv1.5 and 
Kv2.2 being predominant (Aihara et al. 2004). Currents through these channels are 
distinguished from other K+ channels by their sensitivity to the pharmacological channel 
blocker 4-aminopyridine (4-AP) (Okabe et al. 1987). The open probability of these 
channels is voltage-dependent with an increase in open probability (Po) increasing with 
membrane depolarization. Kv channels undergo varying degrees of inactivation with 
membrane depolarization depending upon the subunits involved. The voltage of half-
maximal channel activation (V0.5) for activation and inactivation of Kv currents in 
VSMCs are -9 to -6 mV and -35 (-45 to -25) mV respectively (Nelson and Quayle 1995). 
The Po increases steeply at voltages positive to -30 mV, indicating that a window current 
should exist around the physiological range of membrane voltages (Nelson and Quayle 
1995). The physiological role of the Kv channel varies with the vascular bed in which it 
is expressed. In small cerebral artery myocytes with membrane voltage around -40 mV, 
blockade of these channels leads to membrane depolarization and artery constriction 
(Albarwani et al. 2003). The resting membrane voltage in myocytes derived from most 
other vascular beds are more negative, ranging from -65 to -45 mV indicating that the Kv 
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channels in these vascular beds function to limit the membrane depolarization following a 
vasoconstrictor stimulus, with a relatively minor role under resting conditions. Kv 
channels in dog basilar arteries have V0.5 for activation of  -1.3 mV  (Jahromi et al. 
2008a), whereas the resting membrane voltage of basilar artery myocytes is around -35 
mV in dog (Jahromi et al. 2008a), and between -46 and -60 mV in rats (Chrissobolis and 
Sobey 2002; Weyer et al. 2006a). Hence, Kv channels are likely to provide negative 
feedback following membrane depolarization and vasoconstriction by hyperpolarizing the 
membrane. 
(iv) Ca2+-activated K+ channels: Ca2+-activated K+ (KCa) channels, like Kv 
channels, form as tetrameric assemblies of six transmembrane pore forming α-subunits 
(encoded by slo or SK genes) and regulatory β-subunits. Large-conductance KCa α-
subunits encoded by slo genes are expressed in VSMCs (Coetzee et al. 1999). Channels 
formed by these subunits exhibit large single-channel K+ conductances (~250 pS in 
symmetrical K+), and hence are called “big KCa (BK) channels” or “maxi” channels 
(Nelson and Quayle 1995). The open probability of BK channels increases in response to 
membrane depolarization and/or increased [Ca2+]c. Hence, opening of BK channels 
serves as a negative feedback mechanism to limit the membrane depolarization and 
elevation of [Ca2+]c that leads to vasoconstriction. The membrane hyperpolarization 
induced by BK channel opening also serves to limit the myogenic responses observed in 
resistance arteries and arterioles (Hill et al. 2010). A high [Ca2+]c, in the order of 1-10 
µM, is required to activate BK channels at a membrane voltage of -50 mV (Hille 2001). 
Such high Ca2+ concentrations could be achieved in the subcellular environment of the 
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BK channels by transient local release of Ca2+ (Ca2+ sparks) from the sarcoplasmic 
reticulum through the opening of ryanodine receptors (Perez et al. 1999; Collier et al. 
2000; Wellman et al. 2002). To the extent that Ca2+ sparks occur under resting conditions, 
BK channels could potentially play a role in resting K+ conductance (Wellman and 
Nelson 2003). BK channels are well studied as targets mediating the vasodilator actions 
of endothelin-derived relaxing factors like nitric oxide (NO) and epoxyeicosatrienoic 
acids (Dimitropoulou et al. 2007; Jiang et al. 1998; Kitazono et al. 1997). The channel 
activity is increased by elevated [Ca2+]c, but also modulated by several different 
intracellular signaling intermediates activated following binding of vasoconstrictors to G-
protein-coupled receptors (GPCRs) (Hou et al. 2009).  
 
Pathophysiology and treatment of cerebral vasospasm 
Subarachnoid hemorrhage  
An estimated 1-5% of adults have weakened cerebrovascular blood vessel walls 
causing localized ballooning of arteries called cerebral aneurysm (King 1997). Most of 
the aneurysms are asymptomatic, but their rupture results in a devastating condition 
called subarachnoid hemorrhage (SAH). The extravasation of blood into the 
subarachnoid space is usually presented as a medical emergency with severe headache 
being the most common complaint, though sometimes accompanied by nausea or loss of 
consciousness. SAH affects as many as 30,000 people each year in North America alone 
and accounts for about 5% of all strokes (King 1997; Graf and Nibbelink 1974). 
Prognosis is disproportionately unfavorable for patients with SAH compared to ischemic 
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stroke (Laskowitz and Kolls 2010). SAH is typically diagnosed by non-contrast cranial 
computed tomography scan with the probability of detection of blood in the subarachnoid 
space proportional to the clinical grade and swiftness of performing the scan after SAH 
(Bederson et al. 2009; Vale et al. 1997). Cerebral vasospasm often occurs within a few 
days after SAH and is typically diagnosed by angiographic narrowing of the basilar artery 
or altered basilar artery blood flow as measured by transcranial Doppler ultrasonography 
(Zubkov and Rabinstein 2009).  
Cerebral vasospasm is the leading cause of morbidity and mortality after SAH and 
affects 30-70% of patients with SAH (Heros et al. 1983; Kassell et al. 1985). The 
condition is characterized by sustained constriction of the large arteries in the base of 
brain – including the arteries that form the circle of Willis and the basilar artery. Though 
vasospasm implies reduction in diameter of the artery, in SAH, it involves a complex 
vasculopathy, impaired autoregulatory function, and focal reduction of cerebral perfusion 
to a point of causing ischemia (Keyrouz and Diringer 2007). Under normal conditions, 
the affected arteries account for 10- 39% of resistance to blood flow to the brain (Heistad 
and Konotos 1983). The involvement of smaller diameter cerebral arteries in cerebral 
vasospasm is not clear because of the limitation of angiographic imaging. The onset of 
vasospasm is delayed, and usually starts 3-5 days after hemorrhage, and is sustained until 
it reaches a maximum between 5-14 days. The spasm resolves gradually within 2-4 
weeks. Consequent to the narrowing of the arteries, poor blood perfusion distal to the 
affected artery causes ischemia and neurological deficits that may either resolve or result 
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in cerebral infarction and permanent disability or death (Keyrouz and Diringer 2007; 
Sehba et al. 2011).  
 
Etiology for development of cerebral vasospasm 
The etiology of vasospasm after SAH is not clear but appears to be multifactorial 
(Macdonald et al. 2007). The role of Ca2+ in cerebral vasospasm has been debated mainly 
because there is no known mechanism that causes a sustained increase in [Ca2+]c over a 
period of several  days (Hansen-Schwartz et al. 2008; Hansen et al. 2007; Tani 2002). 
There is evidence however that vasospasm in cerebral arteries is largely Ca2+ dependent 
and that Ca2+ influx is the major mechanism of elevated [Ca2+]c (Wellman 2006; Tani 
2002; Zuccarello et al. 1996a).  
An impairment of cerebral auto-regulation has been observed in a number of 
experimental (Hauerberg et al. 1993; Hauerberg et al. 1995; Kamiya et al. 1983; 
Rasmussen et al. 1992; Takeuchi et al. 1991) and clinical studies (Lang et al. 2001; 
Soehle et al. 2004; Voldby et al. 1985) following SAH. The cause(s) for the impairment 
of the auto-regulation are difficult to ascertain but likely include a multitude of factors 
such as vasospasm itself, acidosis, and hypoxia after SAH (Voldby et al. 1985; Handa et 
al. 1992). Increased resistance due to vasospasm induced by altered neuronal and 
humoral influence and direct vasoconstictor action of the blood components results in 
reduced perfusion. Loss of auto-regulation after SAH may damage the cerebral 
microcirculation and increase cerebral edema. 
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Spasmogens involved in vasospasm 
(i) Endothelin: Endothelin (ET) is a collection of endothelium derived 
vasoconstrictor peptides that exists as isoforms ET-1, ET-2, and ET-3. Endothelin 
induces its biological effects through its interaction with ETA and ETB receptors. ET-1 is 
the most potent of the isoforms and induces dose-dependent long-lasting constriction by 
binding to the ETA receptors in the smooth muscle cells (Zimmermann and Seifert 1998). 
ET constricts rat basilar artery with the Emax that is 122% of that produced by K+, ET has 
a pEC50 of 8.7 (Hansen-Schwartz et al. 2003b). ET is perhaps the most studied of the 
spasmogens that contribute to cerebral vasospasm. The involvement of ET has been 
demonstrated by several pieces of experimental evidence: changes in ET receptors 
(Hansen-Schwartz et al. 2003b; Hansen-Schwartz 2004; Hino et al. 1996), increased 
levels of ET in CSF and plasma (Juvela 2000; Kessler et al. 2005; Masaoka et al. 1989; 
Seifert et al. 1995; Suzuki et al. 2000; Yamaura et al. 1992), experimental induction of 
delayed vasospasm by administration of ET-1 (Asano et al. 1989; Ide et al. 1989; 
Kobayashi et al. 1991; Kobayashi et al. 1990), and attenuation of cerebral vasospasm by 
administration of ET receptor antagonists (Roux et al. 1997).  
Physiologically, the vasoconstrictor actions of ET mediated by ETA receptors in 
smooth muscle cells are antagonized by nitric oxide that is released by stimulation of ETB 
receptors expressed in the endothelium. In cerebral vasospasm, the ET-dependent 
vasocontractility seems to be due to the decreased ETB receptor function and increased 
sensitivity to ETA receptor (Vatter et al. 2007; Vatter et al. 2011). Hence, ETA selective 
antagonists were tested and found to attenuate vasospasm in pre-clinical studies (Roux et 
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al. 1997; Wanebo et al. 1998). One of the ETA antagonists, clazosentan, was found to 
reduce the frequency and severity of cerebral vasospasm in phase II clinical trials 
(Vajkoczy et al. 2005). However, a larger phase 3 placebo-controlled clinical trial failed 
to demonstrate a significant effect on mortality and vasospasm-related morbidity and 
functional outcome (Beck and Raabe 2011; Macdonald et al. 2011), indicating that ET is 
not the only spasmogen that contributes to vasospasm. Experimental evidence from a 
mouse model of SAH showed that clazosentan preserved cerebral blood flow, alleviated 
vasospasm, but did not reduce the neuronal injury. These data indicate that factors other 
than ET-induced vasospasm could still cause the neuronal injury (Sabri et al. 2010). The 
questionable reduction in the neurological deficits associated with administration of ET 
antagonists in patients were offset by adverse effects including hypotension and 
pulmonary complications limiting the use of these drugs to treat vasospasm (Kramer and 
Fletcher 2009; Vergouwen 2009). 
(ii) Serotonin: Serotonin, also known as 5-hydroxytryptamine (5HT), is a well-
recognized neurotransmitter and potent vasoconstrictor. 5HT exerts its physiological 
actions through diverse receptors comprising 7 classes with 15 subclasses (Nichols and 
Nichols 2008). The receptor classes are identified as 5HT1-7. All 5HT receptors except 
the 5HT3 are G-protein coupled receptors; 5HT3 are receptor-operated ion channels. 5HT 
induces a concentration-dependent constriction of rat basilar artery with an Emax of 82% 
(compared to K+) and pEC50 of 7.2 (Hansen-Schwartz 2004). The 5HT receptors 
expressed in the rat basilar artery are 5HT1B, 5HT1D, and 5HT2A (Hansen-Schwartz 2004). 
5HT1B and 5HT2A receptors mediate the constrictor responses and modulate the blood 
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flow through the arteries (Cambj-Sapunar et al. 2003; Nishimura 1996). The mRNA level 
of 5HT1B was found to be increased fivefold in basilar and cerebral arteries from a rat 
model of SAH compared to controls (Hansen-Schwartz 2004; Hansen-Schwartz et al. 
2003a). The basilar artery or cerebral artery derived from SAH rats were more sensitive 
to the constrictor responses of 5HT and the responses were primarily mediated through 
5HT1B receptors (Debdi et al. 1992; Mendelow et al. 1981; Nakagomi et al. 1987; 
Svendgaard et al. 1977). Cerebrospinal fluid 5HT levels are significantly elevated in 
SAH patients from a normal level of 60 ng/ml to 200 ng/ml (Chehrazi et al. 1989). Apart 
from the neuronal source, the majority of the 5HT increase is likely derived from 
aggregated thrombocytes after SAH, which contributes to the long-lasting constriction of 
the arteries in the brain (Allen et al. 1974; Satoh et al. 1991; Voldby et al. 1982). In 
summary, vasoconstriction induced by 5HT is a pivotal component in the pathogenesis of 
cerebral vasospasm. 
(iii) Vasopressin: Vasopressin ([Arg8]vasopressin; AVP) is a nine amino acid 
neuropeptide that exerts its physiological actions predominantly through 2 receptors- V1 
(V1a, V1b) and V2 receptors. Vasoconstrictor responses of AVP are mediated through the 
V1a receptors that are widely expressed in VSMCs. The V2 receptors, expressed in the 
renal collecting tubule, mediate the anti-diuretic effects of AVP. Plasma osmolarity is the 
principle stimulus for release of AVP in the circulation and CSF, but can be influenced 
by several other physiological and pathological conditions (Schrier et al. 1979). The 
normal concentration of AVP in CSF is 0.5-2.0 pg/ml in humans and 3.8-11.5 pg/ml in 
rats (Sorensen 1986). The concentration of AVP increases almost 3 times in the CSF of 
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patients during the incidence of vasospasm after SAH (Barreca et al. 2001; Jenkins et al. 
1984; Mather et al. 1981). Intra cisternal injection of AVP into Brattleboro rats, that lack 
the capacity to produce AVP, resulted in an acute basilar artery vasospasm similar to that 
observed after injection of blood (Delgado et al. 1988). Rat basilar arteries showed a V1a-
receptor-mediated enhancement of reactivity to AVP during the vasospasm phase after 
SAH (Nishihashi et al. 2005). Intravenous administration of SR49059, a V1a antagonist 
attenuated basilar artery vasospasm in a rat model of SAH, suggesting the participation of 
AVP in the development of cerebral vasospasm (Trandafir et al. 2004).  
(iv) Other spasmogens: Other spasmogens including oxyhemoglobin (Asano 
1999; Kolias et al. 2009; Macdonald and Weir 1991), bilirubin oxidation products (BOX) 
(Clark and Sharp 2006) from the hemolysate and eicosanoids (Kolias et al. 2009) also 
induce spasm or potentiate the constriction induced by other spasmogens. The increased 
activity of the spasmogens combined with the reduction in activity of physiological 
endothelium-derived relaxing factors like nitric oxide (Hanggi and Steiger 2006; McGirt 
et al. 2002; Pluta et al. 1996; Pluta 2006; Sobey and Quan 1999) likely causes the 
persistent spasm. 
 
Membrane depolarization and elevation of cytosolic calcium 
A continuous elevation of [Ca2+]c (Kim et al. 1996; Tani and Matsumoto 2004) 
and myosin light chain (MLC20) phosphorylation (Tani and Matsumoto 2004; Bulter et 
al. 1996) has been observed in myocytes derived from spastic arteries, although one 
study failed to observe an increase in Ca2+ levels (Yamada et al. 1994). Stimulation of 
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Gq-coupled receptors by spasmogens generates phospholipase C that hydrolyses PIP2 to 
IP3 and diacylglycerol, with IP3 stimulating release of Ca2+ from the intracellular stores 
(Tani 2002). However, prolonged elevation of [Ca2+]c is sustained only by Ca2+ influx 
through VSCC (Wellman 2006). Myocytes derived from basilar and cerebral arteries of 
rabbits or dogs with experimentally induced SAH were significantly depolarized 
(Jahromi et al. 2008a; Harder et al. 1987; Nystoriak et al. 2010; Waters and Harder 1985; 
Zuccarello et al. 1996b). Given the predominant role of Ca2+ influx through VSCC in 
increasing [Ca2+]c, an increase in open-probability of VSCC in the depolarized vascular 
myocytes is proposed as the primary pathology in cerebral vasospasm (Wellman 2006; 
Marin 1988). The involvement of VSCC is supported by the beneficial effects of blockers 
of these channels in the treatment of cerebral vasospasm (Dorhout Mees et al. 2007; 
Allen et al. 1983). Nimodipine, a dihydropyridine Ca2+ channel blocker with a 
preferential cerebrovascular action (Kazda and Towart 1982), remains the only 
recommended pharmacological treatment available to patients with cerebral vasospasm 
(Bederson et al. 2009). The beneficial effects of nimodipine in cerebral vasospasm 
however remain controversial, because unlike in animal studies, patients on nimodipine 
therapy have no demonstrable reduction in angiographic vasospasm in some studies 
(Allen et al. 1983; Jan et al. 1988), but had remarkable effects in other studies (Cho et al. 
2011; Biondi et al. 2004). There are suggestions that the beneficial effect of nimodipine 
may be predominantly due to its direct neuroprotective effects (Allen et al. 1983; 
Mayberg et al. 1994).  
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Role of potassium channels in cerebral vasospasm 
Since the membrane voltage is primarily regulated by K+ conductance (Faraci and 
Sobey 1998), K+ channels are postulated as mediators in the pathogenesis of cerebral 
vasospasm and have therefore been identified as possible therapeutic targets to treat the 
condition (Wellman 2006). K+ conductance was found to be reduced in basilar arteries 
after SAH (Jahromi et al. 2008a; Harder et al. 1987; Jahromi et al. 2005). The roles of 
the major classes of K+ channels expressed in basilar and cerebral arteries, KATP, KIR, 
BKCa, and 4AP-sensitive-KV channels as contributors to membrane depolarization and 
hence cerebral vasospasm have been investigated. 
KATP channels expressed in basilar artery remain functional after SAH with their 
activity enhanced rather than inhibited. Pharmacological KATP channel activators induced 
enhanced dilation of cerebral arteries from SAH animals (Zuccarello et al. 1996b; Sobey 
et al. 1996; Sugai et al. 1999). Reduced activity of the functional channels after SAH 
may develop due to reduced levels of endogenous KATP channel activators like CGRP 
(Edvinsson et al. 1994; Edvinsson et al. 1990). Activation of KATP channels with 
cromakalim relaxed pre-constricted basilar artery and attenuated basilar artery vasospasm 
in animal models of vasospasm (Zuccarello et al. 1996b; Sugai et al. 1999; Kwan et al. 
2000; Kwan et al. 1998). However, administration of KATP channel activators are 
associated with hypotension and tachycardia limiting its clinical utility (Spinelli et al. 
1990). Alternatively, to avoid systemic hypotension, targeted delivery of CGRP to 
activate cerebrovascular KATP channels by implantation of a time-released capsule in the 
CSF space (Ahmad et al. 1996; Inoue et al. 1996), adenoviral over expression of CGRP 
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in cerebral vasculature (Satoh et al. 2002; Toyoda et al. 2000a; Toyoda et al. 2000b) or 
intranasal delivery of CGRP (Sun et al. 2010) have been tested and found to be effective 
in animal models. Intravenous infusion of CGRP after SAH in patients failed to show any 
beneficial outcome in preventing neuronal deterioration, and produced consistent 
systemic hypotension (Bell 1995; Bell 1992). The efficacy of local delivery rather than 
systemic administration of KATP channel activators remains to be verified in SAH 
patients.  
Dysfunction of 4-AP-sensitive-Kv channels after SAH has been proposed as a 
mechanism contributing to cerebral vasospasm (Jahromi et al. 2008a; Ishiguro et al. 
2006). A significant reduction in the mRNA of Kv channels- Kv2.2, Kv3.4 was observed 
in basilar artery myocytes derived from SAH dogs, and the changes in Kv2.2 mRNA 
correlated with the degree of vasospasm (Aihara et al. 2004). Protein levels of Kv2.1 and 
Kv2.2 channels were also significantly reduced in basilar artery myocytes of SAH dogs 
(Jahromi et al. 2008a). Kv currents measured from the basilar artery myocytes of SAH 
rats had diminished current amplitude, indicating dysfunction of Kv channels (Jahromi et 
al. 2008a; Jahromi et al. 2008c). Both half-activation and inactivation of Kv currents 
were also decreased in the myocytes (Jahromi et al. 2008c). The mechanisms that lead to 
the downregulation of expression of the Kv channels are not known. Oxyhemoglobin 
induces a tyrosine kinase-mediated endocytosis of Kv channels resulting in dysfunction 
of the channels (Ishiguro et al. 2006; Ishiguro et al. 2008). Tyrosine kinase activation by 
oxyhemoglobin involves matrix metalloprotease activation causing heparin binding of 
epidermal growth factor (EGF)-like growth factor shedding and increased epidermal 
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growth factor receptor tyrosine kinase activity (Koide et al. 2007). Kv channels have a 
high voltage threshold for activation (V0.5 = -1.3 mV in dog basilar arteries) (Jahromi et 
al. 2008a). Hence, dysfunction of Kv channels could lead to loss of a compensatory 
vasodilatory mechanism, potentiating the vasospasm. 
The mRNA of the BK channel α-subunit was not found to be altered in the basilar 
artery myocytes from SAH dogs (Aihara et al. 2004). Though mRNA of the β1 subunit of 
the BK channels was found to be reduced, the protein levels were unaltered (Aihara et al. 
2004). Function of the BK channels was preserved in vasospastic basilar artery myocytes 
from a dog model of SAH. There was no difference in the BK current density, kinetics, 
Ca2+ and voltage sensitivity, single channel conductance or apparent Ca2+ affinity after 
SAH (Jahromi et al. 2008c; Jahromi et al. 2008b). Heme breakdown products known as 
bilirubin oxidation end products (BOXs) present in the CSF after hemorrhage have been 
shown to reduce the open probability of BK channels in a heterologous expression 
system (Hou et al. 2011). The in vivo relevance of the modulation of BK currents by 
BOXs remains to be clarified. Pharmacological blockade of BK channels did not 
influence the membrane voltage in basilar artery myocytes from SAH dogs when 
compared to myocytes from control dogs (Jahromi et al. 2008b). Hence, the role of BK 
channel function in the pathogenesis of cerebral vasospasm, at least from the current 
understanding, is likely to be minimal. 
KIR 2.1 mRNA was increased by more than 2-fold in basilar artery myocytes of 
dogs after SAH (Aihara et al. 2004; Weyer et al. 2006a). The mean conductance through 
KIR channels increased several fold, from 1.6 pS/pF to 9.2 pS/pF indicating an 
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upregulation of these channels (Weyer et al. 2006a). The increase in the channel 
expression and function indicate that KIR channels likely act as a compensatory 
mechanism to limit the depolarization induced by dysfunction of other ion channels 
(Aihara et al. 2004; Weyer et al. 2006a).  
In summary, dysfunction of 4AP-sensitive Kv channels might be a contributing 
factor for the persistent membrane depolarization observed in artery myocytes after SAH 
though there are no available activators to use in clinical therapy. KATP channel openers 
have been tested to relieve vasospasm, but were found to have questionable efficacy and 
increased the risk of hypotension. Hence, none of the K+ channel subtypes known to be 
expressed in the cerebral vasculature has emerged as a successful target to treat cerebral 
vasospasm (Wellman 2006). 
 
Involvement of protein kinase C  
Stimulation of phospholipase C either by cell surface receptor activation or 
mechanical force leads to cleavage of PIP2 to IP3 and DAG. DAG can activate some 
members of the family of serine-threonine kinases, called protein kinase C (PKC). 
Twelve isoforms of PKC are known. They have been classified into 3 groups based on 
their regulation; conventional PKCs (comprised of PKC α, β and γ) requires both DAG 
and Ca2+ for activation, novel PKCs (comprised of PKC δ, ε, η and θ) requires DAG for 
activation, independently of Ca2+, and atypical PKCs (comprised of λ, μ and ζ) are 
insensitive to DAG, but activated by phosphatidyl serine and phorbol esters. The role of 
PKCs in mediating the VSMC contraction induced by cell surface receptor activation and 
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myogenic response is not entirely understood. PKC increases the Ca2+ sensitivity of the 
contractile apparatus, and therefore acts as a modulator to amplify the vasoconstrictor 
response to elevated [Ca2+]c in VSMCs (Laher et al. 1989; Laher et al. 1990). The kinase 
phosphorylates contractile proteins calponin and/or caldesmon leading to disinhibition of 
myosin ATPase thereby sensitizing the contractile apparatus.  
The phosphorylation targets mediating the response of PKC also include ion 
channels, pumps and exchangers as well as other kinases (Laher and Zhang 2001). 
Activation of PKC induces membrane depolarization by suppression of K+ channels 
resulting in Ca2+ entry through VSCC. Several potassium channels including KATP, Kv 
and BK channels are sensitive to activation of PKC (Standen and Quayle 1998; Aiello et 
al. 1996; Minami et al. 1993; Shearman et al. 1989). The sustained Ca2+ entry and 
sensitization of contractile apparatus by activated PKC plays a pivotal role in initiation 
and maintenance of chronic vasospasm. 
Activation of PKC and/or increase in DAG has been observed in vasospastic 
arteries undergoing experimental chronic vasospasm (Fujikawa et al. 1999; Sato et al. 
1997; Matsui et al. 1991a; Nishizawa et al. 1992; Nishizawa et al. 1995; Sako et al. 
1993). Application of phorbol ester (12-0-tetradecanoylphorbol-13-acetate), an activator 
of PKC induced sustained constriction of dog basilar artery that lasted 3 days mimicking 
cerebral vasospasm; preemptive injection of staurosporine, a PKC inhibitor abolished the 
constriction induced by phorbol ester (Sako et al. 1993).  
Of the known PKC isoforms, α, δ, η and ζ were the common isoforms present in 
the canine basilar artery (Nishizawa et al. 2000; Nishizawa et al. 2001). A chronological 
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analysis in dog basilar artery myocytes revealed that PKCδ translocated first followed by 
PKCα during the development of experimental cerebral vasospasm. Hence, these 
isoforms are considered important for the development and maintenance of vasospasm 
(Nishizawa et al. 2000). Treatment with topically applied PKC inhibitors, staurosporine, 
and H7, attenuated cerebral vasospasm in a canine model of SAH (Matsui et al. 1991b). 
However, PKC inhibitors failed to show similar beneficial effects in a rabbit model of 
SAH (Zuccarello et al. 1996b).  
  
Current treatments for cerebral vasospasm 
Since Ca2+ entry through VSCC is the principle cause for vasospasm, it is not 
surprising that most of the therapeutic options available today attempt to minimize the 
Ca2+ entry through these channels. Nimodipine, a selective L-type Ca2+ channel 
antagonist, which preferentially dilates cerebral arteries, was shown to improve clinical 
outcomes in multiple clinical trials (Weyer et al. 2006b). The utility of nimodipine 
remains controversial because the improved outcome and reduction in cerebral infarction 
was not always associated with a significant decrease in angiographic vasospasm (Allen 
et al. 1983; Mayberg et al. 1994). However, nicardipine, another L-type Ca2+ channel that 
was expected to work similarly to nimodipine, did not improve the outcome in patients 
with cerebral vasospasm in a randomized clinical trial (Haley et al. 1994). Magnesium, 
which acts as a Ca2+ channel blocker and as an intracellular Ca2+ antagonist, was found to 
reduce the delayed cerebral ischemia in some clinical studies (Wong et al. 2011), but 
most studies failed to show any beneficial effect (Suarez 2011).  
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A commonly practiced medical intervention to overcome cerebral vasospasm is 
triple-H therapy (hypervolemia, hypertension, and hemodilution) (Lee et al. 2006; Sen et 
al. 2003). This is achieved by increasing the volume status in patients accompanied by 
administration of vasoactive drugs like dopamine or phenylephrine (Sen et al. 2003). 
Increased blood volume, high perfusion pressure and reduced viscosity increases the 
cerebral perfusion reducing the risk of ischemia. Triple-H therapy however carries a 
substantial risk of pulmonary edema, myocardial ischemia, and hyponatremia, not to 
mention the risk of re-bleeding in patients after subarachnoid hemorrhage (Sen et al. 
2003; Kassell et al. 1982; Solenski et al. 1995). The efficacy and safety of the triple H 
therapy remains a question, but it continues to be practiced due to the paucity of effective 
alternatives (Dankbaar et al. 2010; Treggiari and Deem 2009). 
Clazosentan, a selective ETA endothelin receptor antagonist, which showed 
promise in several animal models of SAH, did not show a significant decrease in 
vasospasm in a large clinical trial (Macdonald et al. 2011). Nitric oxide donors met with 
a similar fate, limited by significant side effects, which included hypotension and 
increased intracranial pressure (Fathi et al. 2011). Intra-arterial papaverine (Liu and 
Couldwell 2005), administration of antioxidants (Trilizad mesylate), free radical 
scavengers (Nicaravin), anti-inflammatory serine protease inhibitors (nafamostat 
mesilate), immunosuppressive agents (cyclosporine, prednisolone) have demonstrated 
little to no beneficial effect on outcomes (Bederson et al. 2009). 
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Need for new treatment options 
To date nimodipine is the only drug available with proven, but limited efficacy to 
treat cerebral vasospasm (Keyrouz and Diringer 2007; Weyer et al. 2006b; Velat et al. 
2011). The limited efficacy may be due to the presence of heterogeneous Ca2+ channel 
subunits with varying sensitivities to nimodipine (Navarro-Gonzalez et al. 2009; Nikitina 
et al. 2007) and increased expression of nimodipine-insensitive T-type and R-type Ca2+ 
channels in vascular myocytes following SAH (Nikitina et al. 2010; Link et al. 2008). 
Hence, a drug that inhibits the activation of all VSCC subtypes either directly or 
indirectly (e.g. by activation of K+ channels and prevention of the membrane 
depolarization that activates VSCC) would be expected to be more efficacious than 
nimodipine. Therefore understanding the pathophysiological mechanisms that cause 
membrane depolarization and vasospasm could lead to discovery of alternative 
therapeutic strategies (Keyrouz and Diringer 2007; Deshaies et al. 2009). 
 
Kv7 potassium channels  
The following section reviews literature on Kv7 potassium channels with the 
emphasis on why Kv7 channels were chosen to test as candidate channels to control 
VSMC excitability and contractile status of the basilar artery.  
 
Discovery of Kv7 channels 
The KCNQ voltage-sensitive K+ channels (Kv7 channel family) are relatively 
newly found members of the diverse class of K+ channels. KCNQ genes that express Kv7 
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channel subunits were cloned in the 1990s along with several other genes cloned during 
the molecular biology revolution. The name for the family of channels was adopted as 
Kv7 based on the deducted phylogenetic relationships (Gutman et al. 2005), but still 
widely used interchangeably with KCNQ based on the KCN nomenclature developed by 
Human Genome Organization (HUGO) (White et al. 1997). 
The first member of this family– KvLQT1 (later renamed KCNQ1) was 
discovered in the heart (Sanguinetti et al. 1996), where four of the Kv7.1 subunits 
combine to form channels that conduct the slowly activating delayed rectifier K+ current 
(IKs). The interest in Kv7 channels then exploded with the identification of Kv7.2/7.3 
heterotetrameric channels as molecular correlates of the “M-currents” (Wang et al. 1998), 
which were recognized as regulators of membrane excitability in neurons. Wang and his 
collegues demonstrated currents similar to neuronal M-currents by injecting cDNA 
encoding KCNQ2 and KCNQ3 in Xenopus oocytes. 
M-currents (IM), named by virtue of their sensitivity to muscarinic receptor 
stimulation, were first identified in frog and rat sympathetic neurons as non-inactivating 
K+ currents, slowly activated by membrane depolarization (Adams and Brown 1980; 
Constanti and Brown 1981). Identification of M-currents provided the first clear 
demonstration of control of neuronal excitability by voltage-sensitive K+ currents 
described by several investigators since the 1960s (Kobayashi and Libet 1968; Krnjevic 
et al. 1971; Kuba and Koketsu 1976; Weight and Votava 1970). At present, 5 KCNQ 
genes (KCNQ1-5), encoding Kv7.1-7.5 channel subunits, have been cloned and channels 
formed by these subunits have been found to have important functions in various 
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excitable tissues (Jentsch 2000). A great deal of research has focused on demonstrating 
the role of Kv7 channels in membrane excitability of neurons, and QT-interval regulation 
in cardiac myocytes (Delmas and Brown 2005; Robbins 2001).  
 
Structure and composition of functional Kv7 channels 
The molecular composition of Kv7 channels resembles other Kv channels, with 
each functional channel composed of homo- or hetero-tetramers of six transmembrane 
spanning (S1-S6) channel subunits (Jentsch 2000). The single pore loop (P-loop) formed 
between the S5 and S6 domain of each subunit forms the selectivity filter of the pore and 
S4 acts as voltage sensor. Both the amino (N)- and carboxyl (C)-terminus of the channel 
subunits lie within the cytoplasm. Kv7 channels are however distinct from other Kv 
channels in having a long intracellular C-terminus (Delmas and Brown 2005). The C-
terminus has a distinctive conserved A-domain that determines the subunit specificity of 
the channels (Schwake et al. 2003). Apart from conferring subunit specificity, the C-
terminal domain also plays a crucial role in channel gating, assembly, trafficking and 
scaffolding with signaling proteins (Haitin and Attali 2008).  
While all the subunits can combine among themselves to form homo-tetramers, 
the formation of hetero-tetramers, as elucidated by co-expression studies, are restricted to 
certain combinations: Kv7.3 with Kv7.2 (Wang et al. 1998); Kv7.4 with Kv7.3, but not 
Kv7.2 or Kv7.1 (Bal et al. 2008; Kubisch et al. 1999); Kv7.5 with Kv7.3 and Kv7.4, but 
not Kv7.2 (Bal et al. 2010; Schroeder et al. 2000a). Kv7.1 subunits do not 
heterotetramerize with other known Kv7 channel subunits. At present, there is no 
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evidence to suggest existence of channels comprising Kv7 channel subunits and other Kv 
channel subunits (e.g. 4-AP-sensitive Kv channels of the Kv1, Kv2, and Kv4 subtypes).  
 
Expression of Kv7 channels 
Although expression was initially thought to be restricted to neurons and cardiac 
myocytes, recent evidence suggests that the expression of KCNQ channels is rather 
ubiquitous (Brown 2008; Mackie and Byron 2008). In the heart, homotetramers of Kv7.1 
subunits co-assemble with two single-transmembrane ancillary protein called minK or 
IsK, that alters the gating characteristics of the K+ current (IKs) (Sanguinetti et al. 1996; 
Barhanin et al. 1996). MinK is encoded by the KCNE1 gene which belongs to a family of 
5 genes, KCNE1 through 5 (McCrossan and Abbott 2004). Interaction of KCNQ1 with 
KCNE1 in the heart enhances the amplitude and slows the activation of currents 
(Sanguinetti et al. 1996). Dominant mutations in cardiac Kv7.1 channels lead to long QT 
syndrome (LQTS1) also called Romano-Ward syndrome, leading to potentially fatal 
cardiac arrhythmia (Chiang and Roden 2000; Herbert et al. 2002; Jespersen et al. 2005). 
A recessive mutation identified in Kv7.1 or KCNE1 subunits however leads to a severe 
form of the disease called Jervell and Lange-Nielsen syndrome (JLNS), where cardiac 
arrhythmia is associated with congenital deafness (Neyroud et al. 1997). The deafness is 
due to defects in the trans-epithelial transport of K+ through Kv7.1/KCNE1 channels in 
the inner ear (Neyroud et al. 1997). 
Kv7.2/7.3 heterotetramers that underlie M-currents are the predominant subtype 
expressed in neurons (Wang et al. 1998). Channels comprising Kv7.5 and Kv7.4 subunits 
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also add diversification to the M-currents with many regions of brain showing 
overlapping expression of Kv7.2, Kv7.3, and Kv7.5 subunits (Schroeder et al. 2000a; 
Kharkovets et al. 2000). Unlike cardiac Kv7.1 channels, neuronal Kv7 channels do not 
appear to interact with ancillary subunits (Jentsch 2000). Mutations in Kv7.2 subunit or 
rarely in Kv7.3 subunit lead to an epileptic condition in infants called benign familial 
neonatal convulsions (BFNC) (Biervert et al. 1998; Singh et al. 1998). Kv7.4 channels 
are expressed in the inner ear cochlear sensory hair cells and vestibular cells. Mutation of 
Kv7.4 channels leads to slow degeneration of sensory hair cells resulting in progressive 
deafness (Kubisch et al. 1999; Kharkovets et al. 2000).  
Recently, transcripts for all known Kv7 channel subunits and KCNE ancillary 
subunits were found to be expressed in murine gastrointestinal smooth muscle cells, with 
KCNQ4, KCNQ5 and KCNE4 being the predominant transcripts (Jepps et al. 2009). The 
authors proposed that the channels function similarly to neuronal Kv7 channels, in 
stabilizing the membrane voltage and limiting the gastrointestinal contractility. Apart 
from smooth muscle cells, Kv7 channels are expressed in epithelial cells of the colon 
where Kv7.1/KCNE3 channels function in the cyclic-adenosine monophosphate (cAMP)-
stimulated secretion of Cl- ions (Schroeder et al. 2000b).  
K+ currents through Kv7 channels were also shown to induce a hyperpolarizing 
influence in urinary bladder interstitial cells of Cajal (Anderson et al. 2009), modulating 
the contractile status of urinary bladder (Rode et al. 2010). Expression of Kv7 channels 
varied with the stage of gestation in mouse and human myometrial smooth muscle cells 
and was proposed as a mechanism to modulate uterine contractions during pregnancy 
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(McCallum et al. 2011). Expression of Kv7 channels in vascular smooth muscle cells are 
described in detail in a later section of the review of literature. 
 
Biophysical characteristics of Kv7 currents 
Outward K+ currents conducted through Kv7 channels in neurons have unique 
biophysical characteristics - (1) threshold of activation around the resting membrane 
voltage, usually around -60 mV, (2) slow voltage-dependent enhancement of currents 
with membrane depolarization from resting voltages, (3) lack of inactivation. These 
characteristics of Kv7 currents tend to oppose membrane depolarization and hence act as 
a brake for neuronal excitation. Suppression of the currents increases input resistance that 
predisposes to increase in probability of action potential firing, responsiveness to synaptic 
input and spike frequency in neurons (Hernandez et al. 2008; Marrion 1997).  
 
Regulation of Kv7 channels 
(i) Receptors involved in regulation of Kv7/M-current suppression: The 
distinctive biophysical characteristics of the Kv7 channels dispose these channels to be 
targets of various physiological regulators in excitable cells. Since the discovery of the 
sensitivity of M-currents to muscarinic receptor ligands (Brown and Adams 1980), the 
channels were found to be regulated by a plethora of G-protein coupled receptors (Adams 
and Brown 1980; Marrion 1997). Stimulation of substance P (Jones 1985), luteinizing 
hormone releasing hormone (LHRH) (Adams and Brown 1980), purinergic P2Y (Adams 
et al. 1982), β-adrenergic receptors  in bullfrog sympathetic ganglia (Akasu 1988); 
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muscarinic and AT1 angiotensin receptors in rat sympathetic ganglia (Constanti and 
Brown 1981; Shapiro et al. 1994); M1/M3 muscarinic (Halliwell and Adams 1982), 5-
HT2 serotonin (Colino and Halliwell 1987), κ and δ opioid (Moore et al. 1994), and 
metabotropic glutamate (Charpak et al. 1990) receptors in hippocampal pyramidal 
neurons were found to suppress M-currents.  
(ii) PIP2 mediated regulation: A perceptible feature of all the aforementioned 
receptors is that they are all Gq-coupled receptors. Using a wide-range of approaches 
from molecular to knockout mouse models, it is now established that the M-current 
suppression is mediated by the Gαq subunit (Caulfield et al. 1994; Haley et al. 1998; 
Haley et al. 2000). Second messengers downstream of Gαq subunit activation, 
phospholipase(PLC)-β-mediated PIP2 hydrolysis products (IP3, and diacylglycerol), 
protein kinase C (PKC), elevation of cytosolic Ca2+ were each proposed as possible 
mediators of M-current suppression (Marrion 1997). The identity of the mediator 
however remained elusive even after knowledge about the molecular identity of M-
currents. In 2002, Hille and his colleague showed the first evidence that the suppression 
of currents in response to muscarinic receptor stimulation was not mediated by the 
hydrolysis products of PIP2, but by the depletion of membrane-bound precursor PIP2 
itself (Suh and Hille 2002). Since then, several studies have established that PIP2 is 
required to keep the Kv7 channels open and that a reduction in the membrane PIP2 
concentration is the primary mechanism of receptor-induced M-current suppression (Suh 
and Hille 2007; Li et al. 2005; Winks et al. 2005; Zhang et al. 2003). A strong correlation 
was found to exist between the apparent affinity of the Kv7 channel subunits to PIP2 and 
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the divergent maximal open probability (Po) of the channels. Homotetrameric Kv7.3 
channels with a Po of almost unity (Li et al. 2004b) had the maximum apparent affinity; 
Po was in the order of Kv7.3> Kv7.2/7.3> Kv7.2> Kv7.4 channels (Li et al. 2005). 
Taking advantage of the differential affinities of the Kv7 subunits, a recent study 
constructed chimeras of Kv7.3 and 7.4 subunits to identify C-terminal inter-helix linker 
as the site of PIP2 action (Hernandez et al. 2008). 
(iii) Signalosomes orchestrating Kv7 channel regulation: The specificity and 
efficiency of signal transduction pathways to dynamically regulate the function of several 
cell surface proteins are mediated by signalosomes (Negro et al. 2008). Signalosomes are 
discrete multifunction protein complexes that compartmentalize signaling events by 
bringing together the regulatory intermediates and their substrates. Several lines of 
evidence suggest that Kv7 channels are part of a signalasome tethered together by a 
scaffolding protein, A-kinase anchoring protein (AKAP)79/150 in neurons. Named after 
its ability to bind to protein kinase A (PKA) holoenzyme (Rubin 1994), AKAP79/150 is a 
family of 3 known orthologs- human AKAP79, murine AKAP150 and bovine AKAP75 
(Colledge and Scott 1999). Apart from PKA, AKAP binds to protein kinase C (Klauck et 
al. 1996), protein phosphatase 2B or calcineurin (Coghlan et al. 1995), calmodulin (Faux 
and Scott 1997), phosphodiesterases (Dodge et al. 2001) in a multiprotein complex along 
with Kv7 channels (Delmas and Brown 2005). AKAP79/150 constitutively binds to Kv7 
channels; and suppression of M-currents by muscarinic receptors were dampened by 
perturbation of AKAP binding to Kv7 channels (Hoshi et al. 2003; Zhang et al. 2011). 
The requirement of AKAP was further supported by reduced M-current suppression in 
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response to muscarinic receptor stimulation in the sympathetic cervical ganglion neurons 
of AKAP150 knockout mice (Tunquist et al. 2008). The mice were resistant to seizures 
induced by pilocarpine, a non-selective muscarinic agonist (Tunquist et al. 2008). The 
interaction of Kv7 channels to AKAP was further clarified with the evidence that 
AKAP79 associated with KCNQ2-5, but not KCNQ1 using fluorescence resonance 
energy transfer (FRET) under total internal reflection fluorescence (TIRF) microscopy in 
a heterologous expression system (Bal et al. 2010).  
Suppression of M-currents by activation of muscarinic receptors was thought to 
be mediated by PIP2 hydrolysis (Hernandez et al. 2008; Suh and Hille 2002; Suh and 
Hille 2007; Li et al. 2005; Zhang et al. 2003; Robbins et al. 2006) independent of 
diacylglycerol produced during activation of PLC, or the PKC that it might stimulate 
(Hille 1994; Suh and Hille 2006). Later studies however showed that at least part of the 
muscarinic suppression of currents is mediated by an AKAP-dependent pathway that 
involves PKC (Hoshi et al. 2003; Higashida et al. 2005). Knockdown of AKAP79/150 or 
expression of dominant negative AKAP150 that cannot bind PKC showed reduced 
suppression of M-currents with muscarinic receptor stimulation (Hoshi et al. 2003; Zhang 
et al. 2011; Hoshi et al. 2005). Though the PKC bound to AKAP is in the inactive form 
(Klauck et al. 1996; Faux et al. 1999), the anchored pool of PKC seems to be essential 
for muscarinic suppression of M-currents (Hoshi et al. 2005). The mechanisms by which 
muscarinic receptor stimulation activates PKC in the pool anchored to AKAP79/150 
remain unclear. Calmodulin, apart from constitutively binding to the channel, binds to 
AKAP in a Ca2+-dependent manner (Faux and Scott 1997). Calcium-calmodulin was 
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shown to regulate Kv7 currents by competing with and displacing the inactive PKC 
bound to AKAP, facilitating its activation by diacylglycerol (Faux and Scott 1997).   
Activation of PKC induces a large positive shift (~17 mV) in the conductance-voltage 
curve of Kv7 currents (Nakajo and Kubo 2005). PKC likely produces this effect by direct 
phosphorylation of serine or threonine residues in the intracellular loop or the C-terminal 
domain of the Kv7 channels subunits. Serine534 and 541 in KCNQ2 and T553 in 
KCNQ4 have been identified as critical amino acid residues for regulation of the channel 
activity by PKC (Bal et al. 2010; Hoshi et al. 2003).   
Depletion of PIP2 or phosphorylation by PKC however does not account for Kv7 
current suppression by all Gq-coupled receptor-PLC activation. Stimulation of bradykinin 
B2 receptors suppresses Kv7 currents by a distinct Ca2+-dependent mechanism. B2 
receptor stimulation elevates [Ca2+]C by IP3-mediated Ca2+ release. The elevated cytosolic 
Ca2+ interacts with calmodulin bound to the long C-terminal domain of Kv7 channels 
resulting in suppression of the currents (Gamper and Shapiro 2003). Kv7 currents are 
exquisitely sensitive to elevations of [Ca2+]C with a IC50 of 70-100 nM, slightly above the 
resting Ca2+ levels in neurons (Gamper and Shapiro 2003; Selyanko and Brown 1996). 
Ca2+-calmodulin inhibited currents through channels formed by Kv7.2, Kv7.4 and Kv7.5, 
but not Kv7.1 and Kv7.3 demonstrating subtle subunit specificity (Gamper et al. 2005).  
There are 2 non-continuous binding sites for calmodulin in the Kv7 channel 
subunits, with only the apo-calmodulin but not Ca2+ bound calmodulin capable of binding 
to it (Wen and Levitan 2002; Yus-Najera et al. 2002). Apo-calmodulin acts as an 
accessory subunit for the channel and is essential for the normal opening of the channel. 
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Regulation of the channel is likely to be complex with perturbation of calmodulin binding 
reported to either reduce or increase channel activity (Gamper and Shapiro 2003; Wen 
and Levitan 2002). The sensitivity of the channel to Ca2+ requires calmodulin, but the 
mechanism by which calmodulin modulates the channel remains to be understood, 
though modulation of phosphorylation has been ruled out (Selyanko and Brown 1996). 
Muscarinic receptor-induced suppression of Kv7 currents is independent of Ca2+-
calmodulin-mediated action, as [Ca2+]C is not elevated after muscarinic receptor 
stimulation presumably because the muscarinic receptors and IP3 receptors exist in 
distinct “microdomains”. Hence, IP3 produced by PIP2 hydrolysis does not reach 
threshold levels near the endoplasmic reticulum to release Ca2+ through IP3 receptors 
(Delmas et al. 2004). Apart from its role in regulation of Kv7 channels in the membrane, 
calmodulin appears to be a critical regulator for trafficking of the channel to the 
membrane (Etxeberria et al. 2008; Alaimo et al. 2009).  
Tyrosine phosphorylation of Kv7 channels by a non-receptor tyrosine kinase Src 
also suppresses the currents by reducing the open probability of the channels. Src 
phosphorylation is subunit selective for Kv7.2, 7.3, Kv7.2/7.3 and 7.5 subunits (Gamper 
et al. 2003). The tyrosine residues in Kv7.3 subunits were mapped as Y67 in the N 
terminus and Y349 in the C terminus, with simultaneous phosphorylation of both the 
residues a requirement for regulation by Src (Li et al. 2004a). Src phosphorylation was 
however not a mechanism of M current suppression by muscarinic receptor activation in 
sympathetic neurons (Gamper et al. 2003), and the physiological significance of Kv7 
channel phosphorylation by Src is uncertain. Activation of receptor tyrosine kinases like 
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epidermal growth factor receptor (EGFR) and nerve growth factor (NGF) have also been 
reported to suppress Kv7 currents, likely through a tyrosine phosphorylation mechanism 
(Jia et al. 2007; Jia et al. 2008).  
(iv) Transcriptional regulation: Most studies until recently focused on the 
regulation of channels present in the plasma membrane. Recently KCNQ2 and KCNQ3 
genes were found to be regulated in dorsal root ganglia (DRG) neurons by two well 
known transcription factors- sp1 (specificity factor 1), a transcriptional activator and 
REST (Repressor element 1-silencing transcription factor), a transcriptional repressor 
(Mucha et al. 2010). Overexpression of REST reduced M-current density and increased 
excitability of DRG neurons, highlighting the significance of transcriptional regulation of 
Kv7 channels. Neuronal expression of REST increased in response to inflammatory 
mediators and correlates with a reduction in Kv7.2 subunit expression (Mucha et al. 
2010). REST mediated transcriptional downregulation of Kv7.2 channel expression has 
been proposed as a mechanism for neuropathic pain (Rose et al. 2011). Peripheral 
application of flupirtine, a Kv7 channel opener, was able to alleviate neuropathic 
hyperalgesia in a partial sciatic nerve ligation rat model (Rose et al. 2011), possibly by 
activating the reduced population of Kv7 channels and opposing the membrane 
depolarization in neurons (Passmore and Delmas 2011). 
 
Pharmacology of Kv7 channels 
A number of pharmacological agents are available that modulate either all Kv7 
channel subtypes or channels formed by select combinations of Kv7 subunits. 
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Linopirdine [DuP 996, 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2Hindol-2-one], 
a phenylindolinone derivative originally developed as a cognitive enhancer and 
neurotransmitter release enhancer (Nickolson et al. 1990) was subsequently found to be 
an M-channel blocker (Aiken et al. 1995). The drug is selective for Kv7 channels and 
was without appreciable effects on other Kv channels (Wang et al. 1998). The IC50 for 
linopirdine block of pan-Kv7 channel varies between 1.2 - 36 µM depending on the 
heterogeneity in the molecular composition of the channels (Brown et al. 2002; 
Wickenden et al. 2001). Linopirdine and its potent analog XE991 [10,10-bis(4-
pyridinylmethyl)-9(10H)-anthracenone] are not used clinically because of their 
epileptogenic effects produced due to the blockade of Kv7 channels (Zaczek et al. 1998). 
Linopirdine and XE991 are however used extensively in the laboratory for experimental 
purposes usually at concentrations ≤10 µM as selective irreversible blockers of Kv7 
channels (Schnee and Brown 1998; Wladyka and Kunze 2006). XE991 also moderately 
blocks other Kv channels reversibly albeit only at voltages positive to +20 mV (Zhong et 
al. 2010). 
Flupirtine [D-9998, Katadolon®, Ethyl 2-amino-6-((p-fluorobenzyl)amino)-3-
pyridinecarbamate] is a triaminopyridine, clinically used as a non-opioid analgesic in 
Europe since 1984 even before the discovery of Kv7 channels. Though the analgesic 
effect was earlier thought to be due to its N-methyl-D-aspartate (NMDA) receptor-
blocking and γ-amino butyric acid (GABAA) receptor-potentiating effects, it was later 
found that the analgesic activity was due to its ability to enhance IM currents within the 
therapeutic range (2-6 µM) (Kornhuber et al. 1999; Martire et al. 2004). Structural 
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modification of flupirtine yielded retigabine [known as ezogabine in United States; D-
23129, ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate], which was 
10-30 times more potent as a Kv7 channel activator compared to its N-methyl-D-
aspartate (NMDA) receptor-blocking and γ-amino butyric acid (GABAA) receptor-
potentiating effects. Retigabine and flupirtine activate all channels formed by Kv7.2-7.5 
subunits through interaction with residues in the S5 and S6 domains of which a 
tryptophan residue in S5 is a key element. Retigabine and flupirtine do not activate 
channels formed by Kv7.1 subunits, which lack the tryptophan residue in the S5 domain 
(Bentzen et al. 2006; Schenzer et al. 2005). Apart from increasing the open probability of 
the channel, retigabine also induces a hyperpolarizing shift in activation of Kv7 currents 
(Tatulian et al. 2001; Tatulian and Brown 2003). 
Recently, compounds were developed to target specific subtypes of Kv7 channels; 
ICA-27243 [ N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] selectively activates 
heteroterameric channels formed by Kv7.2/7.3 subunits (Wickenden et al. 2008); S(1) 
[(S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide [(S)-1]] preferentially 
activates channels formed by Kv7.4 and Kv7.5 subunits, but blocks homomeric channels 
formed by Kv7.1 subunits (Bentzen et al. 2006; Wu et al. 2003) and BMS-204352 
selectively activates channels formed by Kv7.4 and Kv7.5 subunits (Dupuis et al. 2002; 
Schrøder et al. 2001). The binding site of ICA-27283 is in the S1-S4 voltage sensor 
domain rather than the pore domain in S5-S6 segment as observed with other non-
selective Kv7 channel openers (Padilla et al. 2009). The experiments described in this 
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dissertation utilize the prototypic commonly used Kv7 channel activators- flupirtine, 
retigabine and the inhibitor- XE991 at concentrations selective for Kv7 channels.  
 
Kv7 channels as therapeutic targets 
With increasing recognition that a number of human diseases involve alterations 
in Kv7 channel function, a variety of pharmacological modulators were developed to 
target Kv7 channels in the nervous system (Dalby-Brown et al. 2006). Flupirtine has 
been used for almost 3 decades in Europe as an analgesic with muscle relaxing properties 
to treat cancer, postoperative or traumatic pain without developing tolerance (Miceli et al. 
2008). The more potent analog of flupirtine, retigabine is likely to become available to 
treat partial onset seizures in adults (Gunthorpe et al. 2012; Harris and Murphy 2011). 
ICA-27283 is under development to treat cortical spreading depression associated with 
migrane (Wu et al. 2003). Kv7 channel openers also hold promise to treat other diseases 
with disorders of excessive excitability such as anxiety (Korsgaard et al. 2005), 
neuropathic pain, cognitive disorders, urinary incontinence (Wickenden et al. 2004), 
Alzheimer’s disease and stroke (Czuczwar et al. 2010). 
 
Kv7 channels in vascular smooth muscle cells 
The first evidence of existence of Kv7 channels in VSMCs was provided by Ohya 
et al., who showed the expression of KCNQ1 transcripts in murine portal vein myocytes. 
They demonstrated a linopirdine-sensitive outwardly rectifying K+ current in the presence 
of 5 mM 4-aminopyridine (Ohya et al. 2003). The contribution of Kv7 channels to 
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membrane voltage in the myocytes was demonstrated in a follow up study from the same 
laboratory. Kv7 channel blockers, linopirdine and XE991 depolarized the membrane and 
augmented the spontaneous contractile responses in the portal vein (Yeung and 
Greenwood 2005). Using an analytical subtraction method the authors distinguished the 
voltage-step evoked currents through Kv7 channels from 4AP-sensitive Kv currents 
(Yeung and Greenwood 2005). Another major advancement was made by Brueggemann 
et al., who isolated Kv7 currents in cultured rat embryonic aortic smooth muscle (A7r5) 
cells and demonstrated the expression of KCNQ5 mRNA transcripts in both rat aortic 
smooth muscle cells and A7r5 cells, but KCNQ1 transcripts only in rat aortic smooth 
muscle cells and not in A7r5 cells (Brueggemann et al. 2007). Since then several studies 
have demonstrated the expression of KCNQ channels in different vascular beds, 
mesenteric, carotid, pulmonary, cerebral, femoral artery and aorta showing a consensus in 
the expression of KCNQ1, KCNQ4 and KCNQ5 mRNA transcripts with little or no 
expression of KCNQ2 and 3 (Zhong et al. 2010; Joshi et al. 2009; Mackie et al. 2008; 
Yeung et al. 2007).  
A pivotal role of vascular Kv7 channels in the pulmonary arterial system was 
demonstrated by a concentration-dependent constriction of rat intrapulmonary artery by 
the Kv7 channel blockers, independent of endothelium or neuronal intervention (Joshi et 
al. 2006). The constriction produced was dependent on activation of voltage-sensitive 
Ca2+ channels (Joshi et al. 2006) as a corollary to the membrane depolarization of 
pulmonary artery myocytes induced by Kv7 channel blockers (Joshi et al. 2009).  
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The expression and function of the Kv7 channels in human arteries were found to be 
similar to the rodent models validating the role of Kv7 channels in regulating vascular 
contractility in humans (Ng et al. 2011). Kv7.1 channels, whose expression was earlier 
thought to be restricted to heart was found to be expressed in all rodent and human 
vascular myocytes studied so far. However, K+ channels formed by Kv7.1 subunits are 
not likely important contributors to regulation of vascular reactivity. The conclusions are 
based on the ability of retigabine and acrylamide S1 to dilate the pre-constricted rodent or 
human arteries and the inability of selective Kv7.1 channel blockers, chromanol 293B, L-
768673 to constrict rodent or human arteries (Joshi et al. 2009; Mackie et al. 2008; 
Yeung et al. 2007; Yeung et al. 2007; Ng et al. 2011; Ng et al. 2011). Although channels 
formed by Kv7.1 subunits do not appear to contribute to the resting vascular tone, 
selective activation of these channels dilated pre-constricted arteries indicating that these 
channels may function in VSMCs under some conditions (Chadha et al. 2012). 
The outwardly rectifying currents conducted through Kv7 channels isolated from 
A7r5 cells and mesenteric artery myocytes showed a threshold for voltage-dependent 
activation negative to -60 mV (Brueggemann et al. 2007; Mackie et al. 2008). Thus, Kv7 
channels activate at resting membrane voltages, negative to the threshold for activation of 
the voltage-sensitive Ca2+ channels (~-40 mV), providing a hyperpolarizing influence that 
will tend to oppose the activation of VSCC. Kv7.5 channels are the only subtype of 
channels present in A7r5 cells (Brueggemann et al. 2007). Knockdown of the channels 
using an adenoviral vector expressing KCNQ5 short hairpin(sh)-RNA induced persistent 
membrane depolarization, triggering repetitive spontaneous Ca2+ spiking in A7r5 cells 
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(Mani et al. 2009); Figure 1). The Ca2+ spiking responses observed in A7r5 cells were 
dependent on membrane depolarization and activation of VSCC (Byron and Taylor 
1993). Hence K+ current through Kv7 channels acts as a physiological “sub-threshold 
brake” in regulating Ca2+ entry through VSCC and thereby determining the contractile 
status of VSMCs (Figure 2). The very negative threshold for voltage-dependent 
activation distinguishes Kv7 channels from other voltage-sensitive K+ channels 
previously proposed to regulate vascular tone. These distinct properties of Kv7 channels 
may also enable them to serve as regulators of excitation of VSMCs.  
Suppression of Kv7 channel activity has been proposed as a mechanism by which 
the vasoconstrictor hormone vasopressin induces its physiological constrictor effects 
(Brueggemann et al. 2007; Mackie et al. 2008). The suppression of Kv7 currents by 
vasopressin was dependent on protein kinase C activation (Brueggemann et al. 2007; 
Mackie et al. 2008), a common signal transduction intermediate of Gq/11-coupled-receptor 
activation. Activation of protein kinase A has been shown to enhance the activity of 
certain Kv7 channel subtypes in expression system (Schroeder et al. 1998; Chambard and 
Ashmore 2005). If this is true in VSMCs, it is likely to induce vasodilation, for example 
in response to activation of Gs-coupled β-adrenergic receptors. Kv7 channels are 
therefore well placed to function as common signal transduction effectors to regulate 
vascular tone in response to vasoconstrictors/dilators. The roles of signal transduction 
intermediaries including PIP2 or Ca2+-calmodulin in regulating Kv7 channels in VSMCs 
remain to be tested. 
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Figure 1: Knockdown of Kv7.5 channel depolarizes the membrane and induces Ca2+ 
spiking response in A7r5 cells. A. Effect of Kv7.5 channel knock down on membrane 
voltage measured in single cells using patch-clamp technique. Knockdown of Kv7.5 
channels by expression of KCNQ5 shRNA was confirmed by immunofluorescence and 
abolishment of Kv7 currents (not shown). *Significant difference in membrane voltage 
between control cells (n=6) and cells expressing KCNQ5shRNA (n=9) using Student’s 
“t” test, p<0.005. B. Representative charts show Ca2+ spiking in control A7r5 cells, cells 
expressing KCNQ5 shRNA or scrambled shRNA, measured using Ca2+ binding Fura-2 
florescent dye. [Reproduced from Mani BK et al., Cell Calcium, 2009; 45(4): 400-11].  
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Figure 2: Kv7 channels act as a sub-threshold brake to prevent activation of 
voltage-sensitive Ca2+ channels. Outward K+ conductance through Kv7 channels 
(yellow color) maintains the membrane voltage (Vm) negative to the threshold for 
activation of VSCC (red color) in vascular smooth muscle cells (VSMCs; top left). 
Current-voltage (I-V) relationship (right) shows the activation of Kv7 currents (yellow 
line)  at voltages around the resting Vm (rectangular column). Kv7 currents maintain Vm 
negative to the threshold (~-40 mV) for activation of voltage-sensitive Ca2+ currents 
(broken red line).  Inhibition of the Kv7 currents depolarizes the membrane to voltages 
more positive to -40 mV, activating the steeply voltage-dependent VSCC to allow Ca2+ 
influx and the ensuing contraction of VSMCs (bottom left).  [Reproduced from Mani BK 
and Byron KL., British Journal of Pharmacology, 2011; 162: 38-41]. 
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Cardiovascular effects of cyclooxygenase inhibitors  
Cyclooxygenase (COX)-2 inhibitors 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed drugs 
to treat inflammation and pain. NSAIDs exert their anti-inflammatory effect by blocking 
cyclooxygenase enzymes. These enzymes catalyze the biotransformation of arachidonic 
acid to prostaglandin endoperoxide intermediates PGG2 and PGH2. These intermediates 
are then converted to a variety of prostanoids including prostaglandins, thromboxanes, 
and prostacyclins by action of isomerases and synthases. After purification of 
cyclooxygenase-1 (COX-1) several years ago (Hemler and Lands 1976), a second 
isoform of the enzyme (COX 2) was discovered (Fletcher et al. 1992; Xie et al. 1991) 
with a distinct expression and distribution pattern (Willoughby et al. 2000). COX-1 was 
recognized as a constitutive form of the enzyme, and COX-2 as an inducible isoform that 
catalyzes the production of prostaglandins involved in inflammation and cancer (Grosser 
et al. 2006). It is appreciated that labeling COX-1 as “constitutive” and COX-2 as 
“inducible” form is an oversimplification. However, it is more certain that COX-2 is the 
predominant form elaborated during inflammatory responses (FitzGerald and Patrono 
2001).  
An approach called the “COX-2 hypothesis” lead to selective targeting of the 
COX-2 isoform to treat inflammation and pain. The concept gained traction in an effort 
to avoid the adverse gastrointestinal intolerance associated with COX-1 inhibition. The 
gastrointestinal complication associated with COX-1 inhibition was thought to be due to 
the reduced COX-1 derived PGE2 and PGI2 in gastrointestinal epithelium that protects 
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the mucosa from acid irritation. Though there is some evidence that constitutive actions 
of COX-2 are also involved in the mucosal inflammation and ulcer healing, the 
incidences of GI complications were fewer with COX-2 selective inhibitors compared to 
the non-selective COX inhibitors. Three selective COX-2 inhibitors, celecoxib 
(CelebrexTM, Pfizer, New York, NY), rofecoxib (VioxxTM, Merck, Whitehouse station, 
NJ) and valdecoxib (BextraTM, Pfizer, New York, NY) were approved within a short span 
between 1998 and 2001, based on data from small short-term clinical studies (Psaty and 
Furberg 2005). 
 
Cardiovascular risk with COX-2 inhibitors 
After only a few years into the market, rofecoxib and valdecoxib were withdrawn 
(in 2004 and 2005 respectively) due to observations of an increased incidence of 
myocardial infarction and stroke with prolonged use. However, celecoxib along with 
other “traditional” non-selective COX inhibitors continue to be available to treat 
inflammatory pain, but they are marketed with a “black box” warning to highlight the 
small risk of myocardial infarction and stroke associated with these classes of drug 
(Grosser et al. 2006). The increased cardiovascular risk with use of selective COX-2 
inhibitors has been proposed to be due to increase in synthesis of thromboxane A2, a 
potent platelet activator and vasoconstrictor and reduction in the synthesis of vasodilatory 
and antiaggregatory prostacyclins (Mukherjee et al. 2001).  
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Divergence in cardiovascular risk profile among COX-2 inhibitors 
A systematic review and meta-analysis of controlled observational studies 
revealed a dose-related cardiovascular risk with rofecoxib and diclofenac (another 
NSAID, that was found to have COX-2/COX-1 selectivity similar to celecoxib), but not 
with celecoxib at commonly used doses (Juni et al. 2004; McGettigan and Henry 2006; 
Zhang et al. 2006). The heterogeneity in the risk profile despite belonging to the same 
class of drugs remains poorly understood. The divergence was attributed to differences in 
pharmacokinetic and pharmacodynamic properties, altered metabolism, inhibition of 
carbonic anhydrase and ensuing diuresis (FitzGerald and Patrono 2001; Aw et al. 2005; 
Knudsen et al. 2004; Weber et al. 2004). A meta-analysis of nineteen randomized 
controlled trials involving 45,451 participants revealed an increase in blood pressure with 
COX-2 inhibitors (Aw et al. 2005). A consistently greater increase in systolic and 
diastolic blood pressure was observed with rofecoxib in head-to-head trials vs celecoxib, 
consistent with the increased cardiovascular risk observed with rofecoxib (Aw et al. 
2005; Whelton et al. 2001; Whelton et al. 2002). A disproportionate rise was observed in 
systolic blood pressure, widening the pulse pressure with rofecoxib. A steep relationship 
observed between systolic BP and incidence of cardiovascular complications in the 
Framingham study (Kannel 2000a; Kannel 2000b) indicates that the change in blood 
pressure could be a single large risk factor responsible for the increased incidence of 
cardiovascular events associated with rofecoxib.  
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Vasodilatory effects of celecoxib 
Several recent studies demonstrated vasodilatory effects of celecoxib, but not 
rofecoxib (Hermann et al. 2003; Klein et al. 2007; Widlansky et al. 2003) indicative of a 
vasodilatory compensatory mechanism associated only with celecoxib opposing the 
COX-2 mediated increase in blood pressure. The vasodilatory effect of celecoxib in 
humans was dependent on the endothelial function (Widlansky et al. 2003; Chenevard et 
al. 2003). Using guinea pig coronary artery and aortic rings, Klein et al., suggested that 
phosphodiesterase (PDE) 5 enzyme inhibition and amplification of endothelium-
dependent nitric oxide/ cyclic-guanosine monophosphate (cGMP) signaling as a 
mechanism for the vasodilatory effects of celecoxib (Klein et al. 2007). The study also 
revealed that celecoxib, but not rofecoxib inhibited PDE isoforms 4 and 5 in VSMCs at 
low micromolar concentrations. A recent study from our laboratory provided evidence 
that celecoxib dilated rat mesenteric artery independently of endothelial actions by 
activation of Kv7 channels and inhibition of VSCC in arterial myocytes (Brueggemann et 
al. 2009). It remains to be seen if the ion channel modulatory effects of celecoxib is due 
to inhibition of the PDE enzymes. 
 
Vascular effects of phosphodiesterase enzyme inhibition 
Phosphodiesterase enzymes 
Phosphodiesterases are isoenzymes that cleave the phosphodiester bond in the 
second messenger molecules cAMP and cGMP. Based on the amino acid sequence, the 
overall domain structure, catalytic and regulatory characteristics, 11 distinct PDE enzyme 
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families (PDE1-11) are known to exist (Omori and Kotera 2007). The PDE enzymes 
differ considerably in their substrate specificity. The cAMP-specific enzymes include 
PDE4, 7 and 8; the cGMP-specific enzymes include PDE 5, 6 and 9, while PDE1, 2, 3, 
10 and 11 cleave both cAMP and cGMP (Omori and Kotera 2007; Maurice et al. 2003). 
cAMP and cGMP are key components of intracellular signaling regulating numerous 
cellular functions including metabolism, contractility, motility and transcription in almost 
all cells including VSMCs (Maurice et al. 2003; Antoni 2000; Klein 2002). Modulation 
of PDE enzyme activity is therefore expected to influence a myriad of cell signaling 
pathways in diverse cell systems. The relative expression of the isoenzymes across cell 
types confer some selectivity to target specific systems.  
 
Vasodilatory effects of phosphodiesterase enzyme inhibition 
Of the known PDE isoforms, PDE1, PDE3, PDE4 and PDE 5 are the predominant 
enzyme families expressed in VSMCs (Polson and Strada 1996; Rybalkin et al. 2003). 
PDE4 and PDE5 are targeted pharmacologically to treat several clinical conditions. PDE4 
inhibitors (eg. rolipram, rofulimilast) are used to treat asthma and chronic obstructive 
pulmonary disease (O'Byrne and Gauvreau 2009). PDE5 inhibitors (eg. Sildenafil, 
tadafil) are used to treat erectile dysfunction and pulmonary hypertension (Arif and Poon 
2011; Sandner et al. 2007). A common observation with the inhibition of PDE4 and 5 
isoenzymes is a slight reduction in blood pressure owing to its ability to dilate arteries 
(Jackson et al. 1999; Kloner 2004; Reffelmann and Kloner 2005; Webb et al. 1999). The 
signal transduction mechanisms that lead to relaxation of VSMCs in the arteries (Atalay 
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et al. 2006; Gokce et al. 2010; Han et al. 2012; Inoha et al. 2002; Khajavi et al. 1997; 
Nishiguchi et al. 2010) are not clearly understood. Activation of K+ channels and 
blocking of Ca2+ currents have been proposed as a mechanism of relaxation induced by 
PDE inhibitors, with activation BK currents shown to contribute at least in part to the 
enhanced K+ conductance (Bardou et al. 2002; Fellner and Arendshorst 2010; Prieto et al. 
2006; Salom et al. 2008).  
 
Cerebral vasospasm and phosphodiesterase enzymes 
Several studies have proposed inhibition of PDE5 or PDE3 by using milrinone or 
sildenafil respectively as an effective therapeutic strategy to treat cerebral vasospasm 
(Atalay et al. 2006; Gokce et al. 2010; Han et al. 2012; Inoha et al. 2002; Khajavi et al. 
1997; Nishiguchi et al. 2010). Vasospastic basilar artery isolated from SAH dogs showed 
robust increased expression of PDE5 isoenzyme compared to control non-spastic arteries 
(Inoha et al. 2002). Milrinone, a selective inhibitor of PDE3 that hydrolyses both cAMP 
and cGMP has been shown to attenuate cerebral vasospasm in human subjects (Arakawa 
et al. 2001; Arakawa et al. 2004; Fraticelli et al. 2008; Shankar et al. 2011). Knowledge 
of downstream targets, ion channels in particular that regulate the contractile response 
mechanisms can facilitate identification of pharmacological targets to attenuate cerebral 
vasospasm.  
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CHAPTER 3 
RESEARCH OBJECTIVES AND RATIONALE 
Significance of the project: The project aims to identify the functional existence of Kv7 
channels in basilar artery myocytes. Identification of the function of these channels is 
expected to reveal the mechanism(s) involved in the pathogenesis of vasospasm and 
potentially identify therapeutic targets to treat cerebral vasospasm. 
 
Main hypothesis: Suppression of Kv7 currents by spasmogens is a central phenomenon 
in basilar artery vasospasm after SAH; direct Kv7 channel openers will reverse basilar 
artery spasm (Figure 3).   
The hypothesis was tested by pursuing the following specific aims.  
 
Specific aim 1: To record Kv7 currents from freshly isolated rat basilar artery myocytes 
and to determine whether spasmogens – ET-1, 5-HT, and AVP suppress Kv7 currents 
using whole cell electrophysiology.  
Rationale: Previous studies identified membrane depolarization and Ca2+ influx 
through VSCC in myocytes as the primary mechanism for elevation of [Ca2+]c in 
vasospastic arteries. Outward currents through Kv7 channels, as shown in neurons and 
mesenteric artery myocytes, stabilize membrane voltage of excitable cells. The existence 
and possible involvement of the Kv7 channels in membrane voltage regulation in basilar  
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Figure 3: Hypothetical role of Kv7 channels in the pathogenesis of basilar artery 
vasospasm. We hypothesize that Kv7 (KCNQ) channels are expressed in basilar artery 
myocytes and function to maintain the resting membrane potential. Spasmogens elevated 
in response to SAH bind to cell-surface receptors to suppress Kv7 currents through a 
signal transduction mediated mechanism. Suppression of Kv7 currents induces membrane 
depolarization (ΔVm), which activates voltage-sensitive Ca2+ channels (VSCC) leading to 
continuous influx of Ca2+ resulting in vasospasm. Direct Kv7 channel activators may be 
able to oppose the actions of spasmogens to relieve the vasospasm. 
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artery myocytes will help to elucidate the mechanisms involved in development of  
vasospasm. Knowledge of the ability of Kv7 channel openers to reverse the spasmogen-
induced suppression of currents will provide evidence at the cellular level about the 
feasibility of Kv7 channel openers to reverse vasospasm. Apart from utilizing selective 
Kv7 channel openers, the study also utilized celecoxib, a recently reported dual Kv7 
channel opener and VSCC blocker. The drug was tested as a possible therapeutic agent to 
relieve vasospasm, as it is expected to be more effective because of its dual ion channel 
modulatory action.  
PKC is a common signal transduction intermediate in the constriction induced by 
spasmogens. Activation of PKC in myocytes derived from vasospastic myocytes is 
reported in several studies. Hence, experiments were undertaken to test if activated PKC 
suppresses Kv7 currents. 
Experiments: Sprague-Dawley rats were used as a model to test our hypothesis. 
Myocytes derived from basilar artery, one of the major conduit arteries in the base of 
brain, which undergoes vasospasm after SAH were used in the studies. Single-cell patch-
clamp electrophysiology techniques were utilized to isolate and identify Kv7 currents and 
to test their role in regulating membrane voltage in rat basilar artery myocytes. The 
following experiments tested our hypothesis at a cellular level: 
(1) Isolation and identification of Kv7 currents based on biophysical characteristics and 
their modulation by selective Kv7 channel modulators. 
(2) Sensitivities of Kv7 currents to spasmogens involved in vasospasm were examined. 
(3) Effects of Kv7 channel blockers and spasmogens on membrane voltage were tested. 
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(4) Abilities of direct Kv7 channel openers to reverse the spasmogen-induced 
suppression of Kv7 currents and membrane depolarization in basilar artery 
myocytes was tested. 
(5) Effect of celecoxib on Kv7 currents and voltage-sensitive Ca2+ currents in basilar 
artery myocytes was examined. 
(6) The effect of PKC activation on Kv7 currents was tested.  
Specific aim 2: To evaluate the ability of Kv7 channel opener(s) to reverse/prevent the 
vasoconstriction induced by spasmogens in pressurized rat basilar arteries. 
Rationale: We hypothesize that the potent constrictor actions of spasmogens on 
basilar artery are mediated by suppression of Kv7 currents, membrane depolarization and 
activation of VSCC. Selective small molecule activators of Kv7 channels should hence 
be able to reverse the constriction induced by spasmogens. The electrophysiology 
experiments described in aim 1 tested our hypothesis at the level of individual myocytes, 
whereas the experiments proposed in this aim examined if these cellular mechanisms are 
integrated to induce functional basilar artery constriction/dilation.  
Experiments: Pressure myography was used to examine the role of Kv7 channels on 
the contractile status of basilar artery. The following experiments tested our hypothesis at 
the organ level: 
(1) The effect of a Kv7 channel blocker on the contractile status of basilar artery was 
examined. 
(2) We hypothesized that vasoconstriction induced by spasmogens involve Kv7 current 
suppression and Ca2+ influx through VSCC. Therefore, additivity experiments were 
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performed to reveal whether spasmogen-induced constriction involves suppression 
of Kv7 currents. 
(3) The ability of selective Kv7 channel openers− flupirtine and/or retigabine, VSCC 
blocker− nimodipine and dual Kv7 channel opener and VSCC blocker− celecoxib 
to reverse/prevent spasmogen-induced constriction were tested. 
(4) The ability of PKC activators to constrict basilar artery segments was investigated. 
 
Specific aim 3: Evaluate the ability of Kv7 channel openers to attenuate basilar artery 
vasospasm in a rat model of SAH.  
Rationale: We hypothesize that consequent to SAH, suppression of Kv7 currents in 
basilar artery myocytes by elevated concentrations of spasmogens in cerebrospinal fluid 
is a basic pathology in vasospasm. Hence, administration of Kv7 channel openers is 
expected to overcome Kv7 current suppression and attenuate vasospasm after SAH. 
Sustained hypotension may limit the utility of K+ channel openers or CCBs in the 
effective treatment of cerebral vasospasm. Therefore, the effect of Kv7 channel openers 
on mean arterial pressure (MAP) was measured in normal rats. 
Experiments:  
(1) SAH was experimentally induced in rats by injection of autologous blood into the 
rat's cisterna magna to simulate the presence of blood after SAH. SAH rats were 
administered either the Kv7 channel opener− retigabine or dual Kv7 channel opener 
and VSCC blocker− celecoxib after hemorrhage. The ability of Kv7 channel 
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openers to attenuate vasospasm was assessed by measurement of basilar artery 
diameter 48 hours after hemorrhage. 
(2) The effect of Kv7 channel openers on MAP was measured in normal rats using 
radiotelemetry. The dosage schedule for MAP measurements mimicked the drug 
administration in the diseased animal model. 
 
Specific aim 4: To identify the mechanism by which celecoxib induces ion channel 
modulatory activity.   
Rationale: Celecoxib is clinically utilized as a COX-2 inhibitor to treat 
inflammation and pain. Celecoxib is a unique COX-2 inhibitor that induces vasodilation 
and a modest reduction in blood pressure whereas other drugs that belong to the same 
class have a tendency to increase blood pressure. We presented evidence that celexocib-
induced Kv7 current enhancement and voltage-sensitive Ca2+ current inhibition could 
account for the anti-hypertensive effects of celecoxib. Celecoxib was reported to inhibit 
phosphodiesterase (PDE) enzyme isoforms 4 and 5 in VSMCs, physiologically critical 
targets among the several other known non-specific molecular targets of celecoxib. 
Therefore, we tested if celecoxib induces its ion channel modulatory effect by virtue of 
phosphodiesterase enzyme inhibition. These experiments therefore are also expected to 
reveal if activation of Kv7 channels is the mechanism by which several clinically 
employed PDE inhibitors induce vasodilation and modest reductions in blood pressure. 
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Experiments:  
(1) Determine the effect of clinically utilized PDE inhibitors− rolipram (prototype 
PDE4 inhibitor), sildenafil (prototype PDE5 inhibitor), papaverine (non-selective 
PDE inhibitor) on Kv7 currents in rat aortic smooth muscle (A7r5) cells. 
(2) Determine if PDE inhibitors also mimic the effect of celecoxib as a voltage-
sensitive Ca2+ channel blocker were also tested using A7r5 cells. 
(3) Determine the effect of the PDE inhibitors on AVP-induced Ca2+ entry, measured in 
fura-2 loaded A7r5 cells. 
(4) Determine the effect of PDE inhibition on mesenteric artery segments pre-
constricted with AVP to validate the dilation induced by PDE inhibitors. 
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CHAPTER 4 
MATERIALS AND METHODS 
 
Animal Welfare and Housing 
All animals used in the study were purchased from Harlan laboratories, 
Indianapolis, Indiana. Animals were housed in pairs in standard plexiglass cages, fed 
with standard rat chow under 12 hours dark-light cycle. All procedures described in this 
study were approved by the Institutional Animal Care and Use Committee, Loyola 
University Medical Center, Maywood, IL and were carried out according to the 
guidelines for animal welfare (Guide for the Care and Use of laboratory Animals, 
National Research Council, National Academy press, Washington D.C, Rev. 1996).  
 
Basilar artery dissection 
Male Sprague-Dawley rats, 275-325g, were euthanized by cardiac extirpation 
(surgical removal of heart) under 4% isoflurane anesthesia. The brain was removed 
immediately and placed in ice-cold dissection solution (in mM - 145 NaCl, 4.7 KCl, 1.2 
NaH2PO4, 1.2 MgSO4, 2 CaCl2·2H2O, 2 pyruvic acid, 0.02 EDTA dihydrate, 3 MOPS, 
and 5 D-glucose with 1% bovine serum albumin (BSA), pH 7.4 at 0° C, osmolarity 
adjusted to 300 mOsm/L using D-glucose). The basilar artery was dissected free from the  
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brain and used for isolation of myocytes for patch-clamp procedures, polymerase chain 
reaction (PCR) or pressure myography. 
 
Isolation of basilar artery myocytes 
Myocytes were isolated from the basilar artery by modifying the procedure 
described by Berra-Romani et al. for mesenteric artery myocytes (Berra-Romani et al. 
2005). The dissected basilar artery was cut into 2 or 3 segments and placed in low-Ca2+ 
physiological saline solution (low-Ca2+ PSS, in mM): 140 NaCl, 5.36 KCl, 0.34 
Na2HPO4, 0.44 K2HPO4, 10 HEPES, 1.2 MgCl2, 0.05 CaCl2, and 10 D-glucose, pH 
adjusted to 7.2 at 37°C using NaOH, osmolarity adjusted to 298 mOsm/L using D-
glucose) for 30 min. The arterial segments were then subjected to enzymatic digestion in 
low-Ca2+ PSS containing (in mg/ml) 2 collagenase type XI; 0.16 elastase type IV , and 2 
BSA (fraction V, protease-free) at 37°C for 30 min. The digested segments were 
repeatedly washed with ice-cold low-Ca2+ PSS to remove the enzymes and then the 
individual myocytes or clusters of myocytes were released from the segments by 
trituration using fire-polished Pasteur pipettes.  
 
Polymerase chain reaction 
Reverse transcription polymerase chain reaction (PCR) was used to detect the 
KCNQ gene products (Kv7 channel mRNA transcripts). Myocytes were freshly isolated 
from basilar artery segments by enzymatic digestion and total RNA was isolated using 
RNeasy Kit (Qiagen, Valencia, CA). PCR was performed essentially as described 
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previously (Brueggemann et al. 2007). cDNA was synthesized with iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA), and then one-tenth of the cDNA product was used 
for PCR. PCR was carried out using Platinum PCR Supermix (Invitrogen) and 10 pmols 
of forward and reverse primers at the appropriate annealing temperature (dependent on 
primer pair). Primers were adapted from previous publications: KCNQ1–3 and KCNQ5 
(Ohya et al. 2002) and KCNQ4 (Yeung et al. 2007) to correspond to rat sequences (Table 
1). 
 
Electrophysiology 
Freshly isolated myocytes or A7r5 cells were allowed to attach to glass coverslips 
for 10-15 minutes at room temperature or at 37°C respectively. Whole-cell currents or 
membrane voltage were measured by using perforated patch configuration (120 μg/ml 
Amphotericin B was included in the internal solution) under voltage-clamp or current-
clamp conditions. All measurements were made with continuous perfusion of bath 
solution at room temperature. 
(A) Kv7 currents in basilar artery myocytes: Whole cell Kv7 currents were 
recorded from basilar artery myocytes as described previously (Mackie et al. 2008; 
Brueggemann et al. 2009). Bath solution contained (in mM): 140 NaCl, 5.36 KCl, 1.2 
MgCl2, 2 CaCl2, 10 HEPES, 10 D-glucose. Bath solution pH and osmolarity was adjusted 
to 7.3 and 298 mOsm/L using NaOH and D-glucose respectively. Internal (pipette) 
solution contained (in mM): 135 KCl, 5 NaCl, 10 HEPES, 0.05 K2EGTA, 1 MgCl2, 20 
D-glucose. Internal solution pH and osmolarity was adjusted to 7.2 and 298 mOsm/L 
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using KOH and D-glucose respectively. Currents were recorded by application of 5 s 
voltage steps from a -4 mV holding voltage to test voltages ranging from -84 mV to +16 
mV. Gadolinium chloride (GdCl3; 100 μM) and spermine (100 µM; to inhibit the 
inwardly-rectifying K+ currents) were included to the bath solution. Apart from blocking 
L- and T-type Ca2+ channels (Beedle et al. 2002; Biagi and Enyeart 1990) and non-
selective cation channels (Miyoshi et al. 2004; Setoguchi et al. 1997; Zhang et al. 2000), 
Gd3+ shifts activation of 4-AP-sensitive KV currents to voltages positive to -20 mV 
(Figure 4) enabling isolation of Kv7 currents at voltages negative or equal to -20 mV. 
Whole-cell K+ currents were digitized at 2 kHz and filtered at 200 Hz. Whole-cell 
capacitance was compensated. The steady-state K+ currents recorded during the last 1000 
ms (2000 points) of each voltage step were averaged and normalized to cell capacitance 
to obtain the current-voltage (I-V) relationship. In experiments with variations in current 
density, I-V relationships were derived by normalizing the sustained currents measured at 
each voltage to the mean current measured at -20 mV before treatment. Time-course of 
enhancement or inhibition of isolated Kv7 currents was recorded by continuous 
measurement of outward currents at -20 mV holding potential. 
(B) Membrane voltage measurements in basilar artery myocytes: Membrane 
voltages were recorded from individual myocytes or clusters of myocytes in current 
clamp (I = 0) mode. The bath solution and the internal solution were the same as used to 
record Kv7 currents, but performed in the absence of GdCl3 and spermine. Membrane 
voltage was recorded for at least 5 min before treatment. The effect of treatment on 
membrane 
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Figure 4: Addition of gadolinium enables isolation of Kv7 currents. A. Current-
voltage curves show response of 4-AP-sensitive Kv currents to the addition of 100 µM 
Gd3+. B. Normalized conductance plots of 4-AP-sensitive-Kv currents fitted by a single 
Boltzmann function shows positive shift in activation of the currents with the addition of 
Gd3+ (half maximal activation of currents is shifted by approximately 15 mV, n=3). This 
enabled isolation of Kv7 currents at voltages ≤ -20 mV, without contribution from 4-AP-
sensitive Kv currents. [Reproduced from Mani BK et al., British Journal of 
Pharmacology, 2011; 164: 237-249]. 
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membrane voltage was determined by taking the mean of the values recorded over at 
least a 1 min period, prior to treatment, and at the end of treatment. 
  (C) Voltage-sensitive calcium currents in basilar artery myocytes: To record 
currents through voltage-sensitive Ca2+ channels in basilar artery myocytes, 10 mM Ba2+ 
was used as a charge carrier. Inclusion of Ba2+ as a charge carrier is routinely used in 
patch-clamp experiments to measure voltage-sensitive Ca2+ currents for two reasons: (i) 
switching from Ca2+ to Ba2+  as the charge carrier changes the rapidly inactivating 
currents to a more slowly inactivating and larger currents, (ii) use of Ba2+  as charge 
carrier avoids entry of Ca2+, which would activate the contractile apparatus and constrict 
the myocytes. The bath solution contained (in mM): 140 NaCl, 2.7 KCl, 10 BaCl2, 10 
HEPES. Bath solution pH and osmolarity was adjusted to 7.3 and 298 mOsm/L using 
NaOH and D-glucose or water respectively. Internal solution contained (in mM): 135 
CsCl, 10 HEPES, 10 Cs2EGTA, 2.5 MgCl2, 10 D-glucose. Internal solution pH and 
osmolarity was adjusted to 7.2 and 298 mOsm/L using CsOH and D-glucose respectively. 
Whole-cell capacitance was compensated. Ba2+ currents were recorded in isolation by 
application of a 300 ms voltage step protocol from -90 mV holding voltage to test 
voltages ranging from -85.2 to +44.8 mV. Whole-cell voltage-sensitive Ba2+ currents 
were digitized at 10 kHz and filtered at 5 kHz and the peak inward current was measured 
and normalized to cell capacitance.  
(D) Kv7 currents in A7r5 cells: Whole-cell Kv7 K+ currents were recorded in 
A7r5 cells, essentially as described previously (Brueggemann et al 2009). The standard 
bath solution contained (in mM): 5 KCl, 130 NaCl, 10 HEPES, 2 CaCl2, 1.2 MgCl2, 5 D-
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glucose. Bath solution pH and osmolarity was adjusted to 7.3 and 268-270 mOsm/L 
using NaOH and D-glucose respectively. Standard internal (pipette) solution contained 
(in mM): 110 K gluconate, 30 KCl, 5 HEPES, 1 K2EGTA. Internal solution pH and 
osmolarity was adjusted to 7.2 and 268-270 mOsm/L using KOH and D-glucose 
respectively. GdCl3 (100 μM) was added to external solution to isolate Kv7 currents. The 
currents were recorded using a 5 s voltage steps from a -74 mV holding potential to test 
potentials ranging from -94 mV to +36 mV. Whole-cell capacitance was compensated. 
Whole-cell K+ currents were digitized at 2 kHz and filtered at 200 Hz. The last 2000 
points recorded during each voltage step (corresponding to 1000 ms recording time) were 
averaged and normalized by cell capacitance to obtain end pulse steady-state K+ current 
for each voltage step. In experiments with variations in current density, I-V relationships 
were derived by normalizing the sustained currents measured at each voltage to the mean 
current measured at -20 mV before treatment. Time course of changes in isolated Kv7 
currents with treatment were recorded by continuous measurement of outward current at -
20 mV holding potential.  
(E) Voltage-sensitive calcium currents in A7r5 cells: To record voltage-sensitive 
Ca2+ currents in isolation in A7r5 cells, a Cs+-containing internal solution was used (in 
mM): 110 Cs aspartate, 30 CsCl, 5 HEPES, 1 Cs2EGTA, pH 7.2. Internal solution pH and 
osmolarity was adjusted to 7.2 and 268 mOsm/L using CsOH and D-glucose respectively. 
Voltage sensitive Ca2+ currents were recorded using 10 mM Ba2+ as a charge carrier (in 
mM): 120 Tris-MES, 10 BaCl2, 5 HEPES, 1 MgCl2, pH 7.3, 268 mOsm/L. Isolated Ca2+ 
currents were recorded with a 300 ms voltage step protocol from -90 mV holding 
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potential. Whole-cell Ca2+ currents were digitized at 10 kHz and filtered at 5 kHz; peak 
inward current was measured and normalized by cell capacitance. In experiments with 
variations in current density, I-V relationships were derived by normalizing the peak 
currents measured at each voltage to the maximal peak inward current measured before 
treatment. 
For all electrophysiology measurements, liquid junction potentials were 
calculated using Junction Potential Calculator provided by PCLAMP8 software and 
subtracted off-line. At least two control recordings were made to ensure that the currents 
were stable before treatment. Current-voltage (I-V) curves for the K+ currents and 
voltage-sensitive Ca2+ currents were derived after leak subtraction using a procedure 
described by Passmore et al. (Passmore et al. 2003). To analyze the voltage-dependence 
of channel activation of Kv7 currents, the conductance was calculated from steady-state 
K+ currents according to the equation G=I/(V-Erev) and normalized by maximum 
conductance for each experiment. In the equation, I is the steady-state current, V is the 
step potential and Erev is the reversal potential (Wickenden et al. 2001). Erev for K+ was 
calculated to be -86 mV using the Nernst equation. Normalized conductance was fitted by 
a Boltzmann distribution: G/Gmax=1/[1+exp(V0.5-V)/s], where G/Gmax is fractional 
maximal conductance, V0.5 is the voltage of half-maximal activation and s is the slope 
factor. 
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[Ca2+]c measurements in A7r5 cells using Fura-2 
Changes in the [Ca2+]c were measured using fura-2/acetoxymethyl ester at room 
temperature as described previously (Mani et al. 2009). A7r5 cells cultured to confluent 
monolayers in six-well plates were washed twice with modified Kreb’s medium (135 mM 
NaCl, 5.9 mM KCl, 1.5 mM CaCl2, 1.2 mM MgCl2, 11.5 mM D-glucose, and 11.6 mM 
HEPES, pH adjusted to 7.3 using NaOH) and then incubated in the same medium with 1 
μM fura-2 acetoxymethyl ester (Invitrogen), 0.1% bovine serum albumin, and 0.02% 
Pluronic F127 detergent for 60 min at room temperature (22–25°C) in the dark. Changes 
in [Ca2+]c with treatment were measured using a Biotek Synergy HT plate reader (340- 
and 380-nm excitation, 510-nm emission) (BioTek Instruments, Winooski, VT). 
Frequency of spiking was calculated as the number of spikes per minute from the time of 
onset of repetitive Ca2+ spiking. Each “n” represents the mean of triplicate wells. 
 
Pressure Myography 
The effects of various treatment conditions on basilar artery diameter were 
studied using a pressure myograph system (DMT-USA, Atlanta, GA) as described 
previously (Henderson and Byron 2007). The pipette contained physiological saline 
solution (in mM - 145 NaCl, 4.7 KCl, 1.2 NaH2PO4, 1.2 MgSO4, 2 CaCl2·2H2O, 2 
pyruvic acid, 0.02 EDTA dihydrate, 3 MOPS, and 5 D-glucose with 1% BSA, pH 7.4 
adjusted at 37°C with NaOH, osmolarity adjusted to 300 mOsm/L with D-glucose) and 
the bath contained the same solution without BSA. The artery segment was transferred to 
the pressure myograph system and secured to the glass pipettes using nylon sutures. By 
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gradually increasing the pressure using a pressure column, the arteries were pressurized 
to 80 mmHg (the pressure that would be expected in the basilar artery in vivo) (Weyer et 
al. 2006a). The bath solution was gradually warmed to 37°C. The viability of the vessel 
was confirmed by observation of a quick constrictor response to the depolarization 
induced by transient application of 60 mM KCl saline solution. The artery segment was 
then allowed to equilibrate and arteries with diameters that were stable for at least 30 min 
were used in the study. Arteries that developed myogenic tone (a decrease in diameter 
coinciding with pressurization to 80 mmHg) or that failed to respond to KCl were 
discarded. The concentration of spasmogens was chosen based on the EC50 
concentrations to constrict basilar artery (Nishimura 1996; Katori et al. 2001; Mayhan 
1998). The vasoconstrictor/vasodilator responses to various treatments were measured 
and the results are presented as changes in outer vessel diameter, in micrometers.  
Pressure myography experiments utilizing mesenteric artery segments were also 
performed similar to the basilar artery pressure myography experiments described above. 
Third or fourth order mesenteric artery segments were utilized for the study.  
 
SAH-induced cerebral vasospasm model 
SAH in humans is produced primarily by the spontaneous rupture of aneurysms 
commonly found in cerebral arteries. The syndrome is not reported in animals, but animal 
models of SAH are developed by introduction of blood into the subarachnoid space. Two 
common methods of introduction of autologous blood are stereotactic injection of blood 
into the cisterna magna or endovascular puncture of cerebral blood vessels (Megyesi et 
75 
 
al. 2000; Titova et al. 2009). While dogs and rabbit were commonly used previously, 
many investigators have recently moved to rat model of SAH for ease of use (Nystoriak 
et al. 2010; Titova et al. 2009; Marbacher et al. 2011).   
In the present study, SAH-induced cerebral vasospasm was induced in rats by 
introduction of blood using a posterior cranio-cervical approach under aseptic conditions. 
Male Sprague-Dawley rats (300- 350g) were used for a single-injection SAH model using 
procedures similar to those described previously (Gules et al. 2002). The left or right 
femoral artery was first cannulated under 3% isoflurane anesthesia. The rat was then 
anesthetized by intramuscular administration of ketamine (80 mg/kg) and xylazine (8 
mg/kg) and secured in a stereotaxic apparatus. A small sub-occipital incision was made to 
expose the arch of the atlas, the occipital bone, and the atlanto-occipital membrane. The 
cisterna magna was tapped to remove 0.1 ml of CSF followed by 2 min slow injection of 
0.3 ml of artificial cerebrospinal fluid (aCSF; solution contained, in mMol/L - 125 NaCl, 
2.5 KCl, 1 MgCl.6H2oO, 1.25 NaH2PO4, 2 CaCl2·2H2O, 25 NaHCO3 and 25 D-glucose, 
pH 7.3 at 37° C, 300 mOsm/L) or autologous blood drawn from the femoral artery. 
Immediately after injection, the hole was sealed with glue to prevent fistula. The animal 
was tilted at a 30º angle for 30 min in a head lowered position to permit distribution of 
blood (or aCSF) in the subarachnoid space. Pain was relieved by subcutaneous injection 
of buprenorphine (0.03 mg/kg). The rats were returned to the cage after suturing the skin 
to allow recovery from anesthesia. Of the 51 rats that underwent the surgery, 13 rats, all 
of which were injected with arterial blood into the cisterna magna, died during the 
surgery. The surviving rats were grouped randomly and treated with intra-peritoneal 
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administration of retigabine (7.5 mg/kg), celecoxib (20 mg/kg) or the solubilizing vehicle 
(DMSO; (1 ml/kg) starting an hr after SAH and repeated twice a day until 48 hr (4 doses 
in total). Doses of retigabine and celecoxib were adopted from the previous studies in 
which the drugs were utilized for their anti-seizure and anti-inflammatory properties, 
respectively (Cuzzocrea et al. 2002; Blackburn-Munro et al. 2005). Two SAH rats, one 
treated with vehicle and the other treated with retigabine, died during the course of 
treatment. Body temperature was measured rectally using a digital thermometer (Warner 
Instruments, CT).  
Body temperature measurements were made every 24 hr after the surgical 
induction of SAH before the impending drug treatment. The neurological endpoints were 
assessed using behavioural tests used in ischemic stroke models (Garcia et al. 1995). The 
functions assessed were spontaneous activity, symmetry in movement of limbs when 
suspended by tail, forepaw out reaching, climbing on a wire cage, body proprioception, 
and response to vibrissae touch. All assessments were conducted by personnel who were 
blinded to the treatments given to the rats. The rats were humanely euthanized with 100% 
CO2 inhalation 48 hr after surgery (or 12 hr after last drug treatment). The brain was 
removed immediately and the basilar artery was photographed using a dinocapture digital 
system (AnMo Electronics Corporation, Taipei, Taiwan). Measurements of the outer 
diameter of the basilar artery were made at 10 places along the length of the basilar 
artery. The measurements were averaged to obtain the basilar artery diameter of each rat 
and expressed in micrometers.  
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Blood pressure measurements 
The catheter tips of previously used Physiotel® PA-C40 or C50-PXT transmitters 
(data Science International, St. Paul, MN) were re-gelled, and the pressure and 
temperature offsets were checked as per the instructions provided by the manufacturer. 
The transmitters were then sterilized using Cidex® OPA solution (0.55% Ortho-
phthalaldehyde), rinsed and stored in saline prior to implantation. Thirteen male Sprague-
Dawley rats (275- 325g) were aseptically implanted with PhysioTel® PA-C40 or C50-
PXT radio-telemetry transmitters (Data Sciences International (DSI), St. Paul, MN) to 
allow continuous recording of blood pressure in freely moving rats. Under 3% isoflurane 
anesthesia, a ventral midline laporatomy was performed and the abdominal contents were 
gently exteriorized into a moist and warm sterile gauze. Blood flow through the 
abdominal aorta was briefly interrupted using a bulldog clamp. The catheter of the radio-
transmitter was inserted through a puncture made posterior to the blockade of blood flow. 
The puncture hole was immediately sealed with medical glue and the blood flow was 
restored. The abdominal contents were placed back into the peritoneal cavity. The 
transmitter body was placed in the cavity and secured with abdominal sutures. Rats were 
administered buprenorphine 0.03 mg/kg s/c and ampicillin 50 mg/kg i/m every 8-12 
hours for 2 days or as needed after surgery. The rats were allowed to recover from 
surgery for 10 days and then distributed into 2 groups such that MAP measured before 
treatment was approximately equal in each group. Blood pressure (mm Hg) was 
measured in each rat for 10 seconds every 10 minutes for 72 hours (Dataquest A.R.T 3.1 
Gold Telemetry System, DSI, with RPC1 receivers). Each group underwent 2 treatments 
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separated by a 72-hour recovery period. The first treatment was control (no treatment) or 
vehicle treatment (DMSO, 1ml/kg i.p, every 12 hours) and the second treatment was 
retigabine (7.5 mg/kg i.p, every 12 hours) or celecoxib (50 mg/kg i.p, every 12 hours). 
Prior to each treatment, baseline blood pressure was recorded for 24 hours. This was 
followed by a 48-hour recording during treatment. Data were exported offline using 
Dataquest ART analysis software (DSI) to a spreadsheet for further analysis. 
 
Data presentation and Statistics 
Data are presented as group mean ± standard error of the mean. Data were 
analyzed using Clampfit (Axon Instruments) and SigmaStat (Systat Software, Inc.) 
software programs. Student's ‘t’ test was used for comparison between 2 groups, 
Student's paired‘t’ tests were used for comparisons of parameters measured before and 
after treatments. Data derived by multiple treatments on the same system were 
statistically compared by using repeated measures analysis of variance (RM-ANOVA) 
followed by Holm-Sidak post hoc test. Comparisons among multiple independent 
treatment groups were evaluated by analysis of variance (ANOVA) followed by Holm-
Sidak post hoc test. Differences with P-value ≤ 0.05 were considered statistically 
significant. 
 
Materials 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) with the 
exception of the following. Amphotericin B and nimodipine were from Calbiochem (San 
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Diego, CA), BSA fraction V was from Boehringer Mannheim (Germany), celecoxib were 
from LKT Laboratories, Inc. (St. Paul, MN), retigabine was from LGM Pharma, Inc. 
(Boca Raton, FL), XE991 was from Ascent Scientific (Princeton, NJ). Drugs were 
prepared as stock solutions in vehicle for patch-clamp and pressure myography 
experiments and used at dilutions between 1:1000 and 1:10,000.  
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Gene Primer (+) sense,  (-) antisense Accession # Amplicon 
KCNQ1 (+) CACATCCAGGGCCGCGTCTA (-) GACTACAGAGCCCAGGAGCC AJ133685 453 bp 
KCNQ2 (+) GATTGCCTCCATTGCTGTGCT (-) ATGAGGGTAACGTCGCTGCTA AF087453 372 bp 
KCNQ3 (+) AACAGCACCGTCAGAAGCACT (-) TAGCCCCTGTCTCTGTCATG AF091247 424 bp 
KCNQ4 (+) GCTCACGGTGGATGATGTCA (-) TGTGGTAGTCCGAGGTGATG XM233477  359 bp 
KCNQ5 (+)CCACCACTCAAAACCGTCATCCGAGCCATCAG (-)TCTCGTGTTCTGCCGTTATTTTCTCTCGGCTCTT XM001071249 240 bp 
 
 
Table 1: Primers used for reverse-transcriptase polymerase chain reaction. Presence 
of KCNQ mRNA was assessed in isolated rat basilar myocytes using the primers listed. 
Positive (+) sequences represent the 5’ to 3’ sense strand and the negative (-) sequences 
represent the 5’ to 3’ antisense strand. 
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CHAPTER 5 
RESULTS 
Expression of KCNQ genes in rat basilar arteries 
Reverse transcriptase-PCR was used to evaluate the gene expression pattern of 
Kv7 channels in basilar artery myocytes. The mRNAs of all five mammalian KCNQ 
genes (KCNQ1-5, encoding Kv7.1-Kv7.5 channels) were detected (Figure 5). 
  
Kv7 currents in basilar artery myocytes 
 To assess the presence of functional channels, Kv7 currents were recorded in 
basilar artery myocytes using patch-clamp electrophysiology under voltage-clamp 
conditions (Figure 6A). Kv7 currents were isolated by using a pharmacological approach 
and by utilizing the distinct biophysical properties of Kv7 currents (activation at very 
negative membrane voltages of around -60 mV, non-inactivation). GdCl3 (100 μM) was 
included to the bath solution to block L- and T-type Ca2+ channels, non-selective cation 
channels, and to shift activation of 4-AP-sensitive KV currents to voltages positive to -20 
mV (Figure 4; (Brueggemann et al. 2012). Outwardly rectifying currents were recorded 
with a threshold for voltage-dependent activation < -60 mV and half-maximal activation 
(V0.5) at ~ -34 mV (Figure 6C and D). Addition of 10 µM flupirtine, a selective Kv7 
channel activator, significantly enhanced the Kv7 currents at all voltages tested from -
49.2 to +5.8 mV; at -20 mV, the voltage at which we observed near-maximal activation, 
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Figure 5: Kv7 channels are expressed in basilar artery myocytes. Reverse 
transcriptase (RT)-PCR detection of KCNQ1 through KCNQ5 from mRNA extracted 
from basilar artery myocytes. Expected sizes of each reaction product are KCNQ1, 453 
bp; KCNQ2, 372 bp; KCNQ3, 424 bp; KCNQ4, 359 bp; and KCNQ5, 240 bp. Molecular 
weight marker (100 base-pair ladder, New England Biolabs, Ipswich, MA., is shown in 
the left lane). The reaction products were confirmed by sequencing. [Reproduced from 
Mani BK et al., British Journal of Pharmacology, 2011; 164: 237-249].  
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Figure 6: Kv7 currents in basilar artery myocytes. A. Representative current traces 
recorded form a basilar artery myocyte (capacitance = 38.72 pF) under control conditions 
(left, untreated), treatment with 10 µM flupirtine (middle) and 10 µM XE991 (right; 
dotted lines indicate zero current). Inset shows the schematic of the voltage protocol used 
to record the Kv7 currents. B. Representative time course of Kv7 currents recorded by 
continuous holding at -20 mV in a single basilar artery myocyte before and during the 
application of 10 µM flupirtine. The voltage-activated currents were enhanced with the 
application of flupirtine and restored to control levels after wash out of flupirtine (Bars 
above the trace indicate the duration of treatment or wash out. C.  Summarized I-V 
curves show the outwardly rectifying Kv7 currents (control; ) and the response to 
application of 10 µM flupirtine ( ) and 10 µM XE991 ( ). *Significant enhancement of 
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Kv7 currents at all tested voltages from -49.2 to +5.8 mV compared to control (Paired 
Student's ‘t’ test, p < 0.05; n = 4). D. Normalized conductance plots fitted by a single 
Boltzmann function shows no significant shift in the steady-state voltage dependence of 
activation of currents with addition of flupirtine; G/Gmax, fraction of maximal 
conductance. [Reproduced from Mani BK et al., British Journal of Pharmacology, 2011; 
164: 237-249]. 
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currents more than doubled with the addition of flupirtine (0.04 ± 0.01 pA/pF before 
(control) compared to 0.09 ± 0.02 pA/pF after addition of flupirtine (n=4; Figure 6C). 
The effect of flupirtine was reversible on wash out (Figure 6B). There was no significant 
shift in the steady-state voltage-dependence of activation of the currents with addition of 
flupirtine (V0.5 for flupirtine was -36.8 ± 0.8 mV compared to control -33.9 ± 1.5 mV; 
Figure 6D). XE991 (10 µM), a selective Kv7 channel blocker (Wang et al 1998) 
effectively abrogated the currents after wash out of flupirtine between voltages of -60 to -
20 mV (Figure 6A, C). Outward currents recorded positive to -20 mV are contributed by 
currents through other K+ channels including the 4-AP-sensitive-Kv channels and hence 
were not sensitive to XE991 (Figure 6C). 
  Retigabine, an analog of flupirtine also robustly enhanced Kv7 currents in freshly 
isolated rat basilar artery myocytes and the effect was completely reversible on wash out 
(Figure 7A). Enhancement of currents with retigabine (10 µM) was significant at all 
voltages tested from -59.2 mV to +0.8 mV (Figure 7B). At -20 mV, the voltage where 
near maximal activation of currents were observed (Figure 7C), currents increased from 
0.2 ± 0.09 pA/pF before treatment to 0.46 ± 0.17 pA/pF during treatment with retigabine, 
n=5. Retigabine, unlike flupirtine, induced a significant leftward shift in the steady-state 
voltage dependence of activation; V0.5 (control) was -30.2 ± 1.4 mV, V0.5 (retigabine) was 
-41.4 ± 0.5 mV (Figure 7C).  
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Figure 7: Retigabine enhances Kv7 currents in freshly isolated rat basilar artery 
myocytes. A. Time-course of XE991-sensitive Kv7 currents with the addition of 10 µM 
retigabine, recorded from a single basilar artery myocyte by continuous holding at -20 
mV. B. Current-voltage curves (I-V) of mean steady-state Kv7 currents before (control; 
) and during treatment with 10 µM retigabine ( ) and 10 µM XE991 ( ), normalized to 
control current measured at -20 mV before treatment. *Significantly different from 
control at indicated voltages using paired Student’s “t” test, p<0.05, n=5. C. Normalized 
conductance plotted against membrane voltage was fitted by a single Boltzmann function 
to show the effect of retigabine on steady-state voltage dependence of activation, 
*Significantly different from control using paired Student’s “t” test, p<0.05, n=5.  
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Contribution of Kv7 channels to membrane voltage and contractile status of basilar 
artery 
The Kv7 currents have a very negative threshold for voltage-dependent activation 
(Figure 6D, 7C), suggesting that K+ conductance through Kv7 channels should contribute 
to maintenance of resting membrane voltages. To evaluate this possibility, we measured 
the effect of the Kv7 channel blocker XE991 on whole cell membrane voltage under 
physiological ionic conditions. Addition of 10 µM XE991 significantly depolarized the 
basilar artery myocytes (by ~22 mV; from -57.5 ± 6.3 mV mean resting voltage to -35.3 
± 1.8 mV, n=4; Figures 8A, B). Vehicle for XE991 (deionized water) did not induce 
significant depolarization, n=4 (Figure 8B). To confirm that the depolarization of 
myocytes’ membrane translates functionally into a constrictor response, we assessed if 
blockade of Kv7 channels would constrict the intact basilar artery using pressure 
myography. Application of 10 µM XE991 to pressurized basilar arteries induced a 
significant constrictor response (15.1 ± 1.6 % compared to 0.25 ± 0.06 % constriction 
with vehicle treatment, n=5; Figure 9A, B), which was almost completely reversed by 
addition of the L-type Ca2+ channel blocker nimodipine (2 µM, Fig. 9A). 
 
Spasmogens suppress Kv7 currents and induce membrane depolarization in basilar 
artery myocytes 
 Myocytes derived from basilar artery of SAH-induced animal models are 
persistently depolarized (Jahromi et al. 2008a; Harder et al. 1987), an effect generally 
attributed to increased local concentrations of spasmogens. The cellular mechanism(s) by  
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Figure 8: Kv7 currents determine resting membrane voltage in basilar artery 
myocytes. A. Representative time course of membrane voltage recorded in current-clamp 
mode from a basilar artery myocyte before and during the application of selective Kv7 
channel blocker XE991 (10 µM). B. Mean membrane voltage values in basilar artery 
myocytes before (control; white bars) and during the addition of vehicle or 10 µM XE991 
(black bars). *significantly different from respective control using paired Student’s ‘t’ 
test, p < 0.05; N.S – not significant. n = 4 each). #Change in the membrane potential 
induced by addition of the vehicle of XE991 (3.9 ± 0.96 mV) and XE991 (-22.2 ± 4.69 
mV) were significantly different, using Student’s ‘t’ test, p < 0.05. [Reproduced from 
Mani BK et al., British Journal of Pharmacology, 2011; 164: 237-249]. 
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Figure 9: Kv7 currents determine contractile status of basilar artery. A. 
Representative trace shows XE991 (10 µM)-induced constriction of a pressurized basilar 
artery segment. The constriction was reversed with the addition of 2 µM nimodipine, an 
L-type Ca2+ blocker. B. Bar graph shows the percentage change in the basilar artery outer 
diameter with the addition of 10 µM XE991 or vehicle. *significant constriction 
compared to vehicle using paired Student’s ‘t’ test, p < 0.05; n = 5. [Reproduced from 
Mani BK et al., British Journal of Pharmacology, 2011; 164: 237-249]. 
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which the spasmogens induce membrane depolarization is not clear. Since K+ 
conductance through Kv7 channels is a critical determinant of resting membrane voltage 
in rat basilar artery myocytes and artery tone (Figure 8, 9) we tested if Kv7 currents are 
regulated by spasmogens. We tested three spasmogens (ET-1, 5HT and AVP) that have 
been implicated in cerebral vasospasm. All three spasmogens significantly suppressed 
Kv7 currents measured in the physiological voltage range (Figure 10, 11). Currents 
measured at -20 mV were suppressed by 56%, 49% and 37% with the addition of 
serotonin (100 nM), ET-1 (250 pM) and AVP (250 pM) respectively. The current 
amplitudes at -20 mV were 0.18 ± 0.04 pA/pF before and 0.07 ± 0.02 pA/pF during 
application of 5HT (n=6), 0.12 ± 0.02 pA/pF before and 0.06 ± 0.01 pA/pF during 
application of ET-1 (n=4), 0.37 ± 0.13 pA/pF before and 0.27 ± 0.12 pA/pF during 
application of AVP (n=6). Kv7 current amplitude was more than fully restored with 
addition of 10 µM retigabine in the presence of spasmogens. In the presence of 5HT, ET-
1 and AVP at the concentrations indicated above, 10 µM retigabine increased current 
amplitude (measured at -20 mV) to 72%, 65% and 78% above the control levels, 
respectively.  
Since Kv7 currents are active at resting membrane voltages (Figure 6, 7) and Kv7 
current suppression induces membrane depolarization (Figure 8), we tested if the 
spasmogens also induce membrane depolarization of myocytes. As expected, all three 
spasmogens induced significant depolarization: 5HT, from -57.1 ± 6.3 mV to -35.4 ± 2.4 
mV, n=4; ET-1, from -62.1 ± 2.3 mV to -42.8 ± 1.3 mV, n= 4; AVP from -53.2 ± 4.2 mV 
to -37.9 ±  1.4 mV, n=4 (Figure 12 A, C). More importantly, simultaneous addition of 10  
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Figure 10: Serotonin suppresses Kv7 currents in freshly isolated rat basilar artery 
myocytes. A. Kv7 current amplitude measured in a single basilar artery myocyte by 
continuous holding at -20 mV during application of 100 nM 5HT and subsequent 
addition of 10 µM retigabine as indicated. B. I-V curves of steady-state Kv7 currents 
before (Control; ), during treatment with 5HT ( ) and following addition of 10 µM 
retigabine in the continued presence of 5HT ( ). Currents at each voltage step are 
normalized to control currents measured at -20 mV before treatment. 5HT significantly 
suppressed currents at voltages from -34.2 mV to -14.2 mV (using repeated-measures 
(RM) one-way ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=6). C. 
Summary of 5HT-induced suppression of Kv7 currents measured at -20 mV. Addition of 
retigabine enhanced Kv7 current amplitude in the presence of 5HT. *, #Significantly 
different from control using RM one-way ANOVA followed by post hoc Holm-Sidak 
test, p<0.05, n=6.  
92 
 
 
Control 
AVP 250 pM 
AVP 250 pM + Retigabine 10 µM  
XE991 10µM 
Vm, mV
-80 -60 -40 -20 0 20
1
3
4
5
I/I
 (-
20
 m
V,
 C
on
tr
ol
)
AVP  250 pM 
+
Retigabine 10 µM
I (-
20
 m
V)
/I (
-2
0 
m
V,
 C
on
tr
ol
)
0.0
0.5
1.0
1.5
2.0
AVP  250 pM Control
*
#
A B
C D
-80 -60 -40 -20 0 20
3
4
5
Vm, mV
Control 
ET-1 250 pM 
ET-1 250 pM + Retigabine 10 µM  
XE991 10µM I/I
 (-
20
 m
V,
 C
on
tr
ol
)
0.0
0.5
1.0
1.5
2.0
I (-
20
 m
V)
/I (
-2
0 
m
V,
 C
on
tr
ol
)
ET-1  250 pM 
+
Retigabine 10 µM
ET-1  250 pM Control
*
#
 
 
 
Figure 11: Vasopressin and endothelin suppresses Kv7 currents in freshly isolated 
rat basilar artery myocytes. A. Current-voltage curves (I-V) of steady-state Kv7 
currents before (Control; ), during treatment with 250 pM AVP ( ) and following 
addition of 10 µM retigabine in the continued presence of AVP ( ) (currents at each 
voltage step are normalized to control currents measured at -20 mV before treatment). 
AVP significantly suppressed currents at voltages from -49.2 mV to 5.8 mV (using 
repeated-measures (RM) one-way ANOVA followed by post hoc Holm-Sidak test, 
p<0.05, n=6). B. Summary of AVP-induced suppression of Kv7 currents measured at -20 
mV. Addition of retigabine enhanced Kv7 current amplitude in the presence of AVP. *, 
#Significantly different from control using RM one-way ANOVA followed by post hoc 
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Holm-Sidak test, p<0.05, n=6. C. Current-voltage curves (I-V) of steady-state Kv7 
currents before (Control; ), during treatment with 250 pM ET-1 ( ) and following 
addition of 10 µM retigabine in the continued presence of ET-1 ( ) (currents at each 
voltage step are normalized to control currents measured at -20 mV before treatment). 
ET-1 significantly suppressed currents at voltages from -39.2 mV to -4.2 mV (using 
repeated-measures (RM) one-way ANOVA followed by post hoc Holm-Sidak test, 
p<0.05, n=4). D. Summary of ET-1-induced suppression of Kv7 currents measured at -20 
mV. Addition of retigabine enhanced Kv7 current amplitude in the presence of ET-1. *, 
#Significantly different from control using RM one-way ANOVA followed by post hoc 
Holm-Sidak test, p<0.05, n=4. 
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Figure 12: Spasmogens depolarize membrane voltage in basilar artery myocytes; 
Kv7 channel opener retigabine inhibits spasmogen-induced membrane 
depolarization. A. Time-course of change in the membrane voltage with the addition of 
100 nM 5HT as indicated, in the absence (top) or presence of 10 µM retigabine (bottom). 
B. Summarized result of membrane voltage measured before (control; white bars) or 
approximately 25 min after (grey bars) addition of 5HT in the absence (n=4) or presence 
(n=3) of 10 µM retigabine as indicated. *Significantly different from control using paired 
Student’s “t” test, p<0.05; N.S— Not significant. #Change in the membrane potential 
induced by addition of 100 nM 5HT alone (21.8 ± 4.1 mV) was significantly different 
from the  change induced by addition of 5HT in the presence of retigabine (0.5 ± 1.3 
mV), using Student’s ‘t’ test, p < 0.05. C. Summarized result of membrane voltage 
measured before (control; white bars) or after (grey bars) addition of 250 pmol/L AVP or 
250 pM ET-1 as indicated. *Significantly different from control using paired Student’s 
“t” test, p<0.05, n=4 each. 
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µM retigabine to enhance activation of Kv7 currents prevented membrane depolarization 
by 5HT (Figure 12 A, B). The voltage measured was -65.2 ± 4.6 mV before and -64.7 ± 
4.3 mV after combined treatment with 10 µM retigabine and 100 nM 5HT, n=3. These 
results indicate that activation of Kv7 currents can oppose the membrane depolarization 
induced by spasmogens involved in cerebral vasospasm. 
 
Basilar artery constriction induced by spasmogens involve Kv7 current suppression 
Pharmacological inhibition of Kv7 channels with XE991 was sufficient to 
constrict rat basilar arteries and this effect was almost completely reversed by application 
of the L-type CCB, nimodipine (Figure 9A). Nimodipine (1 µM) also dilated basilar 
artery segments pre-constricted by spasmogens (Figure 13). This finding implicates 
membrane depolarization and Ca2+ influx through VSCC as the predominant mechanism 
for constriction induced by spasmogens at the concentrations measured following SAH. 
Since spasmogens involved in cerebral vasospasm suppressed Kv7 currents and induced 
membrane depolarization (Figure 10, 11 and 12), we sought to determine whether 
spasmogen-induced basilar artery constriction involves suppression of Kv7 currents. To 
address this question, we tested whether addition of spasmogens in the presence of 
XE991 (10 µM, a concentration that fully suppresses Kv7 currents; Figure 6C, 7B) 
induces additive basilar artery constrictor responses. Of the three spasmogens tested, 100 
pM AVP and 100 pM ET-1 induced a slight but non-significant additional constriction in 
the presence of XE991; addition of 75 nM 5HT to XE991 induced a constrictor response  
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Figure 13: Spasmogen-induced basilar artery constriction is dependent on 
activation of voltage-sensitive calcium currents. A. Representative time-course shows 
the reversal of 100 pmol/L AVP-induced basilar artery constriction with addition of 1 
µmol/L nimodipine, a selective L-type Ca2+ channel blocker. B. Mean nimodipine-
induced dilation in basilar artery segments pre-constricted with spasmogens as indicated. 
Numbers within bracket indicates the number of experiments in each group. 
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that was significantly more than the constriction induced by either XE991 alone or the 
spasmogen alone. 
The percentage constriction induced by XE991 before addition of AVP was 15.1 
± 1.6%, AVP in the presence of XE991 was 20.2 ± 2.1% and AVP alone was 15.0 ± 
2.7%; XE991 before addition of 5HT was 17.5 ± 2.3%, 5HT in the presence of XE991 
was 28.3 ± 1.7% and 5HT alone was 19.4 ± 2.5%; XE991 before addition of ET-1 was 
19.0 ± 2.6%, ET in the presence of XE991 was 22.0 ± 1.8% and ET-1 alone was 16.7 ± 
1.0%, n = 4-8 (Figure 14). As the values indicate, none of the spasmogens tested induce 
an additive constrictor response when combined with Kv7 channel blocker XE991 (10 
µM). i.e., percentage constriction induced by the combined presence of spasmogen and 
XE991 is less than the sum of constrictor response induced by spasmogens alone and 
XE991 alone. This indicates involvement of Kv7 current suppression in the constriction 
induced by spasmogens.  
 
Activation of protein kinase C (PKC) suppresses Kv7 currents in basilar artery 
myocytes 
Myocytes isolated from spastic arteries derived from SAH animal models showed 
activation and translocation of PKC to the plasma membrane (Laher and Zhang 2001). 
Inhibition of PKC was previously found to attenuate rat basilar artery constriction 
induced by each of the three spasmogens used in the present study (Murray et al. 1992a; 
Murray et al. 1992b), indicating that activation of PKC is a common signal transduction 
intermediate in spasmogen-induced basilar artery constriction. PKC was previously  
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Figure 14: Kv7 current suppression is sufficient to induce basilar artery 
constriction; lack of additivity with basilar artery spasmogens. A. Representative 
time-course of change in basilar artery outer diameter shows constriction induced by 
application of Kv7 channel blocker, XE991 (10 µM) and subsequent addition of 100 pM 
AVP (left) or 75 nM 5HT (right) during the continued presence of XE991. B. 
Summarized bar graph shows the percentage basilar artery constriction induced by 10 
µM XE991, spasmogens (100 pM AVP, 75 nM 5HT, 100 pM ET-1) alone and addition 
of spasmogens in the continued presence of 10 µM XE991. *Significant additional 
constriction compared to constriction induced by XE991 alone and 5HT alone using one-
way ANOVA followed by post hoc Holm-Sidak test, p<0.05. Addition of 100 pM AVP 
or 100 pM ET-1 in the presence 10 µM XE991 did not induce significant additional 
constriction, n=4-8 in each group.  
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implicated as a mediator of the AVP-induced suppression of Kv7 currents in A7r5 rat 
aortic smooth muscle cells (Brueggemann et al. 2007). Therefore, we tested whether 
activation of PKC is sufficient for suppression of Kv7 currents in basilar artery myocytes 
and constriction of the basilar artery, using a direct activator of PKC: phorbol-12-
myristate-13-acetate (PMA; 10 nM). PMA significantly suppressed Kv7 currents at 
voltages from -44.2 mV to +15.2 mV (Figure 15) and PMA (100 nM) also constricted rat 
basilar artery segments (Figure 16). An inactive phorbol ester did not constrict basilar 
artery segments (Figure 16). 
 
Kv7 channel activators dilate basilar artery segments pre-constricted with 
spasmogens involved in cerebral vasospasm 
To assess the functional consequences of Kv7 current enhancement, we studied 
the efficacy of flupirtine or retigabine in reversing the constriction induced by 
spasmogens involved in the pathogenesis of cerebral vasospasm: 5HT, ET-1 and AVP. 
Flupirtine induced a concentration-dependent relaxation of basilar arteries pre-constricted 
with 100 pM ET-1, 100 pM AVP or 75 nM serotonin (Figure 17A, B). The EC50 of 
relaxation induced by flupirtine was ~40-60 µM (Figure 17B). Flupirtine (100 µM) did 
not reverse 5HT-induced constriction in the presence of 10 µM XE991 (flupirtine 
induced 2.8 ± 2.5 % dilation in the presence of XE991 compared to 97.4 ± 1.7 % dilation 
in the absence of XE991; data not presented) indicating that the dilation induced by 
flupirtine was specifically through activation of Kv7 channels. We then assessed whether 
flupirtine is more efficacious than nimodipine in dilating the basilar artery. Application of  
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Figure 15: Activation of protein kinase C (PKC) suppresses Kv7 currents in basilar 
artery myocytes A. Current-voltage curves (I-V) of steady-state Kv7 currents recorded 
before (control; ) and in the presence of selective PKC activator, phorbol 12-myristate 
13-acetate (PMA, 10 nM; ). Currents at each voltage step were normalized to control 
currents measured at -20 mV. *Significantly different from control at indicated voltages 
using paired Student’s “t” test, p<0.05, n=5. 
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Figure 16: Activation of PKC is sufficient to constrict basilar artery. A. 
Representative time-course shows change in basilar artery outer diameter with addition of 
100 nM PMA (top) or 100 nM 4α PMA (negative control for PMA, bottom). B. 
Summary of basilar artery constriction induced by 4α PMA (n=4) and PMA (n=5), 
*Significant constriction compared to addition of 4α PMA using Student’s “t” test, 
p<0.05. 
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Figure 17: Flupirtine reverses the constriction induced by spasmogens in basilar 
artery. A. Representative trace shows the concentration-dependent effect of flupirtine on 
a basilar artery segment pre-constricted with a 75 nM 5HT. B. Mean concentration-
response curves of the percentage relaxation induced by flupirtine in arteries pre-
constricted with the spasmogens: 5HT, AVP and ET-1. C. Representative time course 
trace shows the dilation induced by nimodipine and flupirtine when pre-constructed with 
5HT. Increasing the concentration of nimodipine above 1 µM did not induce additional 
dilation. However addition of flupirtine induced additional dilation in the same artery. D. 
Summary of the percentage dilation of pre-constricted basilar artery with the application 
of 2 µM nimodipine alone, 2 µM nimodipine + 100 µM flupirtine and 100 µM flupirtine 
alone. *Flupirtine either alone or when added along with nimodipine induced 
significantly more dilation compared to nimodipine alone (One-way ANOVA followed 
by post hoc Holm-Sidak test, p < 0.05, n = 3-6). [Reproduced from Mani BK et al., 
British Journal of Pharmacology, 2011; 164: 237-249]. 
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100 µM flupirtine either alone or combined with nimodipine induced a significant 
additional dilation of basilar artery compared with nimodipine alone (Figure 17C, D). 
Retigabine, an analog of flupirtine and a Kv7 channel activator (Figure 7) also induced 
92.8% reversal of the constriction induced by 5HT with the maximally used 
concentration of 100 µM. The EC50 retigabine was  23.7 µM, n=5 (Figure 18).  
 
Celecoxib enhances Kv7 currents and inhibits voltage-sensitive Ba2+currents in 
basilar artery myocytes 
 Celecoxib was recently reported to be a dual Kv7 channel activator and VSCC 
blocker in cultured rat aortic smooth muscle cells and rat mesenteric artery myocytes 
(Brueggemann et al 2009). The ion channel modulatory effects of celecoxib were tested 
in basilar artery myocytes. Celecoxib (10 µM) significantly enhanced the Kv7 currents in 
basilar artery myocytes at all voltages tested from -34.2 to +0.8 mV;  at -20 mV the 
currents more than doubled in amplitude, from 0.08 ± 0.02 pA/pF to 0.19 ± 0.04 pA/pF 
(Figure 19). Celecoxib did not induce a significant shift in the voltage-dependence of 
activation (V0.5 for celecoxib was -35.6 ± 1.6 mV compared to control -29.8 ± 2.1 mV; 
Figure 19D). 
Voltage–sensitive Ca2+ channels were recorded using Ba2+ as a charge carrier. 
Celecoxib (10 µM) inhibited IBa at all voltages from -20.2 to +39.8 mV (Figure 20A, B). 
The peak inward currents were reduced from 1.78 ± 0.1 pA/pF to 0.08 ± 0.05 pA/pF with 
the addition of 10 µM celecoxib. The effects of celecoxib on the IBa were slightly 
reversible after wash out of celecoxib (Figure 20B). 
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Figure 18: Retigabine reverses serotonin-induced basilar artery constriction. A. 
Representative time-course shows the effect of increasing concentrations of retigabine on 
outer diameter of a basilar artery segment pre-constricted with 5HT (75 nM). B. Bar 
graph shows concentration-dependent retigabine-induced basilar artery dilation 
*Significant dilation compared to absence of retigabine, using RM one-way ANOVA 
followed by post hoc Holm-Sidak test, p<0.05, n=5.  
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Figure 19: Celecoxib enhances Kv7 currents in basilar artery myocytes. A. 
Representative Kv7 current traces before and during the application of 10 µM celecoxib. 
B. Representative time course of Kv7 currents recorded at -20 mV in a single basilar 
artery myocyte before and during the application of 10 µM celecoxib. C. Summarized I-
V curves show the Kv7 currents before and during application of 10 µM celecoxib. 
*Significant enhancement of the voltage-activated Kv7 currents at all tested voltages 
from -34.2 to +0.8 mV (Paired Student's ‘t’ test, p<0.05, n=7). D. Normalized 
conductance plots fitted by a single Boltzmann function shows no significant shift in the 
steady-state voltage dependence of activation with addition of celecoxib. G/Gmax= 
fraction of maximal conductance. [Reproduced from Mani BK et al., British Journal of 
Pharmacology, 2011; 164: 237-249]. 
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Figure 20: Celecoxib inhibits voltage-sensitive Ba2+ currents in basilar artery 
myocytes. A. Representative voltage-sensitive Ba2+ current (IBa) traces before and during 
the application of 10 µM celecoxib. Inset shows the schematic of the voltage protocol 
used to record IBa. B. Summarized I-V curves show the effect of 10 µM celecoxib on IBa. 
*Celecoxib significantly inhibited IBa at all tested voltages from -20.2 to +39.8 mV 
(Student's ‘t’ test, p < 0.05, n = 5). [Reproduced from Mani BK et al., British Journal of 
Pharmacology, 2011; 164: 237-249]. 
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Celecoxib is a more efficacious voltage-sensitive calcium channel blocker than 
nimodipine 
Since nimodipine is the standard therapeutic agent used to treat patients with 
cerebral vasospasm, we compared the ability of nimodipine to inhibit IBa with that of 
celecoxib. The concentration of nimodipine used (2 µM) was found to be maximally 
effective in dilation of basilar artery segments pre-constricted with vasoconstrictor 
agonists (Figure 17C, 22C). Celecoxib was significantly more effective in inhibiting IBa 
in basilar artery myocytes than was 2 µM nimodipine (Figure 21). The inhibition of peak 
inward Ba2+ currents with application of 2 µM nimodipine alone was 85.5 ± 2.9%; with 2 
µM nimodipine + 10 µM celecoxib it was 97.0 ± 0.3%; and with 10 µM celecoxib alone, 
it was 96.0 ± 2.2%.  
 
Celecoxib reverses/prevents basilar artery constriction induced by spasmogens 
involved in cerebral vasospasm 
Celecoxib, the dual Kv7 channel activator and VSCC blocker, was a more potent 
dilator of the basilar artery compared to flupirtine. Basilar artery segments pre-constricted 
with ET-1, AVP or 5HT were dilated by celecoxib in a concentration-dependent manner, 
with an EC50 of relaxation between 14 and 17 µM (Figure 22A, B). Celecoxib (30 µM) 
either alone or when combined with nimodipine (2 µM) induced significant additional 
dilation of basilar arteries compared to dilation induced by nimodipine alone (Figure 
22D, E).  
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Figure 21: Celecoxib is a more effective voltage-sensitive Ca2+ blocker than 
nimodipine. A. Time course shows the blockade of peak inward IBa with addition of 2 
µM nimodipine followed by addition of 10 µM celecoxib in the presence of nimodipine.  
B. Percentage inhibition of peak IBa with the application of 2 µM nimodipine alone, 2 µM 
nimodipine + 10 µM celecoxib and 10 µM celecoxib alone. *Celecoxib either alone or 
when added along with nimodipine produced significantly more inhibition of IBa 
compared to nimodipine alone (One-way ANOVA followed by post hoc Holm-Sidak test, 
p < 0.05; n = 5-6). 
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Figure 22: Celecoxib reverses the spasmogen-induced constriction in basilar artery 
more effectively than nimodipine. A. Representative trace shows the concentration-
dependent effect of celecoxib on a basilar artery segment pre-constricted with a 75 nM 
5HT. B. Mean concentration-response curves of the percentage relaxation induced by 
celecoxib in arteries pre-constricted with the spasmogens: 5HT, AVP and ET-1. C. 
Representative time course trace shows the dilation induced by nimodipine and celecoxib 
when pre-constructed with 5HT. Increasing the concentration of nimodipine above 1 µM 
did not induce additional dilation. However addition of celecoxib induced additional 
dilation in the same artery. D. Summary of the percentage dilation of basilar artery with 
the application of 2 µM nimodipine alone, 2 µM nimodipine + 10 µM celecoxib and 10 
µM celecoxib alone. *Celecoxib either alone or when added along with nimodipine 
induced significantly more dilation compared to nimodipine alone (One-way ANOVA 
followed by post hoc Holm-Sidak test, p < 0.05, n = 3-6). [Reproduced from Mani BK et 
al., British Journal of Pharmacology, 2011; 164: 237-249]. 
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Development of cerebral vasospasm is delayed and is appreciable usually 3 days 
after SAH. Therefore, we also sought to address whether celecoxib could prevent the 
development of vasospasm when administered preemptively. In order to simulate that in 
an acute experimental system, the ability of a spasmogen to constrict basilar artery in the 
presence of celecoxib was tested. Serotonin was not able to constrict basilar artery 
segments pre-treated with 30 µM celecoxib, but after wash out of both 5HT and 
celecoxib, re-addition of 5HT in the presence of the vehicle of celecoxib induced a robust 
constriction in the same artery (Figure 23A). The mean constriction induced by 5HT in 
the presence of celecoxib was 0.11 ± 0.34% compared to 17.3 ± 1.7% induced in the 
presence of vehicle for celecoxib in the same arteries (Figure 23B). The constriction 
induced by 5HT in the presence of vehicle was subsequently overcome by application of 
30 µM celecoxib (Figure 23A).  
 
Kv7 channel openers attenuate basilar artery vasospasm in a rat model of SAH 
Single-cell electrophysiology and pressure myography studies strongly indicated 
the ability of Kv7 channel openers to attenuate spasmogen-induced membrane 
depolarization and basilar artery constriction (Figure 12, 17, 18, 22 and 23). We therefore 
tested the efficacy of Kv7 channel openers to relieve basilar artery vasospasm in vivo 
using a rat model of SAH. We used an established single hemorrhage model that induces 
biphasic vasospasm of basilar artery, reaching its peak at day 2 after initiation of SAH 
(Delgado et al. 1985; Nikaido et al. 2004). Rats were treated with either retigabine (7.5 
mg/kg, i.p) or celecoxib (20 mg/kg, i.p) twice daily starting an hour after hemorrhage and  
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Figure 23: Celecoxib prevents spasmogen-induced constriction in basilar artery A. 
Time-course shows that 75 nM 5HT was not able to constrict the basilar artery segment 
in the presence of 30 µM celecoxib. However after wash out, serotonin was able to 
constrict the same artery in the absence of celecoxib. Re-application of celecoxib 
completely reversed the 5HT-induced constriction (representative of n=3). B. Summary 
of the percentage constriction induced by 5HT in the presence of 30 µM celecoxib and 
vehicle of celecoxib. *Significant constriction by serotonin in the presence of vehicle 
compared to constriction induced in the presence of 30 µM celecoxib (Student’s ‘t’ test 
n=3, p < 0.05).  [Reproduced from Mani BK et al., British Journal of Pharmacology, 
2011; 164: 237-249]. 
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continuing for 48 hours (4 doses in total). Basilar artery outer diameter measured at 48 
hours (12 hours after the last injection) was used as the endpoint criterion to assess the 
severity of vasospasm and efficacy of treatments. SAH induced by an intracisternal 
injection of autologous blood induced significant basilar artery vasospasm compared to 
control rats that had no surgery or that were injected with artificial cerebrospinal fluid 
(aCSF) instead of blood (Figure 24). Both retigabine and celecoxib significantly 
attenuated the basilar artery spasm when compared with vehicle control in the rat model  
of SAH (Figure 24). The mean diameter of basilar artery in the treatment groups were— 
no surgery control: 147.0 ± 9.2 µm, sham surgery (aCSF) group: 143.5 ± 6.7 µm, SAH 
group: 114.9 ± 9.9 µm, SAH + retigabine treatment group: 158.4 ± 9.0 µm  and SAH 
group + celecoxib treatment group: 176.8 ± 10.7 µm, n=9 in each group.  
A striking observation was a pronounced hypothermia with administration of 
retigabine in SAH rats. Rats administered retigabine had significant hypothermia even 12 
hours after drug administration. The rectal temperature of rats in the retigabine group 
(33.1 ± 1.4 °C) was approximately 5°C lower than the mean temperature in all untreated 
control groups (Figure 25). Celecoxib also tended to induce mild hypothermia, though 
this effect was not statistically significant. Rats treated with retigabine and celecoxib 
demonstrated a significant reduction in locomotor activity. Both the ambulatory 
movements (scored by consecutive breaks of adjacent photobeams) and fine movements 
(scored by consecutive break in a single photobeam) were reduced with treatment (Figure 
26). Neurological endpoints assessed using behavioural tests used in ischemic stroke 
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Figure 24: Kv7 channel openers attenuate basilar artery spasm in a rat model of 
SAH. A. Illustrative photographs show basilar artery in the base of brain from rats in 
different treatment groups. Brains were photographed 48 hours after injection of blood or 
aCSF and compared with brains of control rats (no surgery). B. Bar graph shows the 
mean basilar artery outer diameter measured in each of the treatment groups— Control 
(no surgery), aCSF control (sham surgery), SAH rats treated with vehicle (DMSO, 
1ml/kg, ip, bid), SAH rats treated with retigabine (7.5 mg/kg, ip, bid) and SAH rats 
treated with celecoxib (20 mg/kg, ip, bid). *Significant difference between the treatment 
groups as indicated using one-way ANOVA followed by post hoc Holm-Sidak test, 
p<0.001, n=9 in each group.  
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Figure 25: Retigabine induces hypothermia in the rat model of SAH. A. Rectal 
temperature of rats in different groups (as indicated), measured 48 hours after induction 
of SAH or sham surgery to inject aCSF, along with control rats (no surgery). 
*Significantly different from controls (open bars) and SAH rats treated with vehicle, 
using one-way ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=9 in each 
group. In treatment groups, body temperature was measured 12h after last treatment time.  
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Figure 26: Kv7 openers dampen locomotor activity performance of SAH rats. Line 
plot of fine (A) and ambulatory (B) movements of rats belonging to various treatment or 
control groups, measured on days before and after surgery (day 0 is the day of surgery). 
*significant reduction in activity compared to vehicle treated SAH rats (One-way 
ANOVA test followed by post hoc Holm-Sidak test, p<0.05, n=9) in each group. 
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models (Garcia et al. 1995) showed no significant change in neurological function 
compared to rats injected with aCSF into the cisterna magna.  
 
Kv7 channel openers induce transient hypotension, but do not alter long-term mean 
arterial pressure  
One of the limitations in the use of direct CCBs like nimodipine to treat cerebral 
vasospasm is its propensity to induce sustained hypotension (Porchet et al. 1995). 
Systemic hypotension reduces the perfusion pressure to the brain further exacerbating 
ischemia (Ahmed et al. 2000). We tested the effect of the Kv7 channel opener retigabine 
(7.5 mg/kg i.p) and the dual Kv7 channel opener and CCB celecoxib (50 mg/kg i.p) on 
systemic mean arterial pressure (MAP) in conscious rats (MAP was monitored by 
radiotelemetry). The drugs were administered intraperitoneally every 12 hours for 48 
hours (4 doses in total) to mimic the schedule of test drug administration in SAH rats. 
Both the drugs induced a transient drop in MAP lasting for 30-60 min after each 
administration (Figure 27). By comparison vehicle administration tended to increase 
MAP transiently (Figure 27A). Despite the differences in MAP immediately after drug 
administration, the 24 h MAP (Figure 27B) and heart rate (Figure 28) were not 
significantly different between vehicle- and drug-treated groups. 
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Figure 27: Kv7 channel openers induce a transient drop in blood pressure. A. 
Change in mean arterial pressure (MAP) during treatment, compared to the 24h baseline 
MAP measured before treatment. Areas in grey shade are dark hours and areas in white 
are light hours during the 12h dark/light cycle. Arrows indicate treatment times. Each 
data point represents the average change in BP during a 30 min interval. Standard error is 
not represented for clarity. *Significantly different from vehicle group, using one-way 
ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=6-7. B. Line graph shows the 
24h mean BP recorded in untreated rats (control) or rats treated with vehicle (DMSO, 
1ml/kg, ip, bid), retigabine (7.5 mg/kg, ip, bid) or celecoxib (50 mg/kg, ip, bid), N.S— no 
significant difference from control, n=6-7.  
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Figure 28: Kv7 channel openers do not alter 24h heart rate in rats.  A. Change in 
mean heart rate (HR) during treatment, compared to the 24h baseline HR measured 
before treatment. Areas in grey shade are dark hours and areas in white are light hours 
during the 12h dark/light cycle. Arrows indicate treatment times. Each data point 
represents the average change in HR during a 30 min interval. Standard error is not 
represented for clarity. *Significantly different from vehicle group, using one-way 
ANOVA followed by post hoc Holm-Sidak test, p<0.05, n=6-7. B. Line graph shows the 
24h mean HR recorded in untreated rats (control) or rats treated with vehicle (DMSO, 
1ml/kg, ip, bid), retigabine (7.5 mg/kg, ip, bid) or celecoxib (50 mg/kg, ip, bid), N.S— no 
significant difference from control, n=6-7.  
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Phosphodiesterase inhibitors activate Kv7 channels and inhibit voltage-sensitive 
calcium currents in A7r5 cells 
Celecoxib is prescribed in clinical practice to treat prostaglandin-mediated 
inflammation and pain (Frampton and Keating 2007). Celecoxib induces its anti-
inflammatory effect by inhibiting a specific class of prostaglandin producing enzyme 
called cyclooxygenase (COX)-2. We tested if the ion channel-mediated vasodilatory 
effect of celecoxib is due to its ability to inhibit COX-2. Rofecoxib, a more potent and 
selective COX-2 inhibitor than celecoxib (FitzGerald and Patrono 2001), did not dilate 
basilar artery segments pre-constricted with 5HT (75 nM). Application of celecoxib at 
equimolar concentrations (30 µM) in the same arteries almost completely reversed the 
5HT-induced constriction (Figure 29A, C). Dimethyl celecoxib, an analog of celecoxib, 
which is devoid of COX-2 inhibitory activity (Kardosh et al. 2005), but retains the Kv7 
channel and VSCC modulatory activity (Brueggemann et al. 2009), mimicked the 
vasodilatory effects of celecoxib (Figure 29B, C). These results indicate that celecoxib-
induced ion channel-mediated vasodilatory effects are independent of its COX-2 
inhibitory effects, therefore not a “class-effect” (Figure 29).  
 Celecoxib, but not rofecoxib, was reported to be an inhibitor of phosphodiesterase 
enzyme isoform 4 and 5 (Klein et al. 2007). Hence, we hypothesized that celecoxib 
induces the ion channel modulatory effects (Kv7 channel activation and VSCC block) 
through inhibition of the PDE enzyme(s). To that end, we tested the effect of selective 
PDE enzyme inhibitors on Kv7 currents in A7r5 cells. Rolipram, a selective PDE4 
inhibitor, induced a concentration dependent enhancement of Kv7 currents in A7r5 cells 
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Figure 29: Vasodilatory effect of celecoxib is not dependent on COX-2 inhibition. 
Representative time course trace shows that 30 µM rofecoxib failed to dilate basilar 
artery segments pre-constricted with a 75 nM serotonin. Application of 30 µM celecoxib 
(CXB) completely reversed the serotonin-induced constriction of the same artery. B.  
Representative time course trace shows that 30 µM dimethyl celecoxib (DMC) 
completely reversed the serotonin-induced constriction of basilar artery. C. Summary of 
the percentage dilation induced by rofecoxib and dimethyl celecoxib. *Significant 
dilation compared to 30 µM rofecoxib (One-way ANOVA followed by post hoc Holm-
Sidak test, p < 0.05, n = 3 each). [Reproduced from Mani BK et al., British Journal of 
Pharmacology, 2011; 164: 237-249]. 
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(Figure 30). Rolipram at concentrations as low as 1 nM induced about 50% enhancement 
of Kv7 currents in A7r5 cells. The concentration response curve for enhancement of Kv7 
currents was bell shaped, with a maximal 3.4-fold enhancement of currents with addition 
of 100 nM rolipram and suppression of currents at a concentration above 100 nM (Figure 
30B, C). Rolipram also mimicked the voltage-sensitive Ca2+ current inhibitory action of 
celecoxib (Figure 31). Rolipram inhibited IBa with a maximal suppression of peak inward 
currents at a concentration of 100 nM. The concentration response curves for 
enhancement of Kv7 currents and inhibition of voltage-sensitive Ca2+ currents with 
rolipram showed similar concentration-dependence (Figure 30C, 31C). Sildenafil, a 
PDE5 inhibitor and papaverine, a non-selective PDE inhibitor also enhanced Kv7 
currents in A7r5 cells (Figure 32, 34). Sildenafil induced a maximal 2.7-fold 
enhancement of Kv7 currents at a concentration of 10 μM and papaverine induced a 3.1 
fold enhancement of the currents at a maximally tested concentration of 100 μM. 
Sildenafil also inhibited voltage-sensitive Ca2+ currents similar to the effects of celecoxib 
and rolipram (Figure 33). These results indicate that inhibition of either PDE4 or PDE5 
enzyme is sufficient to simulate the ion channel modulatory action of celecoxib. 
 
Phosphodiesterase inhibitors attenuate AVP-induced calcium spiking response in 
A7r5 cells; dilate mesenteric artery segments  
We then tested if the ion channel modulatory effects of PDE inhibitors translated 
 
functionally to inhibition of Ca2+ entry in A7r5 cells. Physiological concentrations of 
AVP (10-100 pM) induces Ca2+ spiking responses attributed to Kv7 current suppression, 
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Figure 30: Rolipram enhances Kv7 currents in A7r5 cells. A. Current traces show 
enhancement of non-inactivating outward Kv7 K+ currents with the addition of rolipram, 
a selective PDE4 inhibitor. B. Current-voltage curves of steady-state Kv7 currents 
recorded before (control) and during treatment with increasing concentrations of rolipram 
as indicated (currents recorded at each voltage step were normalized to control currents 
measured at -20 mV before treatment). C. Concentration-response relationship 
demonstrates a more than 3-fold maximal enhancement of Kv7 currents with the addition 
of rolipram. Currents measured at -20 mV in the presence of rolipram were normalized to 
currents measured at -20 mV before the addition of rolipram. *significantly different 
from pre-treatment levels, using repeated measures one-way ANOVA followed by Holm-
Sidak post hoc test,  p < 0.001, n= 4-5).  
 
 
 
 
123 
 
 
 
250 mS
Vm, mV
-100 -80 -60 -40 0 20 40 60
I/I (Control, peak inward)
-1.2
-0.8
0.2
Control 
Rolipram 1 nM
Rolipram 10 nM
Rolipram 100 nM
Rolipram 1 µM
Rolipram 10 µM
B
I, 
pA
-3.0
-2.0
-1.0
0
I, 
pA
-3.0
-2.0
-1.0
0
A
Control Rolipram 100 nM
Log [Rolipram]
I (P
ea
k
in
w
ar
d)
/I 
(C
on
tr
ol
 p
ea
k 
in
w
ar
d)
0.0
0.2
0.4
0.6
0.8
1.0
C
*
*
* *
Ctrl -9 -8 -5-7 -6
I, 
pA
I, 
pA
I, 
pA
I, 
pA
I (P
ea
k
in
w
ar
d)
/I 
(C
on
tr
ol
 p
ea
k 
in
w
ar
d)
 
 
 
Figure 31: Rolipram inhibits voltage-sensitive Ba2+ currents in A7r5 cells. A. Inward 
Ba2+ current traces recorded before (control) and during treatment with 100 nM rolipram. 
B. Current-voltage curves show the mean IBa  recorded across the voltages tested with the 
addition of different concentrations of rolipram. (Currents at each voltage step were 
normalized to the peak inward IBa measured before treatment). C. Summarized 
concentration-response relationship shows significant suppression of peak inward IBa with 
increasing concentrations of rolipram. Peak inward IBa measured in the presence of 
rolipram were normalized to the peak inward IBa measured before treatment. 
(*significantly different from pre-treatment levels, repeated measures one-way ANOVA 
followed by Holm-Sidak post hoc test, p < 0.001, n=3-5).  
 
 
 
 
 
 
124 
 
 
 
 
 
B
Ctrl -6.0 -5.5 -5.0 -4.5
1
2
3
4
Log [Sildenafil]
*
*
*
Vm, mV
-100 -80 -60 -40 -20 0 20 40
I/I (-20 mV, Control)
1
4
5
Control 
Sildenafil 1μM
Sildenafil 3 μM
Sildenafil 10 μM
Sildenafil 30 μM
A
I (-
20
 m
V)
/I (
-2
0 
m
V,
 C
on
tr
ol
)
I (-
20
 m
V)
/I (
-2
0 
m
V,
 C
on
tr
ol
)
 
 
 
 
Figure 32: Sildenafil enhances Kv7 currents in A7r5 cells. A. Current-voltage curves 
of the steady-state Kv7 currents recorded before (control), during treatment with 
increasing concentrations of sildenafil as indicated (currents recorded at each voltage step 
were normalized to control currents measured at -20 mV before treatment). B. 
Concentration-response relationship demonstrates enhancement of Kv7 currents with the 
addition of sildenafil. Currents measured at -20 mV in the presence of sildenafil were 
normalized to currents measured at -20 mV before the addition of sildenafil. 
*significantly different from pre-treatment levels, using repeated measures one-way 
ANOVA followed by Holm-Sidak post hoc test,  p < 0.05, n= 4 each).  
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Figure 33: Sildenafil inhibits voltage-sensitive Ba2+ currents in A7r5 cells. A. 
Current-voltage curves show the mean IBa recorded across the voltages tested with 
addition of different concentrations of sildenafil. (Currents at each voltage step were 
normalized to the peak inward IBa measured before treatment). B. Summarized 
concentration-response relationship shows significant suppression of peak inward IBa with 
increasing concentrations of sildenafil. Peak inward IBa measured in the presence of 
sildenafil were normalized to the peak inward IBa measured before treatment. 
(*significantly different from pre-treatment levels, RM one-way ANOVA followed by 
Holm-Sidak post hoc test, p < 0.05, n=3-5).  
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Figure 34: Papaverine enhances Kv7 currents in A7r5 cells. A. Current-voltage 
curves of steady-state Kv7 currents recorded before (control) and during treatment with 2 
different concentrations of papaverine (10 and 100 µM) (currents recorded at each 
voltage step were normalized to control currents measured at -20 mV before treatment). 
B. Concentration-response relationship demonstrates enhancement of Kv7 currents with 
the addition of papaverine. Currents measured at -20 mV in the presence of papaverine 
were normalized to currents measured at -20 mV before the addition of papaverine. 
*significantly different from pre-treatment levels, using repeated measures one-way 
ANOVA followed by Holm-Sidak post hoc test,  p < 0.001, n= 4 each).  
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membrane depolarization and Ca2+ entry through VSCC in A7r5 cells (Brueggemann et 
al. 2007; Mani et al. 2009; Byron 1996). Pre-treatment with 100 nM rolipram (Figure 
35), 10 μM sildenafil or 100 μM papaverine (not shown) significantly attenuated AVP 
(25 pM)- induced Ca2+ spiking responses in A7r5 cells. Rolipram and sildenafil also 
induced concentration-dependent relaxation of mesenteric artery segments pre-
constricted with 30 pM AVP, indicating that the ion channel modulatory effects of PDE 
inhibitors translate functionally into vasodilatory response (Figure 36). 
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Figure 35: Rolipram inhibits calcium spiking responses in A7r5 cells. A. 
Representative traces show Ca2+ spiking in response to addition of 25 pM AVP (indicated 
by arrow) in fura-2 loaded A7r5 cells pretreated with vehicle or 100 nM rolipram for 30 
min. B. Bar graph summarizes the effect of rolipram on AVP-induced Ca2+ spiking 
response. **significant reduction in the Ca2+ spiking frequency in cells pre-treated with 
100 nM rolipram, Student’s ‘t’ test, p < 0.001, n=4 (Data generated by Kakad).   
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Figure 36: Phosphodiesterase4/5 inhibitors reverse AVP-induced constriction in rat 
mesenteric artery. A. Representative time course shows rolipram-induced 
concentration-dependent dilation of mesenteric artery pre-constricted with 30 pM AVP. 
Summarized dose-response relationship of the dilation induced by rolipram (B) and 
sildenafil (C) in arteries pre-constricted with AVP. **Significant dilation with addition of 
rolipram or sildenafil compared to absence of the drugs, using RM one-way ANOVA 
followed by Holm-Sidak post hoc test, p < 0.001, n=4-5. 
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CHAPTER 6 
                                                          DISCUSSION 
This study presents several novel findings: 
(1) Kv7 channels are expressed and functional in rat basilar artery myocytes.  
(2) K+ conductance through the Kv7 channels maintains hyperpolarized resting 
membrane voltages, limiting the activation of VSCC in myocytes, thereby regulating 
the contractile status of basilar artery.  
(3) Suppression of Kv7 currents is a central mechanism by which multiple spasmogens 
implicated in SAH-induced cerebral vasospasm induce membrane depolarization and 
constrict basilar artery. 
(4) Direct Kv7 channel openers (retigabine or flupirtine) are able to restore the Kv7 
current amplitude in the presence of spasmogens. This action attenuates the 
spasmogen-induced membrane depolarization and artery constriction. 
(5) Celecoxib is a dual Kv7 channel activator and VSCC blocker in basilar artery 
myocytes. Celecoxib was able to reverse/prevent spasmogen-induced basilar artery 
constrictor responses. 
(6) Flupirtine and celecoxib are more effective in dilating basilar artery than the L-type-
calcium channel blocker, nimodipine, which is currently used as the standard care for 
patients with cerebral vasospasm.
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(7) Retigabine and celecoxib are effective in preventing the sustained basilar artery 
vasospasm in a rat model of SAH. These drugs do not alter long-term mean arterial 
pressure. 
These findings suggest that Kv7 channels are critical mediators of cerebral 
vasospasm and that clinically used drugs that enhance Kv7 channel activity may be 
effective in reducing vasospasm and preventing or attenuating stroke following SAH.  
 
Expression of Kv7 channels in rat basilar artery myocytes 
Message transcripts of all the known KCNQ genes (KCNQ1-5, encoding Kv7.1-
7.5 channels) were detected in rat basilar artery myocytes (Figure 5). A quantitative 
assessment of the expression of KCNQ genes in rat basilar artery and middle cerebral 
artery myocytes by Zhong et al. also revealed the presence of all five KCNQ mRNAs, 
though the mRNAs of KCNQ2 and KCNQ3 were much less abundant than those of 
KCNQ1, KCNQ4 and KCNQ5 (Zhong et al. 2010). Kv7.1 channels are insensitive to 
drugs (e.g., flupirtine, retigabine, and N-ethyl maleimide) that activate the other Kv7 
channel subtypes (Gamper et al. 2005; Munro and Dalby-Brown 2007) and Kv7.1 
subunits do not heteromerize with other Kv7 channel subunits (Schwake et al. 2003). 
Considering that the whole cell Kv7 currents measured in basilar artery myocytes were 
robustly enhanced by flupirtine and retigabine (Figure 6, 7), the contribution of outward 
K+ conductance through homomeric Kv7.1 channel is likely to be minimal. Using 
selective pharmacological modulators for Kv7.1 channels, a recent study indicated that 
Kv7.1 channels may be functional, but do not contribute to the resting tone of mesenteric 
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arteries (Chadha et al. 2012). Hence, the functional Kv7 channels that contribute to the 
resting tone in basilar artery myocytes are likely to be predominantly constituted by 
homo- or hetero-tetramers of Kv7.4 and Kv7.5 channel subunits. 
Expression profiles of KCNQ channel transcripts in VSMCs from various 
vascular beds reveal expression of KCNQ1, KCNQ4 and KCNQ5 subunits, and either 
absence or very little expression of KCNQ2 and KCNQ3 subunits (Zhong et al. 2010; 
Joshi et al. 2009; Mackie et al. 2008; Yeung et al. 2007). This indicates that the 
expression profile of KCNQ genes in basilar artery and VSMCs in general is different 
from neurons where the predominant expression is KCNQ2 and KCNQ3 (Jentsch 2000; 
Delmas and Brown 2005).  
 
Kv7 currents in rat basilar artery myocytes 
This study presents the first successful isolation of Kv7 currents in the cerebral 
vasculature (Figure 6, 7). Whole cell KV currents were recorded using voltage-clamp 
conditions. Currents recorded at test voltages between -60 mV and -20 mV can 
reasonably be attributed to Kv7 channel activity based on several observations: 1) the 
currents measured under our recording conditions were robustly enhanced by 10 µM 
flupirtine or retigabine, selective Kv7 channel activators, 2) the currents were completely 
inhibited by 10 µM XE991, a selective Kv7 channel blocker, 3) the currents had 
electrophysiological characteristics of Kv7 currents (non-inactivating, voltage-dependent 
with a very negative threshold for activation and half-maximal activation (V0.5) of ~ -34 
mV (Wickenden et al. 2001; Brueggemann et al. 2007; Mackie et al. 2008; Adams and 
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Brown 1982). Currents recorded at voltages more positive than -20 mV were not 
completely blocked by XE991 suggesting that at these more depolarized voltages we 
were recording a mix of currents, with likely contributions of other K+ channels, such as 
4-AP-sensitive Kv channels and Ca2+-activated K+ channels (KCa) channels. 
In the present study, both Kv7 channel activators− retigabine and flupirtine 
significantly enhanced Kv7 currents over the physiological voltage range, with more than 
100% enhancement of Kv7 currents measured at -20 mV (Figure 6, 7). Retigabine 
induced a significant hyperpolarizing shift in voltage-dependence of activation of the 
currents (Figure 7C). The voltage of half-maximal activation of the currents (V0.5) shifted 
with addition of 10 μM retigabine from  -30.2 ± 1.4 mV in control conditions to -41.4 ± 
0.5 mV. Retigabine induced a similar hyperpolarizing shift in activation of currents 
through Kv7.2/Kv7.3 heteromeric channels expressed in CHO cells; V0.5 shifted from -
28.7 mV to -40.1 mV with addition of retigabine (Tatulian and Brown 2003). Flupirtine 
only induced a small non-significant shift in the voltage-dependence of activation of 
currents (Figure 6D), similar to our previous observation in mesenteric artery myocytes 
(not shown). Flupirtine, however, induced a significant hyperpolarizing shift in voltage-
dependence of activation of Kv7 currents (~ 11 mV) measured in guinea pig airway 
smooth muscle cells (Brueggemann et al. 2012). The reason for the difference is not 
immediately apparent, but could be due to the difference in cell type and differential 
expression of Kv7 channel subtypes. Retigabine increased the maximal Po of single 
Kv7.2/Kv7.3 channels expressed in CHO cells from 0.13 to 0.38 (Tatulian and Brown 
2003). Hence, the increase in whole cell current amplitude with addition of Kv7 channel 
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openers in basilar artery myocytes is likely due to increase in open probability (Po) of the 
channels. 
The subunits constituting the functional channel is difficult to ascertain because of 
the lack of subunit-selective pharmacological activators and the difficulty in using 
molecular approaches. The present study utilized well established Kv channel activators 
retigabine and flupirtine, both of which activate all Kv7 channel subtypes, except Kv7.1 
channel homomers. Recently, several classes of Kv7 channel activators have started to 
emerge with the identification of a new target site in these channels (Xiong et al. 2008). 
Most of these compounds were tested only against neuronal Kv7.2/7.3 heterotetramers. 
While some recent compounds showed relative selectivity to certain channel subtypes, 
compounds that can serve as tools to identify channel subunits and/or for selective 
cardiovascular or neuronal therapy remain to be identified (Bentzen et al. 2006; 
Wickenden et al. 2008; Gribkoff 2008; Brueggemann et al. 2011). 
 
Kv7 channels are critical contributors to resting membrane voltage and basilar 
artery contractile status 
The resting membrane voltage of basilar artery myocytes measured in the current 
study was -57.5 ± 6.3 mV, within the range reported in previous studies for basilar artery 
myocytes (Jahromi et al. 2008a; Chrissobolis and Sobey 2002; Allen et al. 2002). The 
maximal density of K+ currents through Kv7 channels is small (< 0.3 pA/pF, Figure 6C) 
compared to maximal current densities reported for 4-AP-sensitive-KV (36.9 pA/pF) and 
KCa channels (~140 pA/pF) (Jahromi et al. 2008a; Jahromi et al. 2008b). However, Kv7 
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channels are likely to play an important role in determining the resting membrane 
voltage, more so than  KV and KCa channels, as they are activated at negative membrane 
voltages than 4-AP-sensitive-KV and KCa channels [V0.5 for Kv7 currents is -34 mV 
(Figure 6D), compared to V0.5 of -1.3 mV for 4-AP-sensitive-KV currents (Jahromi et al. 
2008a) and +86.8 mV for large-conductance KCa currents at 200 nM [Ca2+]c (Jahromi et 
al. 2008b)].  This is supported by the evidence that blockade of Kv7 channels with 
XE991 significantly depolarized the cell membrane (Figure 8). This brought the 
membrane voltage from -58 mV, at which L-type VSCC have very low activity, to -35 
mV, which is in the range of membrane voltage where VSCC activity increases in a 
steeply voltage-dependent manner (Figure 8B). Our results shown in Figure 9 support 
this hypothetical mechanism: XE991 robustly constricted the basilar artery and this effect 
was reversed by the L-type VSCC blocker nimodipine. Kv7 channels have a well-
established role in stabilizing resting membrane voltages and suppression of their activity 
is a common depolarizing stimulus in neurons and arterial myocytes (Joshi et al. 2009; 
Mackie et al. 2008; Adams and Brown 1982).  
 
Suppression of Kv7 currents as a mechanism of vasoconstriction by spasmogens 
Though it is well established that basilar artery spasmogens depolarize the 
vascular myocytes and trigger Ca2+ influx through VSCC to induce constriction, the 
signal transduction events that lead to membrane depolarization remain poorly 
understood. Most previous evidence points to activation of non-selective cation channels 
as a mechanism for spasmogen-induced membrane depolarization (Albert and Large 
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2006). Our results show that spasmogens suppress Kv7 currents (Figure 10, 11) that are 
active at resting membrane voltages, an effect which is associated with significant 
membrane depolarization (Figure 8, 12). Direct inhibition of Kv7 currents by XE991 was 
sufficient to induce constriction of basilar arteries (Figure 9), suggesting that resting 
inward leak currents are sufficient to induce membrane depolarization. Suppression of the 
K+ channel activity at resting voltages would be expected to increase membrane 
resistance and thereby amplify the voltage change induced by inward currents, further 
enhancing membrane depolarization. The additional constriction induced by 5HT when 
Kv7 currents were already fully inhibited by XE991 (Figure 14B, C) could be due to 
activation of inward currents (non-selective cation currents and/or chloride currents) that 
induces further membrane depolarization (Albert and Large 2006) and/or direct activation 
of VSCC (Worley et al. 1991). Neither ET-1 nor AVP induced significant additional 
constriction in the presence of XE991, suggesting that Kv7 current suppression may be 
sufficient to account for their constrictor actions at the concentrations tested (Figure 
14C).  
 
Protein kinase C as a mediator of the spasmogen-induced suppression of Kv7 
currents  
The signal transduction intermediates involved in the spasmogen-induced 
suppression of Kv7 currents are not currently known. Activation of PKC, a common 
signal transduction intermediate following activation of Gq/11–coupled receptors, is 
consistently observed in vasospastic myocytes after SAH (Laher and Zhang 2001). 
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Previous studies reported that PKC inhibitors attenuate spasmogen-induced constrictor 
responses in rat basilar artery, indicating activation of PKC as an intermediate for the 
constrictor response to spasmogens (Murray et al. 1992a; Murray et al. 1992b). In our 
experiments, activation of PKC using phorbol-12-myristate-13-acetate (PMA) suppressed 
Kv7 currents (Figure 15) and constricted basilar artery (Figure 16), mimicking the effects 
of the direct Kv7 channel blocker XE991. Hence, PKC activated during vasospasm is 
likely mediating its constrictor responses at least in part via the suppression of Kv7 
currents in basilar artery myocytes. Suppression of the Kv7 currents by PKC could be 
due to either direct phosphorylation of the channels (Higashida et al. 2005) or through 
activation of other kinases like Src (Gamper et al. 2003; Li et al. 2004a) that can 
phosphorylate the channels. 
 
Kv7 current enhancement attenuates spasmogen-induced membrane depolarization 
and vasoconstriction 
Retigabine reversed the spasmogen-induced suppression of Kv7 current amplitude 
(Figures 10, 11) and attenuated membrane depolarization in basilar artery myocytes 
(Figure 12). These effects translated functionally into dilation of the basilar artery when it 
was pre-constricted by spasmogens (Figure 18). Retigabine alone more than doubled the 
amplitude of resting Kv7 currents (Figure 7). In the presence of the spasmogens, when 
Kv7 currents were suppressed, retigabine still enhanced currents to about 65-80% above 
control levels (an approximately 3-fold increase in current compared with current levels 
measured in the presence of spasmogen alone (Figure 10, 11)). The increase in Kv7 
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current amplitude was accompanied by a hyperpolarizing shift of more than 10 mV in the 
voltage dependence of steady-state current activation (Figure 7C). Thus, in the presence 
of retigabine at physiological resting membrane voltages, Kv7 channels would have 
much greater probability of opening and hence provide a greater stabilization of negative 
membrane voltage. This would effectively oppose spasmogen-induced membrane 
depolarization (Figure 12) and opening of L-type voltage-sensitive Ca2+ channels. The 
latter is the primary stimulus for constriction of the basilar artery at physiological 
concentrations of vasoconstrictor agonists (Figure 13). This mechanism can explain why 
retigabine and flupirtine oppose the constrictor effects of spasmogens (Figure 17, 18). 
The actions of retigabine and flupirtine might be due to enhanced voltage-dependent 
activation of the proportion of Kv7 channels that were not suppressed by the spasmogens. 
Alternatively, (or perhaps in addition) the Kv7 channel openers may reverse the 
suppression of the Kv7 channels by spasmogens by virtue of their direct binding to the 
channel. Our findings do not distinguish between these two possibilities. 
Addition of flupirtine in the presence of nimodipine induced additional dilation of 
basilar artery segments (Figure 17C, D). We speculate that flupirtine induced an 
additional vasodilatory effect by opposing the membrane depolarization induced by the 
spasmogens, and thereby preventing the activation of both nimodipine-sensitive and 
nimodipine-insensitive VSCC. Our results shown in Figure 21 are consistent with this 
idea in that we can detect Ba2+ currents in basilar artery myocytes that are activated by 
membrane depolarization, but not fully blocked by 2 µM nimodipine.  
139 
 
The spasmogen and Kv7 channel opener concentrations used in the patch-clamp 
experiments and the vascular reactivity studies in pressure myography differ because of 
the varying sensitivities of the two systems used (Figures 6, 7, 10-14, 17-23). The 
differential sensitivity is likely because in intact arteries depolarization of a small 
proportion of smooth muscle cells leads to depolarization of the adjacent smooth muscle 
cells connected by gap junctions. Hence, lower concentrations of Kv7 current suppressors 
(spasmogens) and higher concentrations of Kv7 channel openers were required in artery 
preparations compared to patch clamp experiments. 
 
Celecoxib is a Kv7 channel activator and voltage-sensitive calcium channel blocker 
Celecoxib (Celebrex®) is marketed as a selective inhibitor of the cyclooxygenase-
2 (COX-2) enzyme and is widely prescribed to treat pain and inflammation. However, 
our present findings indicate that celecoxib is also a robust Kv7 channel activator (like 
flupirtine and retigabine) (Figure 19). Enhancement of the currents (Figure 19C) was not 
accompanied by a significant shift in the voltage-dependence of activation (Figure 19D). 
Previous work from our laboratory demonstrated similar effects of celecoxib in 
mesenteric artery myocytes and provided evidence that these effects are apparent at 
concentrations of celecoxib that could be achieved with clinical therapy (Brueggemann et 
al. 2009). Potassium currents conducted by human Kv7.5 channels expressed in VSMCs 
were also shown to be activated by celecoxib further indicating the translational 
relevance for the action of celecoxib (Brueggemann et al. 2009). Using an expression 
system, Du et al., expanded the repertoire of Kv7 channels activated by celecoxib. 
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Celecoxib activated Kv7.2-7.4, Kv7.2/7.3 and Kv7.3/7.5 channels, but inhibited Kv7.1 
and Kv7.1/KCNE1 channels (Du et al. 2011). The actions of celecoxib on Kv7 channels 
in that study were concentration-dependent with a half-maximal concentration between 2-
5 μM, within the concentration range used in the present study.  
Incidentally, Kv7 channels are not the only K+ channels modulated by celecoxib. 
Celecoxib has been shown to block 4AP-sensitive Kv1.5, Kv4.3 and Kv2.1 channels 
apart from blocking Kv7.1 channels (Frolov et al. 2010; Macías et al. 2010). Celecoxib 
inhibited Kv2.1 currents by modifying the gating kinetics and by inducing open- and 
closed-channel block (Frolov et al. 2010). It is also worthy to note that celecoxib is not 
the first COX inhibitor known to activate Kv7 channels. Several N-phenylanthranilic acid 
derivatives, that are mostly non-selective COX-inhibitors including meclofenamic acid, 
flufenamic acid, mefenamic acid, niflumic acid and diclofenac activate Kv7 currents 
(Brueggemann et al. 2011; Abitbol et al. 1999; Busch et al. 1994; Peretz et al. 2005). 
These compounds activate Kv7 currents by direct binding to the channel, and the activity 
is independent of its COX inhibitory effects (Peretz et al. 2007). Celecoxib is a 
benzenesulfonamide, structurally unrelated to the N-phenylanthranilic acid derivatives. 
The mechanism(s) by which celecoxib activates Kv7 channels are currently not known. 
Du et al., suggested possible direct binding of celecoxib to Kv7 channels (Du et al. 
2011), but that remains to be validated. 
Celecoxib also inhibited voltage-sensitive Ca2+ currents in basilar artery myocytes 
independently of its enhancement of Kv7 currents (Figure 20). Celecoxib was more 
effective as a VSCC blocker than 2 µM nimodipine in basilar artery myocytes (Figure 
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21). The concentration of nimodipine (2 µM), which induced significantly less 
suppression of VSCC than did 10 µM celecoxib, is more than 1000-fold higher than 
concentrations achieved in cerebrospinal fluid after nimodipine administration in patients 
(Allen et al. 1983). A similar Ca2+ channel blocking activity of celecoxib was observed in 
rat undifferentiated pheochromocytoma cells derived from adrenal gland (Zhang et al. 
2007).  
As expected from its dual ion channel effects, celecoxib very effectively reversed 
the constriction induced by the spasmogens (Figure 22A, B). And, like flupirtine, 
celecoxib was a more effective dilator of basilar artery than nimodipine (Figure 22C, D). 
The additional dilation induced by celecoxib can be plausibly due to two mechanisms: 1) 
enhancement of Kv7 currents, thereby limiting the voltage change necessary to activate 
all of the VSCCs; or 2) Kv7 channel-independent inhibition of nimodipine-insensitive 
VSCC. Our results provide evidence for both of these mechanisms. The finding that 
flupirtine induces an additional dilation in the presence of nimodipine supports the former 
(Figure 17D) and that celecoxib induces additional inhibition of voltage-sensitive Ba2+ 
currents in the presence of 2µM nimodipine supports the latter (Figure 21). Celecoxib 
also prevented the constrictor effect of 5HT, indicating that celecoxib can potentially be 
employed as a pre-emptive therapy to prevent vasospasm (Figure 23).  
Rofecoxib, a more potent COX-2 inhibitor than celecoxib (FitzGerald and 
Patrono 2001), but devoid of the ion channel modulatory activity (Brueggemann et al. 
2009; Du et al. 2011), did not induce vasodilatory responses (Figure 29A, C). Dimethyl 
celecoxib, a structural analog of celecoxib modified to eliminate COX-2 activity 
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(Kardosh et al. 2005), that retained the ion channel modulatory actions of celecoxib 
(Brueggemann et al. 2009), almost completely dilated spasmogen pre-constricted artery 
segments (Figure 29B, C). Hence, the vasodilatory effects observed with celecoxib are 
independent of its ability to inhibit the COX-2 enzyme. Disruption of endothelium did 
not attenuate the vasodilatory effect of celecoxib in pressurized mesenteric arteries 
(Brueggemann et al. 2009). Hence, the vasodilatory action of celecoxib are mediated 
through action on vascular smooth muscle cells rather than modulation of endothelial 
function as implicated previously (Klein et al. 2007). Though Kv7 channel activation and 
VSCC blockade in vascular smooth muscle cells are likely the principle mechanisms for 
vasodilatory responses observed with celecoxib, it is not possible to rule out modulation 
of other ion channels or intracellular Ca2+ mobilization pathways by celecoxib that may 
also contribute in part to the responses.  
 
Kv7 channel activators prevent basilar artery vasospasm in a rat model of SAH 
Since Kv7 channel openers were able to reverse and/or prevent the constrictor 
responses of spasmogens (Figure 17, 18, 22 and 23), we tested the efficacy of two Kv7 
channel openers, retigabine and celecoxib, as potential therapies to reduce basilar artery 
vasospasm in a rat model of SAH. We used a single hemorrhage model that produces 
biphasic vasospasm of basilar artery that peaks at day 2 after injection (Delgado et al. 
1985). The basilar artery is the most common artery that undergoes spasm after injection 
of arterial blood into cisterna magna (Gules et al. 2002). In our disease model, injection 
of autologous arterial blood (but not aCSF) into the cisterna magna induced a sustained 
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constriction of the basilar artery that persisted 48 hours after the initial injury (Figure 24). 
Both the Kv7 channel openers, retigabine (7.5 mg/kg, i.p) and celecoxib (20 mg/kg, i.p), 
when administered twice daily, significantly attenuated the sustained basilar artery 
vasospasm in this model (Figure 24). Basilar artery outer diameter measured at 48 hr (12 
hr after the last injection) was used as the endpoint criterion to assess the severity of 
vasospasm and efficacy of treatments. 
Celecoxib offers a dual action (Kv7 current enhancement and voltage-sensitive 
Ca2+ current inhibition), which may account for its tendency to induce a greater dilation 
of the basilar artery in the SAH model (Figure 24), translating its ex vivo vasodilatory 
efficacy (Figure 22, 23). Apart from modulating the activities of vascular ion channels, 
celecoxib is likely to provide neuroprotective and anti-inflammatory effects due to its 
clinically utilized COX-2 inhibitory activity. Cytokine-mediated upregulation of COX-2 
expression has been observed in endothelial cells of basilar artery in several animal 
models of SAH contributing to the inflammatory response after SAH (Tran Dinh et al. 
2001; Osuka et al. 2006; Osuka et al. 1998). COX-2 inhibition has been demonstrated to 
significantly reduce neuronal deterioration in a mouse model of aneurysmal SAH (Ayer 
et al. 2011). Thus, celecoxib may have multiple beneficial effects for patients suffering 
from SAH-induced cerebral vasospasm. 
The limitation of the rat animal model is that the rats did not exhibit the 
neurological deficits (Gules et al. 2002; Germano et al. 1994) observed in humans. A 
double hemorrhage model, involving a second injection of blood into cisterna magna 48 
hours after the first injection, induces a more sustained basilar artery constriction 
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simulating the timeline of vasospasm development in humans (Gules et al. 2002). Despite 
that improvement, rats in the double hemorrhage model did not exhibit a neurological 
profile similar to humans (Gules et al. 2002; Jeon et al. 2009). We attempted to assess the 
neurological endpoints using behavioural tests used in ischemic stroke models (Garcia et 
al. 1995). The SAH rats did not exhibit any significant change in neurological function 
compared to rats injected with aCSF into the cisterna magna (not shown). Assessment of 
neurological endpoints were further limited due to the significant reduction in the activity 
of rats with treatment of retigabine and celecoxib (Figure 26). A limitation in most of the 
neurological tests used in this study and elsewhere in the literature is that these 
neurological tests were developed to detect deficits caused by focal ischemia as seen in 
traumatic brain injury models (Jeon et al. 2009). Focal ischemic lesions are very 
uncommon in patients after SAH. The patients suffer from deficits in neurobehavioural 
function such as memory, visuospatial/construction ability and executive function (Jeon 
et al. 2009; Al-Khindi et al. 2010; Anderson et al. 2006; Kreiter et al. 2002). Since focal 
deficits are rare in animal models of SAH (Jeon et al. 2009), it is not surprising that none 
of the neurological tests showed a change with SAH. Impaired memory and behavior 
deficits after SAH in rodents can be assessed using paradigms like morris water maze, 
matching-to-sample tests, and open field behavior. However, these assessments were not 
feasible because of the significant reduction in the locomotor activity of rats treated with 
retigabine or celecoxib (Figure 26).  
Direct neuroprotective effects of Kv7 channel activators: Emerging evidence 
suggests that cortical spreading depression (CSD) is a major contributing factor to 
145 
 
cerebral ischemia after SAH (Leng et al. 2011). CSD is manifested as slow (2-5 mm/min) 
waves of depolarization in cerebral gray matter that propagate across the brain (Leao 
1944). The spreading depression is characterized by near-complete depolarization of 
neurons (from -70 mV resting voltage to -10 mV) and a maximal shunt in membrane 
resistance in neurons (Canals et al. 2005; Dreier 2011). The ensuing depolarization-
induced hypermetabolic rate of neurons results in disrupted neurovascular coupling, 
hypoxia, and toxic accumulation of metabolic end products. This cascading events lead to 
an inverse hemodynamic effect in response to depolarization of neurons and a reduction 
of regional cerebral blood flow (Dreier 2011). A vicious cycle is likely established- the 
spreading depolarization maintains vasoconstriction and ischemia, and the ischemia 
maintains spreading depolarization (Dreier 2011). Hence, CSD is likely a co-morbid 
pathology with chronic vasospasm that contributes to delayed cerebral ischemia in 
patients (Bosche et al. 2010; Dreier et al. 2009). Electrocorticography recordings 
detected spreading depolarizations in 72% of patients after SAH and recurrent spreading 
depolarizations had a time locked correlation to cerebral ischemia (Lauritzen et al. 2011). 
The events that instigate CSD (and vasospasm) after SAH remain unclear. The fact that 
endothelin can induce CSD (Dreier et al. 2002) and vasospasm (Asano et al. 1990) 
indicates there might be some common etiological factors involved.  
Neuronal Kv7 channels may be important regulators of CSD, based on previous 
findings that inhibition of Kv7 channels with linopirdine induced spreading depression in 
hippocamal slices (Okada et al. 2003) and S(1)-acrylamide, a Kv7.2-selective channel 
opener, prevented CSD induced by K+ in a rat model (Wu et al. 2003). Thus, a Kv7.2-7.5 
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channel opener like retigabine is expected to reduce cerebral ischemic deficits by exerting 
direct neuroprotective effects by antagonizing CSD after SAH. Direct neuroprotective 
effects of retigabine and flupirtine have been reported in several studies (Boscia et al. 
2006; Gamper et al. 2006; Seyfried et al. 2000). Therefore, Kv7 channel openers will 
likely reduce neuronal deficits after SAH through direct neuroprotective effects as well as 
from their direct vasodilatory actions mediated by Kv7 channels in the basilar artery 
myocytes (Figure 24). 
Kv7 channel activators induce hypothermia in a the rat model of SAH: 
Increased body temperature after SAH is associated with vasospasm, increased functional 
disability and cognitive impairment, and high mortality in patients (Badjatia et al. 2010; 
Fernandez et al. 2007; Oliveira-Filho et al. 2001). Mild hypothermia (33-34°C) has been 
reported to have a neuroprotective effect and increases the functional outcome in patients 
with delayed cerebral vasospasm (Gasser et al. 2003; Maekawa et al. 1994; Nagao et al. 
2000; Nagao et al. 2003) and in a rat model of SAH (Torok et al. 2009). Induction of 
moderate hypothermia also reduced the hypoperfusion-induced metabolic alterations in a 
rat model of SAH (Schubert et al. 2008). Therapeutic hypothermia has emerged as a 
potent and practicable neuroprotective treatment for ischemic and hemorrhagic stroke and 
intracerebral hemorrhage (Feigin et al. 2002; Hemmen and Lyden 2009; Linares and 
Mayer 2009). The mechanism for the neuroprotective effects likely includes reduced 
metabolic demand of the brain parenchyma (Erecinska et al. 2003; Jiang et al. 1992), 
stabilization of the blood-brain barrier (Jiang et al. 1992; Smith and Hall 1996), reduced 
post-ischemic cerebral edema (Kurasako et al. 2007), reduction of ischemia-induced 
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neurotoxic glutamate release (Busto et al. 1989; Globus et al. 1995) and free radical 
production (Globus et al. 1995; Lee et al. 2009).  
We found that retigabine induced significant hypothermia in the rat model of 
SAH, even 12 hours after administration (Figure 25). Celecoxib (20 mg/kg) also tended 
to lower body temperature. A recent study also observed hypothermia with 
intraperitoneal administration of Kv7 channel openers: retigabine, ICA-27243, S(1)-
acrylamide and BMS-204352 in mice (Kristensen et al 2011). The hypothermic response 
in mice (about 4°C reduction in temperature) with retigabine administration was rapid in 
onset and lasted only up to an hour after administration (Kristensen et al. 2011). The 
reason for the long lasting hypothermia observed in the rat model of SAH in not clear, 
but could involve modulation of Kv7 channels in the hypothalamus that encompasses the 
thermoregulatory center (Cooper et al. 2001; Weber et al. 2006). Nevertheless, the 
hypothermic effect observed with Kv7 channel activators is likely to improve the 
functional outcome in patients after SAH. Severe hypothermia produces several 
complications ranging from electrolyte imbalances to multiple organ failure in patients 
with cerebral vasospasm (Seule et al. 2009). Therefore, a careful individualized 
examination of the risk: beneficial effects of the Kv7 channel activation-induced 
hypothermia need to be undertaken if administered to patients with cerebral vasospasm.  
 
Kv7 channel activators do not induce sustained hypotension 
Sustained hypotension may limit the utility of other classes of K+ channel openers 
(e.g. KATP channel openers) or CCBs in the effective treatment of cerebral vasospasm 
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(Spinelli et al. 1990; Porchet et al. 1995). In contrast, intraperitoneal administration of 
either retigabine (7.5 mg/kg) or celecoxib (50 mg/kg) induced only a transient drop in 
MAP without any appreciable change in the 24-hour MAP (Figure 27) or heart rate 
(Figure 28). The reason for resiliency to effects of Kv7 channel openers on MAP is likely 
because (1) these channels are active under physiological conditions in a sub-threshold 
voltage range (-60 to -40 mV, Figure 6) in which VSCCs are not appreciably active; (2) 
the whole-cell conductance through Kv7 channels is very small compared to 4-AP-
sensitive Kv and BK channels (Jahromi et al. 2008c). 
The half-life of retigabine in male rats is 2 h and that of celecoxib is 3.7 h 
(Mazarati et al. 2008; Paulson et al. 2000). Both the drugs accumulate significantly in the 
brain, exceeding the plasma concentrations when administered to rats (Rostock et al. 
1996; Pfizer Canada 2007). This could also account for the short-lived effect on systemic 
arterial blood pressure, but long-lasting vasodilatory effect on basilar artery. 
The vascular effects (vasodilation) of enhanced Kv7 channel activity would 
primarily result from relaxation of myocytes with depolarized membrane voltages (e.g. 
basilar artery myocytes following SAH), with little effect on the systemic vasculature 
where arterial myocytes have resting voltages between -60 and -40 mV. In this regard, 
the function of Kv7 channels in vascular myocytes is analogous to their function in the 
excitability of neurons, where dysfunction, either by suppression of M-currents, or 
inactivating mutations of Kv7 channels, results in hyperexcitability precipitating seizures 
(Jentsch 2000). In arteries, activation of Kv7 currents relaxes the constricted arterial 
myocytes (Figure 24) without producing marked systemic hypotension (Figure 27) 
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similar to the effects of retigabine used as an anti-epileptic agent, where it dampens 
neuronal hyperexcitability with little effect on the normal function of the nervous system 
(Gunthorpe et al. 2012).   
 
Kv7 channel activators as candidates to treat cerebral vasospasm 
A number of pharmaceutical companies are currently developing novel Kv7 
channel openers to treat epilepsy and neuropathic pain (Miceli et al. 2008). Retigabine 
was recently approved by the US Food and Drug Administration as an adjunctive 
treatment for partial-onset seizures in adult patients (Gunthorpe et al. 2012; Harris and 
Murphy 2011; Stafstrom et al. 2011). More than 20 patents for selective openers of 
Kv7.2-7.5 channels have been issued and an estimated more than 100 applications are 
currently under review (Castle 2010; Wulff et al. 2009). Therefore, it is reasonable to 
expect that Kv7 channel openers with better pharmacodynamic and pharmacokinetic 
profiles will be available soon. Our findings suggest that, in addition to their direct 
neuroprotective effects (Boscia et al. 2006), these drugs with established safety profiles 
(Blackburn-Munro et al. 2005; Frampton and Keating 2007; Brodie et al. 2010; French et 
al. 2011; Ueberall et al. 2011) can be readily adopted to prevent or limit cerebral 
vasospasm after SAH. Based on the pronounced antivasospastic effect of Kv7 channel 
openers reported here, we would add cerebral vasospasm to the expanding repertoire of 
conditions potentially treatable with Kv7 channel openers. 
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Phosphodiesterase inhibitors activate Kv7 channels and block voltage-sensitive 
calcium channels in A7r5 cells 
We utilized cultured aortic smooth muscle (A7r5) cells derived from rat embryos 
to study the mechanism by which celecoxib modulates ion channels. Since a previous 
study suggested that celecoxib is a PDE4 and 5 inhibitor (Klein et al. 2007), we tested if 
selective PDE inhibitors simulate celecoxib’s action on ion channels. Selective 
pharmacological inhibition of PDE4 (with rolipram), PDE5 (with sildenafil) or a non-
selective PDE inhibition (with papaverine) significantly enhanced the voltage-activated 
Kv7 currents (Figure 30, 32 and 34). Similarly, all these PDE inhibitors also inhibited 
voltage-sensitive Ca2+ currents (Figure 31, 33, (Han et al. 2007)) in vascular smooth 
muscle cells. Application of either rolipram or sildenafil attenuated AVP-induced Ca2+ 
spiking responses in A7r5 cells (Figure 35; sildenafil results not shown) and dilated pre-
constricted mesenteric artery segments (Figure 36), again simulating the effect of 
celecoxib (Brueggemann et al. 2009). However, whether inhibition of PDE enzymes 
accounts for all (or even any) of the ion channel modulatory effects of celecoxib is not 
known. Experiments undertaken to address that question using whole cell patch-clamp 
experiments were inconclusive because of the bell-shaped dose-reponse for the ion 
channel modulatory actions of both celecoxib and the PDE inhibitors (Figure 30, 31 
(Brueggemann et al. 2009)). Another possible mechanism for the ion channel modulatory 
effects of celecoxib could be due direct binding of the drug to the channels as proposed 
for Kv7 channels (Du et al. 2011). The ability of celecoxib to enhance single channel 
currents through overexpressed Kv7 channels would be an approach to test whether 
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activation of Kv7 channels by celecoxib is due to direct binding of the drug to the 
channels or mediated through a signal transduction pathway as proposed here. 
Nevertheless, these present experiments suggest enhancement of Kv7 currents and 
inhibition of voltage-sensitive Ca2+ currents as likely contributors to the vasodilatory 
responses observed with PDE inhibitors. Further experiments are needed to confirm 
whether inhibition of PDE enzymes fully accounts for ion channel modulatory effects of 
celecoxib.  
All the aforementioned PDE inhibitors are used clinically to treat a variety of 
clinical conditions. Rolipram was used to treat depression and chronic obstructive 
pulmonary disease (O'Byrne and Gauvreau 2009), sildenafil is used to treat erectile 
dysfunction (Sandner et al. 2007) and papaverine is used to treat cerebral vasospasm (Liu 
and Couldwell 2005). Despite their extensive clinical utility and the well-characterized 
vasodilatory responses and reduction in blood pressure associated with their use (Oliver 
et al. 2006; Zusman et al. 1999), understanding of the cellular mechanisms leading to 
vascular responses is nascent. 
PDE4 selectively hydrolyses cAMP [Km (μM), cAMP/cGMP=2/>300), and 
PDE5 selectively hydrolyses cGMP [Km (μM), cAMP/cGMP=150/1) (Keravis and 
Lugnier 2012). Inhibition of either PDE4 or PDE5 with selective blockers rolipram or 
sildenafil produced the same tendency to activate Kv7 channels and block Ca2+ channels 
(Figure 30-33). Downstream kinases activated by the nucleotides have been shown to 
exert feedback regulation of the activity of either the same PDE family of enzymes that 
hydrolyses the nucleotides or distinct family of PDE enzymes (Keravis and Lugnier 
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2012). Furthermore, activation of the downstream kinases by the nucleotides: PKA by 
cAMP and PKG by cGMP, while selective, are known to cross-activate the other kinase 
(Keef et al. 2001). Therefore, a simplistic model with both or either of the nucleotides 
regulating the channel through activation of a vertical downstream signal transduction 
cascade may be unlikely.  
In neurons, Kv7 channels exist in a signaling complex along with PKC, PKA, and 
protein phosphatase 2B (PP2B) held together by a multivalent scaffolding protein, AKAP 
(Hoshi et al. 2003; Higashida et al. 2005; Hoshi et al. 2005). AKAP has also been shown 
to immunoprecipitate with Kv7.5 channels in A7r5 cells and is proposed to be in a 
signaling complex that includes PKC (Hummert et al. 2011), similar to the existence in 
neurons. PDE4 enzymes have been also demonstrated to be constitutively associated with 
AKAP in VSMCs (Dodge et al. 2001; Raymond et al. 2009; Houslay et al. 2007). Hence, 
there is a possibility that AKAP tethers Kv7 channels in a signalosome, along with PDE4 
and PKA, thereby facilitating phosphorylation of the channels by the cAMP-activated 
PKA to enhance Kv7 currents.  
Functional analysis in cardiomyocytes indicated that PDE4 and cAMP-activated-
PKA are in close proximity, and are held together by AKAP (Dodge et al. 2001). 
Enhanced activity of PDE4 was found to reduce PKA activity; elevated cAMP and kinase 
activity had a negative feedback stimulation of PDE4 enzyme in cardiac or vascular 
myocytes (Dodge et al. 2001; Rose et al. 1997). Another study also showed that long-
term elevation of cAMP by exogenous administration of cAMP-elevating drugs to rats 
stimulated transcription of PDE 3 and 4 enzymes in vascular myocytes (Tilley and 
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Maurice 2002). This highlights the complex overlapping feedback loops at different 
levels, which enables a tight control of the cAMP levels and the downstream PKA 
activity. The possible existence of the signalosome and the negative feedback 
mechanisms in vascular myocytes could contribute to the bell shaped concentration 
response curves observed here (Figure 30, 31).  
The mechanism by which sildenafil regulates the Kv7 channels is not known and 
requires further investigation. As an inhibitor of PDE5, sildenafil is expected to increase 
cGMP levels. Voltage-sensitive Ca2+ channels are known to be modulated by cyclic 
nucleotides, cAMP and cGMP. Elevation of cGMP using a membrane-permeable analog, 
8Br-cGMP or nitric oxide (NO) donors have been shown in several studies to inhibit 
VSCC in a PKG-dependent manner (Keef et al. 2001). PKG-mediated VSCC blockade 
may therefore explain the sildenafil effect observed here. PKG has been shown to 
phosphorylate both the Cav1.2 α1c subunit and the accessory β2 subunit of VSCC in a 
heterologous expression system; phosphorylation of a serine residue in the β2 subunit 
accounted for the PKG-induced inhibition of the currents (Yang et al. 2007). Thus, a 
direct phosphorylation of VSCC by PKG could account for the inhibition of voltage-
sensitive Ca2+ currents observed with sildenafil.  
In the present study, addition of rolipram, which is expected to increase cAMP, 
inhibited voltage-sensitive Ca2+ currents. Regulation of voltage-sensitive Ca2+ currents by 
cAMP and the downstream kinase (PKA) in VSMCs is controversial, with several studies 
showing either enhancement, inhibition, or no effect on the currents (Keef et al. 2001). 
Elevation of intracellular cAMP by stimulation of Gs-coupled seven transmembrane 
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receptors results in dilation of intact arteries (Satake and Shibata 1997), consistent with 
our electrophysiological and functional results with rolipram. However, further studies 
are needed to elucidate the downstream effectors that lead to inhibition of VSCC with 
addition of rolipram. 
An increase in the expression of PDE5 enzyme and enhanced PDE5 enzyme 
activity was observed in vasospastic canine basilar artery myocytes compared to control 
basilar artery myocytes (Inoha et al. 2002). Another study using a mouse model of SAH 
found increased PDE5 enzyme activity, but no increase in the expression of the enzyme 
in vasospastic arteries (Han et al. 2012). Treatment with sildenafil attenuated the basilar 
artery vasospasm in the canine, rat and mouse models of SAH (Gokce et al. 2010; Han et 
al. 2012; Inoha et al. 2002). The fact that sildenafil is a Kv7 channel activator (Figure 32) 
indicates that at least part of its anti-vasospastic effects might be mediated through 
activation of Kv7 channels.  
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CHAPTER 7 
CONCLUSIONS 
This comprehensive dissertation provides the first evidence for the presence of 
Kv7 channels in basilar artery and a central role of the channels in regulating the 
contractile status of the artery. The results show that known basilar artery spasmogens, 
including the Gq/11-coupled receptor agonists, serotonin, endothelin, and vasopressin, 
potently suppress the activity of Kv7 channels in basilar artery myocytes and induce 
membrane depolarization. This may account for the depolarization that has been observed 
in myocytes following SAH. This study also demonstrates for the first time that celecoxib 
is an effective dilator of basilar artery by activating Kv7 channels as well as by blocking 
voltage-sensitive Ca2+ channels. Pharmacological Kv7 channel activators oppose the 
effect of spasmogens on Kv7 currents and membrane depolarization, and relax 
pressurized basilar arteries that are pre-constricted with these spasmogens. We also 
demonstrate that clinically used Kv7 channel activators, retigabine, and celecoxib were 
effective in relieving basilar artery spasm in vivo in rats with experimentally-induced 
SAH. Hence, these results provide evidence supporting the use of Kv7 channel activators 
as a novel class of drugs to treat patients who develop or are likely to develop cerebral 
vasospasm (Figure 37).  
Our laboratory was the first to propose that Kv7 potassium channels are signal 
transduction intermediates in the vasoconstrictor actions of physiological concentrations 
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of vasopressin. This dissertation provides the first evidence that this mechanism is shared 
by multiple vasoconstrictors that activate Gq/11-coupled receptors in basilar artery 
myocytes. As such, its significance extends beyond the role of these channels in the 
cerebral circulation, providing mechanistic insights into the signal transduction processes 
that contribute to physiological and pathological regulation of blood flow and blood 
pressure in general. This dissertation also provides the first evidence that activation of 
Kv7 channels is a mechanism by which phosphodiesterase inhibitors induce vasodilation 
and reduction in blood pressure (Figure 37).  
In summary, Kv7 channels in basilar artery myocytes are critical regulators of the 
vasoconstrictor/dilator response. Apart from revealing a potential novel therapeutic target 
for treatment of cerebral vasospasm, identification of the role of Kv7 channels in the 
vasculature is likely to aid in the development of alternative treatment options for other 
dreadful cardiovascular disorders like coronary vasospasm, hypertension, and septic 
shock, which are conditions characterized by dysregulated vasoconstriction. This 
dissertation project, thus, identifies a possible solution to contain several epidemic 
cardiovascular diseases that engulf our society and continue to expand.  
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Figure 37: Spasmogens suppress Kv7 currents to induce basilar artery vasospasm; 
Kv7 channel activators oppose the spasm. Spasmogens, by binding to their specific 
receptors, suppress the Kv7 currents through a signal transduction mediated mechanism. 
Suppression of the Kv7 currents depolarizes the membrane, activating voltage-sensitive 
Ca2+ channels, resulting in influx of Ca2+ and, initiation and maintenance of constriction. 
Administration of the Kv7 channel activator, retigabine, or the dual Kv7 channel 
activator and voltage-sensitive Ca2+ channel blocker, celecoxib, prevents/overcomes the 
spasmogen-induced vasospasm. 
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CHAPTER 8 
FUTURE DIRECTIONS 
The dissertation project presents the first evidence for the presence and function 
of Kv7 channels in rat basilar artery myocytes. This study adds to the previous findings 
that Kv7 channels play a pivotal role in maintaining the resting membrane voltage of 
excitable cells. Single-cell patch-clamp and pressure myography studies provided 
evidence for the mechanism by which Kv7 channel activators could be a novel class of 
drugs to treat patients with cerebral vasospasm. The study also provided “proof-of-
concept” evidence that Kv7 channel activators attenuate basilar artery vasospasm in an 
acute model of SAH. However, the study does not address whether the anti-vasospastic 
effects of Kv7 channel activators would result in a favorable clinical outcome in terms of 
reduction in neurological deficits and perhaps reduction in mortality. This is not an easy 
question to address in the current scenario, given that there are no good animal models 
that can predict the neurological outcome in patients. Alternatively, since both the Kv7 
channel activators employed here are clinically utilized drugs with established safety 
profile, a clinical study with a small cohort of patients can be performed.  
The findings from the study, if they hold in humans, could have immense 
translational value and offer a possible effective alternative therapeutic approach for 
cerebral vasospasm. However, additional information is needed to realize the potential of 
the current study. For one thing, there is a paucity of information regarding the 
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expression of Kv7 channels in the human cerebral vasculature and even vascular 
myocytes in general. To date there is only one report, which shows the existence of Kv7 
channels in human vasculature (Ng et al. 2011). Evidence for the expression and function 
of these channels in human cerebral vasculature is therefore required before initiation of 
clinical trials using Kv7 channel activators to treat cerebral vasospasm.   
The study provides strong evidence that inhibition of phosphodiesterase 
enzymes(s) using clinically utilized drugs activate Kv7 currents in cultured A7r5 cells. 
The findings need to be validated in myocytes derived from human vasculature to address 
the translational relevance of the presence findings. In a classic case of reverse 
pharmacology, the findings opens the door for understanding signal transduction 
mediated regulation of ion channels, including Kv7 channels and voltage-sensitive Ca2+ 
channels. As mentioned in the discussion section, there is a very high likelihood that Kv7 
channels are in a signalasome that includes PKA and PDE, held together by AKAP 
(Figure 38). Studying the mechanisms by which celecoxib and phosphodiesterase 
inhibitors regulate Kv7 channels is therefore expected to shed more light on the 
regulation of vascular tone and therefore potentially identify new targets to modulate 
vascular tone. 
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Figure 38: Hypothetical mechanism by which celecoxib and rolipram regulate Kv7 
currents in vascular smooth muscle cells. Activation of the membrane-bound enzyme 
adenlyl cyclase synthesizes cyclic adenosine monophosphate (cAMP) from adenosine 
triphosphate (ATP). The cytosolic levels of cAMP is dynamically regulated by 
degradation to adenosine monophosphate (AMP) by cAMP-selective phosphodiesterase 
(PDE) enzymes, like PDE4. PDE4 is likely tethered in a signalasome that also 
encompasses protein kinase A (PKA), and Kv7 channels, held together by a scaffolding 
protein, A-kinase anchoring protein (AKAP). Inhibition of PDE4 enzyme by celecoxib or 
rolipram results in accumulation of cAMP, which activates PKA. PKA likely 
phosphorylates the channels in setine/threonine residue(s) to activate the Kv7 channels. 
Sildenafil similarly enhances cyclic guanosine monophosphate (cGMP) levels, protein 
kinase G (PKG) activity, which could modulate the Kv7 channel activity either by direct 
phosphorylation of the channels or by modulating the cAMP-PKA pathway. 
 
 161 
 
 
 
 
 
REFERENCES 
Abitbol I, Peretz A, Lerche C, Busch AE, Attali B (1999) Stilbenes and fenamates rescue 
the loss of I(KS) channel function induced by an LQT5 mutation and other IsK 
mutants. The EMBO journal 18:4137-48.  
Adams PR, Brown DA (1982) Synaptic inhibition of the M-current: slow excitatory post-
synaptic potential mechanism in bullfrog sympathetic neurones. J Physiol 332:263-
72.  
Adams PR, Brown DA, Constanti A (1982) Pharmacological inhibition of the M-current. 
J Physiol 332:223-262.  
Adams PR, Brown DA (1980) Luteinizing hormone-releasing factor and muscarinic 
agonists act on the same voltage-sensitive K+-current in bullfrog sympathetic 
neurones. Br J Pharmacol. 68:353-5.  
Aguilar-Bryan L, Clement JPt, Gonzalez G, Kunjilwar K, Babenko A, Bryan J (1998) 
Toward understanding the assembly and structure of KATP channels. Physiological 
reviews 78:227-45.  
Ahmad I, Imaizumi S, Shimizu H, Kaminuma T, Ochiai N, Tajima M, Yoshimoto T 
(1996) Development of calcitonin gene-related peptide slow-release tablet 
implanted in CSF space for prevention of cerebral vasospasm after experimental 
subarachnoid haemorrhage. Acta neurochirurgica 138:1230-40.  
Ahmed N, Nasman P, Wahlgren NG (2000) Effect of intravenous nimodipine on blood 
pressure and outcome after acute stroke. Stroke 31:1250-5.  
Aiello EA, Clement-Chomienne O, Sontag DP, Walsh MP, Cole WC (1996) Protein 
kinase C inhibits delayed rectifier K+ current in rabbit vascular smooth muscle 
cells. The American journal of physiology 271:H109-19.  
Aihara Y, Jahromi BS, Yassari R, Nikitina E, Agbaje-Williams M, Macdonald RL (2004) 
Molecular profile of vascular ion channels after experimental subarachnoid 
hemorrhage. J Cereb Blood Flow Metab 24:75-83.  
162 
 
Aiken SP, Lampe BJ, Murphy PA, Brown BS (1995) Reduction of spike frequency 
adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 
996), a neurotransmitter release enhancer. British journal of pharmacology  115:1163-8.  
kasu T (1988) Adrenaline depolarization in paravertebral sympathetic neurones of 
bullfrogs. Pflugers Archiv. European Journal of Physiology 411:80-7.  
Akata T (2007a) Cellular and molecular mechanisms regulating vascular tone. Part 1: 
basic mechanisms controlling cytosolic Ca2+ concentration and the Ca2+-
dependent regulation of vascular tone. Journal of anesthesia 21:220-31.  
Akata T (2007b) Cellular and molecular mechanisms regulating vascular tone. Part 2: 
regulatory mechanisms modulating Ca2+ mobilization and/or myofilament Ca2+ 
sensitivity in vascular smooth muscle cells. Journal of anesthesia 21:232-42.  
Alaimo A, Gomez-Posada JC, Aivar P, Etxeberria A, Rodriguez-Alfaro JA, Areso P, 
Villarroel A (2009) Calmodulin activation limits the rate of KCNQ2 K+ channel 
exit from the endoplasmic reticulum. J Biol Chem 284:20668-20675.  
Albarwani S, Nemetz LT, Madden JA, Tobin AA, England SK, Pratt PF, Rusch NJ 
(2003) Voltage-gated K+ channels in rat small cerebral arteries: molecular identity 
of the functional channels. J Physiology 551:751-763.  
Albert AP, Large WA (2006) Signal transduction pathways and gating mechanisms of 
native TRP-like cation channels in vascular myocytes. The Journal of physiology 
570:45-51.  
Al-Khindi T, Macdonald RL, Schweizer TA (2010) Cognitive and Functional Outcome 
After Aneurysmal Subarachnoid Hemorrhage. Stroke:STROKEAHA.110.581975.  
Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, 
Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits 
DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR 
(1983) Cerebral arterial spasm--a controlled trial of nimodipine in patients with 
subarachnoid hemorrhage. The New England journal of medicine 308:619-24.  
Allen GS, Gold LH, Chou SN, French LA (1974) Cerebral arterial spasm. 3. In vivo 
intracisternal production of spasm by serotonin and blood and its reversal by 
phenoxybenzamine. Journal of neurosurgery 40:451-8.  
Allen T, Iftinca M, Cole WC, Plane F (2002) Smooth muscle membrane potential 
modulates endothelium-dependent relaxation of rat basilar artery via myo-
endothelial gap junctions. J Physiol 545:975-986.  
163 
 
Anderson SW, Todd MM, Hindman BJ, Clarke WR, Torner JC, Tranel D, Yoo B, Weeks 
J, Manzel KW, Samra S (2006) Effects of intraoperative hypothermia on 
neuropsychological outcomes after intracranial aneurysm surgery. Annals of 
neurology 60:518-27.  
Anderson UA, Carson C, McCloskey KD (2009) KCNQ currents and their contribution 
to resting membrane potential and the excitability of interstitial cells of Cajal from 
the guinea pig bladder. The Journal of urology 182:330-6.  
Antoni FA (2000) Molecular diversity of cyclic AMP signalling. Frontiers in 
neuroendocrinology 21:103-32.  
Arakawa Y, Kikuta K, Hojo M, Goto Y, Yamagata S, Nozaki K, Hashimoto N (2004) 
Milrinone reduces cerebral vasospasm after subarachnoid hemorrhage of WFNS 
grade IV or V. Neurologia medico-chirurgica 44:393-400; discussion 401.  
Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S (2001) Milrinone for the 
treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven 
cases. Neurosurgery 48:723-8; discussion 728-30.  
Arif SA, Poon H (2011) Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the 
treatment of pulmonary arterial hypertension. Clinical therapeutics 33:993-1004.  
Asano T (1999) Oxyhemoglobin as the principal cause of cerebral vasospasm: a holistic 
view of its actions. Crit Rev Neurosurg 9:303-318.  
Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Sugita K, Hidaka H (1990) 
Endothelin: a potential modulator of cerebral vasospasm. European journal of 
pharmacology 190:365-72.  
Asano T, Ikegaki I, Suzuki Y, Satoh S, Shibuya M (1989) Endothelin and the production 
of cerebral vasospasm in dogs. Biochemical and biophysical research 
communications 159:1345-51.  
Atalay B, Caner H, Cekinmez M, Ozen O, Celasun B, Altinors N (2006) Systemic 
administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of 
cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 
59:1102-7; discussion 1107-8.  
Aw TJ, Haas SJ, Liew D, Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors 
and their effects on blood pressure. Arch Intern Med. 165:490-6. Epub 2005 Feb 14.  
164 
 
Ayer R, Jadhav V, Sugawara T, Zhang JH (2011) The neuroprotective effects of 
cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid 
hemorrhage. Acta neurochirurgica 111:145-9.  
Badjatia N, Fernandez L, Schmidt JM, Lee K, Claassen J, Connolly ES, Mayer SA 
(2010) Impact of induced normothermia on outcome after subarachnoid 
hemorrhage: a case-control study. Neurosurgery 66:696-700; discussion 700-1.  
Bal M, Zhang J, Hernandez CC, Zaika O, Shapiro MS (2010) Ca2+/calmodulin disrupts 
AKAP79/150 interactions with KCNQ (M-Type) K+ channels. J Neurosci 30:2311-
23.  
Bal M, Zhang J, Zaika O, Hernandez CC, Shapiro MS (2008) Homomeric and 
Heteromeric Assembly of KCNQ (Kv7) K+ Channels Assayed by Total Internal 
Reflection Fluorescence/Fluorescence Resonance Energy Transfer and Patch Clamp 
Analysis. Journal of Biological Chemistry 283:30668-30676.  
Bardou M, Goirand F, Bernard A, Guerard P, Gatinet M, Devillier P, Dumas JP, Morcillo 
EJ, Rochette L, Dumas M (2002) Relaxant effects of selective phosphodiesterase 
inhibitors on U46619 precontracted human intralobar pulmonary arteries and role of 
potassium channels. Journal of cardiovascular pharmacology 40:153-61.  
Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey G (1996) K(V)LQT1 
and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. 
Nature 384:78-80.  
Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, Franceschini R 
(2001) Evaluation of the secretory pattern of plasma arginine vasopressin in stroke 
patients. Cerebrovascular Diseases 11:113-8.  
Beck J, Raabe A (2011) Clazosentan: prevention of cerebral vasospasm and the potential 
to overcome infarction. Acta neurochirurgica 110:147-50.  
Bederson JB, S. CE,Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, E. DJ,Jr, Harbaugh 
RE, Patel AB, Rosenwasser RH (2009) Guidelines for the management of 
aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals 
from a special writing group of the Stroke Council, American Heart Association. 
Stroke; a journal of cerebral circulation 40:994-1025.  
Beedle AM, Hamid J, Zamponi GW (2002) Inhibition of transiently expressed low- and 
high-voltage-activated calcium channels by trivalent metal cations. The Journal of 
membrane biology 187:225-38.  
165 
 
Bell BA (1995) The neuroprotective effect of calcitonin gene-related peptide following 
subarachnoid hemorrhage. European CGRP in Subarachnoid Haemorrhage Study 
Group. Annals of the New York Academy of Sciences 765:299-300.  
Bell BA (1992) Effect of calcitonin-gene-related peptide in patients with delayed 
postoperative cerebral ischaemia after aneurysmal subarachnoid haemorrhage. 
European CGRP in Subarachnoid Haemorrhage Study Group. Lancet 339:831-4.  
Bentzen BH, Schmitt N, Calloe K, Dalby Brown W, Grunnet M, Olesen S (2006) The 
acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. 
Neuropharmacology 51:1068-1077.  
Berra-Romani R, Blaustein MP, Matteson DR (2005) TTX-sensitive voltage-gated Na+ 
channels are expressed in mesenteric artery smooth muscle cells. American Journal 
of Physiology - Heart & Circulatory Physiology 289:H137-45.  
Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of calcium 
signalling. Nature reviews 1:11-21.  
Berridge MJ, Galione A (1988) Cytosolic calcium oscillators. Faseb J 2:3074-82.  
Biagi BA, Enyeart JJ (1990) Gadolinium blocks low- and high-threshold calcium currents 
in pituitary cells. The American journal of physiology 259:C515-20.  
Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein 
OK (1998) A potassium channel mutation in neonatal human epilepsy. Science. 
279:403-6.  
Biondi A, Ricciardi GK, Puybasset L, Abdennour L, Longo M, Chiras J, Van Effenterre 
R (2004) Intra-arterial nimodipine for the treatment of symptomatic cerebral 
vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR 
Am J Neuroradiol 25:1067-1076.  
Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, Blackburn-Munro RE 
(2005) Retigabine: chemical synthesis to clinical application. CNS drug reviews 
11:1-20.  
Bonev AD, Nelson MT (1996) Vasoconstrictors inhibit ATP-sensitive K+ channels in 
arterial smooth muscle through protein kinase C. The Journal of general physiology 
108:315-23.  
Bootman MD, Lipp P (1999) Ringing changes to the 'bell-shaped curve'. Curr Biol 
9:R876-8.  
166 
 
Bosche B, Graf R, Ernestus RI, Dohmen C, Reithmeier T, Brinker G, Strong AJ, Dreier 
JP, Woitzik J (2010) Recurrent spreading depolarizations after subarachnoid 
hemorrhage decreases oxygen availability in human cerebral cortex. Annals of 
neurology 67:607-17.  
Boscia F, Annunziato L, Taglialatela M (2006) Retigabine and flupirtine exert 
neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 
51:283-94.  
Brayden JE (2002) Functional roles of KATP channels in vascular smooth muscle. 
Clinical and Experimental Pharmacology and Physiology 29:312-6.  
Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H, 
RESTORE 2 Study Group (2010) Efficacy and safety of adjunctive ezogabine 
(retigabine) in refractory partial epilepsy. Neurology 75:1817-1824.  
Brown DA, Selyanko AA, Hadley JK, Tatulian L (2002) Some Pharmacological 
Properties of Neural KCNQ Channels. Neurophysiology 34:91-94; 91.  
Brown DA, Adams PR (1980) Muscarinic suppression of a novel voltage-sensitive K+ 
current in a vertebrate neurone. Nature 283:673-6.  
Brown DA (2008) Kv7 (KCNQ) potassium channels that are mutated in human diseases. 
J Physiol 586:1781-1783.  
Brueggemann LI, Kakad PP, Love RB, Solway J, Dowell ML, Cribbs LL, Byron KL 
(2012) Kv7 potassium channels in airway smooth muscle cells: signal transduction 
intermediates and pharmacological targets for bronchodilator therapy. American 
journal of physiology 302:L120-32.  
Brueggemann LI, Mackie AR, Martin JL, Cribbs LL, Byron KL (2011) Diclofenac 
distinguishes among homomeric and heteromeric potassium channels composed of 
KCNQ4 and KCNQ5 subunits. Mol Pharmacol 79:10-23.  
Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL (2009) Differential 
effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion 
channels may account for differences in cardiovascular risk profiles. Molecular 
Pharmacology 76:1053-1061.  
Brueggemann LI, Moran CJ, Barakat JA, Yeh JZ, Cribbs LL, Byron KL (2007) 
Vasopressin stimulates action potential firing by protein kinase C-dependent 
inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. American Journal of 
Physiology Heart and Circulatory Physiology 292:H1352-H1363.  
167 
 
Brueggemann LI, Markun DR, Henderson KK, Cribbs LL, Byron KL (2006) 
Pharmacological and electrophysiological characterization of store-operated 
currents and capacitative Ca(2+) entry in vascular smooth muscle cells. Journal of 
Pharmacology & Experimental Therapeutics 317:488-99.  
Bulter WE, Peterson JW, Zervas NT, Morgan KG (1996) Intracellular calcium, myosin 
light chain phosphorylation, and contractile force in experimental cerebral 
vasospasm. Neurosurgery 38:781-7; discussion 787-8.  
Busch AE, Herzer T, Wagner CA, Schmidt F, Raber G, Waldegger S, Lang F (1994) 
Positive regulation by chloride channel blockers of IsK channels expressed in 
Xenopus oocytes. Molecular pharmacology 46:750-3.  
Busto R, Globus MY, Dietrich WD, Martinez E, Valdes I, Ginsberg MD (1989) Effect of 
mild hypothermia on ischemia-induced release of neurotransmitters and free fatty 
acids in rat brain. Stroke; a journal of cerebral circulation 20:904-10.  
Byron K, Taylor CW (1995) Vasopressin stimulation of Ca2+ mobilization, two bivalent 
cation entry pathways and Ca2+ efflux in A7r5 rat smooth muscle cells. J Physiol 
485 ( Pt 2):455-68.  
Byron KL (1996) Vasopressin stimulates Ca2+ spiking activity in A7r5 vascular smooth 
muscle cells via activation of phospholipase A2. Circulation Research 78:813-20.  
Byron KL, Taylor CW (1993) Spontaneous Ca2+ spiking in a vascular smooth muscle cell 
line is independent of the release of intracellular Ca2+ stores. Journal of Biological 
Chemistry 268:6945-6952.  
Cambj-Sapunar L, Yu M, Harder DR, Roman RJ (2003) Contribution of 5-
hydroxytryptamine1B receptors and 20-hydroxyeiscosatetraenoic acid to fall in 
cerebral blood flow after subarachnoid hemorrhage. Stroke; a journal of cerebral 
circulation 34:1269-75.  
Canals S, Makarova I, Lopez-Aguado L, Largo C, Ibarz JM, Herreras O (2005) 
Longitudinal depolarization gradients along the somatodendritic axis of CA1 
pyramidal cells: a novel feature of spreading depression. Journal of 
neurophysiology 94:943-51.  
Castle NA (2010) Pharmacological modulation of voltage-gated potassium channels as a 
therapeutic strategy. Expert opinion on therapeutic patents 20:1471-503.  
Catterall WA (2000) Structure and regulation of voltage-gated Ca2+ channels. Annu Rev 
Cell Dev Biol 16:521-555.  
168 
 
Caulfield MP, Jones S, Vallis Y, Buckley NJ, Kim GD, Milligan G, Brown DA (1994) 
Muscarinic M-current inhibition via G alpha q/11 and alpha-adrenoceptor inhibition 
of Ca2+ current via G alpha o in rat sympathetic neurones. The Journal of 
physiology 477 ( Pt 3):415-22.  
Chadha PS, Zunke F, Davis AJ, Jepps TA, Linders JT, Schwake M, Towart R, 
Greenwood IA (2012) Pharmacological dissection of K(v) 7.1 channels in systemic 
and pulmonary arteries. Br J Pharmacol.  
Chambard JM, Ashmore JF (2005) Regulation of the voltage-gated potassium channel 
KCNQ4 in the auditory pathway. Pflugers Arch 450:34-44.  
Charpak S, Gahwiler BH, Do KQ, Knopfel T (1990) Potassium conductances in 
hippocampal neurons blocked by excitatory amino-acid transmitters. Nature 
347:765-767.  
Chehrazi BB, Giri S, Joy RM (1989) Prostaglandins and vasoactive amines in cerebral 
vasospasm after aneurysmal subarachnoid hemorrhage. Stroke; a journal of cerebral 
circulation 20:217-24.  
Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, 
Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F (2003) 
Selective COX-2 inhibition improves endothelial function in coronary artery 
disease. Circulation 107:405-409.  
Cheng H, Lederer WJ (2008) Calcium sparks. Physiological reviews 88:1491-545.  
Chiang C, Roden DM (2000) The long QT syndromes: genetic basis and clinical 
implications. Journal of the American College of Cardiology 36:1-12.  
Cho WS, Kang HS, Kim JE, Kwon OK, Oh CW, Son YJ, Know BJ, Jung C, Hang MH 
(2011) Intra-arterial nimodipine infusion for cerebral vasospasm in patients with 
aneurysmal subarachnoid hemorrhage. Interv Neuroradiol 17:169-178.  
Chrissobolis S, Sobey CG (2002) Inhibitory effects of protein kinase C on inwardly 
rectifying K+- and ATP-sensitive K+ channel-mediated responses of the basilar 
artery. Stroke; a journal of cerebral circulation 33:1692-7.  
Clark JF, Sharp FR (2006) Bilirubin oxidation products (BOXes) and their role in 
cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 
26:1223-33.  
Coetzee WA, Amarillo Y, Chiu J, Chow A, Lau D, McCormack T, Moreno H, Nadal 
MS, Ozaita A, Pountney D, Saganich M, Vega-Saenz de Miera E, Rudy B (1999) 
169 
 
Molecular diversity of K+ channels. Annals of the New York Academy of Sciences 
868:233-85.  
Coghlan VM, Perrino BA, Howard M, Langeberg LK, Hicks JB, Gallatin WM, Scott JD 
(1995) Association of protein kinase A and protein phosphatase 2B with a common 
anchoring protein. Science (New York, N Y 267:108-11.  
Colino A, Halliwell JV (1987) Differential modulation of three separate K-conductances 
in hippocampal CA1 neurons by serotonin. Nature 328:73-77.  
Colledge M, Scott JD (1999) AKAPs: from structure to function. Trends in cell biology 
9:216-21.  
Collier ML, Ji G, Wang Y, Kotlikoff MI (2000) Calcium-induced calcium release in 
smooth muscle: loose coupling between the action potential and calcium release. 
The Journal of general physiology 115:653-62.  
Constanti A, Brown DA (1981) M-Currents in voltage-clamped mammalian sympathetic 
neurones. Neurosci Lett. 24:289-94.  
Cooper EC, Harrington E, Jan YN, Jan LY (2001) M channel KCNQ2 subunits are 
localized to key sites for control of neuronal network oscillations and 
synchronization in mouse brain. J Neurosci 21:9529-40.  
Cox RH (2005) Molecular determinants of voltage-gated potassium currents in vascular 
smooth muscle. Cell Biochemistry and Biophysics 42:167-95.  
Cuzzocrea S, Mazzon E, Sautebin L, Dugo L, Serraino I, De Sarro A, Caputi AP (2002) 
Protective effects of Celecoxib on lung injury and red blood cells modification 
induced by carrageenan in the rat. Biochem Pharmacol 63:785-795.  
Czuczwar P, Wojtak A, Cioczek-Czuczwar A, Parada-Turska J, Maciejewski R, 
Czuczwar SJ (2010) Retigabine: the newer potential antiepileptic drug. Pharmacol 
Rep 62:211-9.  
Dalby-Brown W, Hansen HH, Korsgaard MP, Mirza N, Olesen SP (2006) K(v)7 
channels: function, pharmacology and channel modulators. Curr Top Med Chem 
6:999-1023.  
Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf IC (2010) Effect of different components of 
triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid 
haemorrhage: a systematic review. Critical care (London, England) 14:R23.  
170 
 
Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L 
(1990) Hypoxic dilation of coronary arteries is mediated by ATP-sensitive 
potassium channels. Science (New York, N Y 247:1341-4.  
Debdi M, Seylaz J, Sercombe R (1992) Early changes in rabbit cerebral artery reactivity 
after subarachnoid hemorrhage. Stroke; a journal of cerebral circulation 23:1154-
62.  
Delgado TJ, Arbab MA, Warberg J, Svendgaard NA (1988) The role of vasopressin in 
acute cerebral vasospasm. Effect on spasm of a vasopressin antagonist or 
vasopressin antiserum. Journal of Neurosurgery 68:266-73.  
Delgado TJ, Brismar J, Svendgaard NA (1985) Subarachnoid haemorrhage in the rat: 
angiography and fluorescence microscopy of the major cerebral arteries. Stroke; a 
journal of cerebral circulation 16:595-602.  
Delmas P, Brown DA (2005) Pathways modulating neural KCNQ/M (Kv7) potassium 
channels. Nature Reviews Neuroscience 6:850-62.  
Delmas P, Crest M, Brown DA (2004) Functional organization of PLC signaling 
microdomains in neurons. Trends in neurosciences 27:41-7.  
Deshaies EM, Boulos AS, Drazin D, Popp AJ (2009) Evidence-based pharmacotherapy 
for cerebral vasospasm. Neurological research 31:615-20.  
Dietrich A, Kalwa H, Gudermann T (2010) TRPC channels in vascular cell function. 
Thromb Haemost 103:262-270.  
Dietrich A, Kalwa H, Rost BR, Gudermann T (2005) The diacylgylcerol-sensitive 
TRPC3/6/7 subfamily of cation channels: functional characterization and 
physiological relevance. Pflugers Arch 451:72-80.  
Dimitropoulou C, West L, Field MB, White RE, Reddy LM, Falck JR, Imig JD (2007) 
Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-
epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. 
Prostaglandins & other lipid mediators 83:50-61.  
Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, 
Langeberg LK, Scott JD (2001) mAKAP assembles a protein kinase A/PDE4 
phosphodiesterase cAMP signaling module. The EMBO journal 20:1921-30.  
Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, 
van Gijn J (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. 
Cochrane database of systematic reviews (Online):CD000277.  
171 
 
Dreier JP (2011) The role of spreading depression, spreading depolarization and 
spreading ischemia in neurological disease. Nature medicine 17:439-47.  
Dreier JP, Major S, Manning A, Woitzik J, Drenckhahn C, Steinbrink J, Tolias C, 
Oliveira-Ferreira AI, Fabricius M, Hartings JA, Vajkoczy P, Lauritzen M, Dirnagl 
U, Bohner G, Strong AJ (2009) Cortical spreading ischaemia is a novel process 
involved in ischaemic damage in patients with aneurysmal subarachnoid 
haemorrhage. Brain 132:1866-81.  
Dreier JP, Kleeberg J, Petzold G, Priller J, Windmuller O, Orzechowski HD, Lindauer U, 
Heinemann U, Einhaupl KM, Dirnagl U (2002) Endothelin-1 potently induces 
Leao's cortical spreading depression in vivo in the rat: a model for an endothelial 
trigger of migrainous aura? Brain 125:102-12.  
Du X, Zhang X, Qi J, An H, Li J, Wan Y, Fu Y, Gao H, Gao Z, Zhan Y, Zhang H (2011) 
Characteristics and molecular basis of celecoxib modulation on Kv7 potassium 
channels. British journal of pharmacology.  
Dunn KM, Nelson MT (2010) Potassium channels and neurovascular coupling. Circ J 
74:608-16.  
Dupuis DS, Schroder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, 
Olesen SP (2002) Activation of KCNQ5 channels stably expressed in HEK293 cells 
by BMS-204352. European journal of pharmacology 437:129-37.  
Edvinsson L, Juul R, Jansen I (1994) Perivascular neuropeptides (NPY, VIP, CGRP and 
SP) in human brain vessels after subarachnoid haemorrhage. Acta neurologica 
Scandinavica 90:324-30.  
Edvinsson L, Delgado-Zygmunt T, Ekman R, Jansen I, Svendgaard NA, Uddman R 
(1990) Involvement of perivascular sensory fibers in the pathophysiology of 
cerebral vasospasm following subarachnoid hemorrhage. J Cereb Blood Flow 
Metab 10:602-7.  
Edwards FR, Hirst GD, Silverberg GD (1988) Inward rectification in rat cerebral 
arterioles; involvement of potassium ions in autoregulation. The Journal of 
physiology 404:455-66.  
Erecinska M, Thoresen M, Silver IA (2003) Effects of hypothermia on energy 
metabolism in Mammalian central nervous system. J Cereb Blood Flow Metab 
23:513-30.  
172 
 
Etxeberria A, Aivar P, Rodriguez-Alfaro JA, Alaimo A, Villace P, Gomez-Posada JC, 
Areso P, Villarroel A (2008) Calmodulin regulates the trafficking of KCNQ2 
potassium channels. Faseb J 22:1135-43.  
Faraci FM, Sobey CG (1998) Role of potassium channels in regulation of cerebral 
vascular tone. J Cereb Blood Flow Metab 18:1047-63.  
Fathi AR, Bakhtian KD, Pluta RM (2011) The role of nitric oxide donors in treating 
cerebral vasospasm after subarachnoid hemorrhage. Acta neurochirurgica 110:93-7.  
Faux MC, Rollins EN, Edwards AS, Langeberg LK, Newton AC, Scott JD (1999) 
Mechanism of A-kinase-anchoring protein 79 (AKAP79) and protein kinase C 
interaction. Biochem J. 343:443-52.  
Faux MC, Scott JD (1997) Regulation of the AKAP79-protein kinase C interaction by 
Ca2+/Calmodulin. The Journal of biological chemistry 272:17038-44.  
Feigin VL, Anderson CS, Rodgers A, Anderson NE, Gunn AJ (2002) The emerging role 
of induced hypothermia in the management of acute stroke. J Clin Neurosci 9:502-
7.  
Fellner SK, Arendshorst WJ (2010) Complex interactions of NO/cGMP/PKG systems on 
Ca2+ signaling in afferent arteriolar vascular smooth muscle. American journal of 
physiology 298:H144-51.  
Fernandez A, Schmidt JM, Claassen J, Pavlicova M, Huddleston D, Kreiter KT, 
Ostapkovich ND, Kowalski RG, Parra A, Connolly ES, Mayer SA (2007) Fever 
after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology 
68:1013-9.  
FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. 
The New England journal of medicine 345:433-42.  
Fleischmann BK, Murray RK, Kotlikoff MI (1994) Voltage window for sustained 
elevation of cytosolic calcium in smooth muscle cells. Proceedings of the National 
Academy of Sciences of the United States of America 91:11914-8.  
Fletcher BS, Kujubu DA, Perrin DM, Herschman HR (1992) Structure of the mitogen-
inducible TIS10 gene and demonstration that the TIS10-encoded protein is a 
functional prostaglandin G/H synthase. The Journal of biological chemistry 
267:4338-44.  
Foskett JK, White C, Cheung KH, Mak DO (2007) Inositol trisphosphate receptor Ca2+ 
release channels. Physiol Rev 87:593-658.  
173 
 
Frampton JE, Keating GM (2007) Celecoxib: a review of its use in the management of 
arthritis and acute pain. Drugs 67:2433-2472.  
Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D (2008) Milrinone for 
the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. 
Stroke; a journal of cerebral circulation 39:893-8.  
French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, Mansbach H, 
Nohria V, RESTORE 1/Study 301 Investigators (2011) Randomized, double-blind, 
placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 
76:1555-1563.  
Frolov RV, Bondarenko VE, Singh S (2010) Mechanisms of Kv2.1 channel inhibition by 
celecoxib--modification of gating and channel block. British journal of 
pharmacology 159:405-18.  
Fujikawa H, Tani E, Yamaura I, Ozaki I, Miyaji K, Sato M, Takahashi K, Imajoh-Ohmi S 
(1999) Activation of protein kinases in canine basilar artery in vasospasm. J Cereb 
Blood Flow Metab 19:44-52.  
Gamper N, Zaika O, Li Y, Martin P, Hernandez CC, Perez MR, Wang AY, Jaffe DB, 
Shapiro MS (2006) Oxidative modification of M-type K(+) channels as a 
mechanism of cytoprotective neuronal silencing. EMBO Journal 25:4996-5004. 
Epub 2006 Oct 5.  
Gamper N, Li Y, Shapiro MS (2005) Structural requirements for differential sensitivity of 
KCNQ K+ channels to modulation by Ca2+/calmodulin. Mol Biol Cell. 16:3538-51.  
Gamper N, Shapiro MS (2003) Calmodulin mediates Ca2+-dependent modulation of M-
type K+ channels. The Journal of general physiology 122:17-31.  
Gamper N, Stockand JD, Shapiro MS (2003) Subunit-specific modulation of KCNQ 
potassium channels by Src tyrosine kinase. Journal of Neuroscience 23:84-95.  
Garcia JH, Wagner S, Liu KF, Hu XJ (1995) Neurological deficit and extent of neuronal 
necrosis attributable to middle cerebral artery occlusion in rats. Statistical 
validation. Stroke 26:627-34; discussion 635.  
Gasser S, Khan N, Yonekawa Y, Imhof HG, Keller E (2003) Long-term hypothermia in 
patients with severe brain edema after poor-grade subarachnoid hemorrhage: 
feasibility and intensive care complications. Journal of neurosurgical anesthesiology 
15:240-8.  
174 
 
Germano AF, Dixon CE, d'Avella D, Hayes RL, Tomasello F (1994) Behavioral deficits 
following experimental subarachnoid hemorrhage in the rat. Journal of neurotrauma 
11:345-53.  
Globus MY, Alonso O, Dietrich WD, Busto R, Ginsberg MD (1995) Glutamate release 
and free radical production following brain injury: effects of posttraumatic 
hypothermia. Journal of neurochemistry 65:1704-11.  
Gokce C, Gulsen S, Yilmaz C, Guven G, Caner H, Altinors N (2010) The effect of the 
sildenafil citrate on cerebral vasospasm and apoptosis following experimental 
subarachnoid hemorrhage in rats. Journal of neurosurgical sciences 54:29-37.  
Graf CJ, Nibbelink DW (1974) Cooperative study of intracranial aneurysms and 
subarachnoid hemorrhage. Report on a randomized treatment study. 3. Intracranial 
surgery. Stroke; a journal of cerebral circulation 5:557-601.  
Gribkoff VK (2008) The therapeutic potential of neuronal Kv7 (KCNQ) channel 
modulators: an update. Expert Opin Ther Targets. 12:565-81.  
Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular 
consequences of COX-2 inhibition: therapeutic challenges and opportunities. The 
Journal of clinical investigation 116:4-15.  
Gules I, Satoh M, Clower BR, Nanda A, Zhang JH (2002) Comparison of three rat 
models of cerebral vasospasm. Am J Physiol Heart Circ Physiol. 283:H2551-9.  
Gunthorpe MJ, Large CH, Sankar R (2012) The mechanism of action of retigabine 
(ezogabine), a first-in-class K(+) channel opener for the treatment of epilepsy. 
Epilepsia In press:doi: 10.1111/j.1528-1167.2011.03365.x. [Epub ahead of print].  
Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson 
GA, Rudy B, Sanguinetti MC, Stuhmer W, Wang X (2005) International Union of 
Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated 
potassium channels. Pharmacol Rev 57:473-508.  
Haitin Y, Attali B (2008) The C-terminus of Kv7 channels: a multifunctional module. J 
Physiol. 586:1803-10. Epub 2008 Jan 24.  
Haley EC,Jr, Kassell NF, Torner JC, Truskowski LL, Germanson TP (1994) A 
randomized trial of two doses of nicardipine in aneurysmal subarachnoid 
hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80:788-
796.  
175 
 
Haley JE, Delmas P, Offermanns S, Abogadie FC, Simon MI, Buckley NJ, Brown DA 
(2000) Muscarinic inhibition of calcium current and M current in Galpha q-
deficient mice. J Neurosci 20:3973-9.  
Haley JE, Abogadie FC, Delmas P, Dayrell M, Vallis Y, Milligan G, Caulfield MP, 
Brown DA, Buckley NJ (1998) The alpha subunit of Gq contributes to muscarinic 
inhibition of the M-type potassium current in sympathetic neurons. J Neurosci 
18:4521-31.  
Halliwell JV, Adams PR (1982) Voltage-clamp analysis of muscarinic excitation in 
hippocampal neurons. Brain research 250:71-92.  
Han BH, Vellimana AK, Zhou ML, Milner E, Zipfel GJ (2012) Phosphodiesterase 5 
inhibition attenuates cerebral vasospasm and improves functional recovery after 
experimental subarachnoid hemorrhage. Neurosurgery 70:178-86; discussion 186-7.  
Han DH, Bai GY, Yang TK, Sim BS, Kwak YG, Kim CJ (2007) The effect of papaverine 
on ion channels in rat basilar smooth muscle cells. Neurol Res 29:544-550.  
Handa Y, Hayashi M, Takeuchi H, Kubota T, Kobayashi H, Kawano H (1992) Time 
course of the impairment of cerebral autoregulation during chronic cerebral 
vasospasm after subarachnoid hemorrhage in primates. Journal of neurosurgery 
76:493-501.  
Hanggi D, Steiger HJ (2006) Nitric oxide in subarachnoid haemorrhage and its 
therapeutics implications. Acta neurochirurgica 148:605-13; discussion 613.  
Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Kruger J, Mikkelsen JD (2007) 
The neuronal KCNQ channel opener retigabine inhibits locomotor activity and 
reduces forebrain excitatory responses to the psychostimulants cocaine, 
methylphenidate and phencyclidine. European journal of pharmacology 570:77-88.  
Hansen-Schwartz J, Ansar S, Edvinsson L (2008) Cerebral vasoconstriction after 
subarachnoid hemorrhage--role of changes in vascular receptor phenotype. Front 
Biosci 13:2160-4.  
Hansen-Schwartz J (2004) Receptor changes in cerebral arteries after subarachnoid 
haemorrhage. Acta neurologica Scandinavica 109:33-44.  
Hansen-Schwartz J, Hoel NL, Xu CB, Svendgaard NA, Edvinsson L (2003a) 
Subarachnoid hemorrhage-induced upregulation of the 5-HT1B receptor in cerebral 
arteries in rats. Journal of neurosurgery 99:115-20.  
176 
 
Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L (2003b) 
Subarachnoid hemorrhage enhances endothelin receptor expression and function in 
rat cerebral arteries. Neurosurgery 52:1188-94; 1194-5.  
Harder DR, Dernbach P, Waters A (1987) Possible cellular mechanism for cerebral 
vasospasm after experimental subarachnoid hemorrhage in the dog. The Journal of 
clinical investigation 80:875-80.  
Harris JA, Murphy JA (2011) Retigabine (ezogabine) as add-on therapy for partial-onset 
seizures: an update for clinicians. Therapeutic Advances in Chronic Disease 2:371-
376.  
Hauerberg J, Rasmussen G, Juhler M, Gjerris F (1995) The effect of nimodipine on 
autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat. Acta 
neurochirurgica 132:98-103.  
Hauerberg J, Juhler M, Rasmussen G (1993) Cerebral blood flow autoregulation after 
experimental subarachnoid hemorrhage during hyperventilation in rats. Journal of 
neurosurgical anesthesiology 5:258-63.  
Heistad D, Konotos H (1983) Cerebral circulation. In: Handbook of Physiology.(Shepard 
J, Abboud F, eds): American Physiological Society: Bethesad, MD, pp. 137–182.-
Section 2: The Cardiovascular System.  
Hemler M, Lands WE (1976) Purification of the cyclooxygenase that forms 
prostaglandins. Demonstration of two forms of iron in the holoenzyme. The Journal 
of biological chemistry 251:5575-9.  
Hemmen TM, Lyden PD (2009) Multimodal neuroprotective therapy with induced 
hypothermia after ischemic stroke. Stroke; a journal of cerebral circulation 
40:S126-8.  
Henderson KK, Byron KL (2007) Vasopressin-induced vasoconstriction: two 
concentration-dependent signaling pathways. Journal of Applied Physiology 
102:1402-1409.  
Herbert E, Trusz-Gluza M, Moric E, Smilowska-Dzielicka E, Mazurek U, Wilczok T 
(2002) KCNQ1 gene mutations and the respective genotype-phenotype correlations 
in the long QT syndrome. Med Sci Monit. 8:RA240-8.  
Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, 
Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F (2003) 
Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial 
Function in Salt-Induced Hypertension. Circulation 108:2308-2311.  
177 
 
Hernandez CC, Zaika O, Shapiro MS (2008) A carboxy-terminal inter-helix linker as the 
site of phosphatidylinositol 4,5-bisphosphate action on Kv7 (M-type) K+ channels. 
The Journal of general physiology 132:361-81.  
Heros RC, Zervas NT, Varsos V (1983) Cerebral vasospasm after subarachnoid 
hemorrhage: an update. Annals of neurology 14:599-608.  
Higashida H, Hoshi N, Zhang JS, Yokoyama S, Hashii M, Jin D, Noda M, Robbins J 
(2005) Protein kinase C bound with A-kinase anchoring protein is involved in 
muscarinic receptor-activated modulation of M-type KCNQ potassium channels. 
Neuroscience Research 51:231-4.  
Hill MA, Yang Y, Ella SR, Davis MJ, Braun AP (2010) Large conductance, Ca2+-
activated K+ channels (BKCa) and arteriolar myogenic signaling. FEBS letters 
584:2033-42.  
Hille B (1994) Modulation of ion-channel function by G-protein-coupled receptors. 
Trends in neurosciences 17:531-6.  
Hill-Eubanks DC, Werner ME, Heppner TJ, Nelson MT (2011) Calcium Signaling in 
Smooth Muscle. Cold Spring Harbor perspectives in biology:a004549.  
Hino A, Tokuyama Y, Kobayashi M, Yano M, Weir B, Takeda J, Wang X, Bell GI, 
Macdonald RL (1996) Increased expression of endothelin B receptor mRNA 
following subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab 
16:688-97.  
Hirano K, Hirano M, Kanaide H (2004) Regulation of myosin phosphorylation and 
myofilament Ca2+ sensitivity in vascular smooth muscle. Journal of smooth muscle 
research = Nihon Heikatsukin Gakkai kikanshi 40:219-36.  
Hirano K, Derkach DN, Hirano M, Nishimura J, Kanaide H (2003) Protein kinase 
network in the regulation of phosphorylation and dephosphorylation of smooth 
muscle myosin light chain. Molecular and cellular biochemistry 248:105-14.  
Hong KW, Pyo KM, Lee WS, Yu SS, Rhim BY (1994) Pharmacological evidence that 
calcitonin gene-related peptide is implicated in cerebral autoregulation. The 
American journal of physiology 266:H11-6.  
Hoshi N, Langeberg LK, Scott JD (2005) Distinct enzyme combinations in AKAP 
signalling complexes permit functional diversity. Nature cell biology 7:1066-73.  
Hoshi N, Zhang JS, Omaki M, Takeuchi T, Yokoyama S, Wanaverbecq N, Langeberg 
LK, Yoneda Y, Scott JD, Brown DA, Higashida H (2003) AKAP150 signaling 
178 
 
complex promotes suppression of the M-current by muscarinic agonists. Nature 
Neuroscience 6:564-71.  
Hou S, Xu R, Clark JF, Wurster WL, Heinemann SH, Hoshi T (2011) Bilirubin oxidation 
end products directly alter K+ channels important in the regulation of vascular tone. 
J Cereb Blood Flow Metab 31:102-12.  
Hou S, Heinemann SH, Hoshi T (2009) Modulation of BKCa channel gating by 
endogenous signaling molecules. Physiology (Bethesda, Md 24:26-35.  
Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 
enzymes in the cardiovascular system: a molecular toolbox for generating 
compartmentalized cAMP signaling. Circ Res 100:950-966.  
Hummert V, Brueggemann L, Byron KL (2011) Elucidating new mechanisms in 
vasoconstrictor signal transduction: inhibition of Kv7.5 channel activity by 
PKC. FASEB J 25:1081.7.  
Ide K, Yamakawa K, Nakagomi T, Sasaki T, Saito I, Kurihara H, Yosizumi M, Yazaki Y, 
Takakura K (1989) The role of endothelin in the pathogenesis of vasospasm 
following subarachnoid haemorrhage. Neurological research 11:101-4.  
Inoha S, Inamura T, Ikezaki K, Nakamizo A, Amano T, Fukui M (2002) Type V 
phosphodiesterase expression in cerebral arteries with vasospasm after 
subarachnoid hemorrhage in a canine model. Neurological research 24:607-12.  
Inoue T, Shimizu H, Kaminuma T, Tajima M, Watabe K, Yoshimoto T (1996) 
Prevention of cerebral vasospasm by calcitonin gene-related peptide slow-release 
tablet after subarachnoid hemorrhage in monkeys. Neurosurgery 39:984-90.  
Ishiguro M, Murakami K, Link T, Zvarova K, Tranmer BI, Morielli AD, Wellman GC 
(2008) Acute and chronic effects of oxyhemoglobin on voltage-dependent ion 
channels in cerebral arteries. Acta neurochirurgica 104:99-102.  
Ishiguro M, Morielli AD, Zvarova K, Tranmer BI, Penar PL, Wellman GC (2006) 
Oxyhemoglobin-induced suppression of voltage-dependent K+ channels in cerebral 
arteries by enhanced tyrosine kinase activity. Circ Res. 99:1252-60.  
Jackson G, Benjamin N, Jackson N, Allen MJ (1999) Effects of sildenafil citrate on 
human hemodynamics. The American journal of cardiology 83:13C-20C.  
Jaggar JH, Nelson MT (2000) Differential regulation of Ca(2+) sparks and Ca(2+) waves 
by UTP in rat cerebral artery smooth muscle cells. Am J Physiol Cell Physiol 
279:C1528-39.  
179 
 
Jaggar JH, Porter VA, Lederer WJ, Nelson MT (2000) Calcium sparks in smooth muscle. 
American journal of physiology 278:C235-56.  
Jahromi B, Aihara Y, Yassari R, Nikitina E, Ryan D, Weyer G, Agbaye-Williams M, 
Macdonald R (2005) Potassium Channels in experimental cerebral vasospasm. New 
York: Thieme.  
Jahromi BS, Aihara Y, Ai J, Zhang ZD, Nikitina E, Macdonald RL (2008a) Voltage-
gated K(+) channel dysfunction in myocytes from a dog model of subarachnoid 
hemorrhage. J Cereb Blood Flow Metab 28:797-811.  
Jahromi BS, Aihara Y, Ai J, Zhang ZD, Weyer G, Nikitina E, Yassari R, Houamed KM, 
Macdonald RL (2008b) Preserved BK Channel Function in Vasospastic Myocytes 
from a Dog Model of Subarachnoid Hemorrhage. Journal of vascular research 
45:402-415.  
Jahromi BS, Aihara Y, Ai J, Zhang ZD, Weyer G, Nikitina E, Yassari R, Houamed KM, 
Macdonald RL (2008c) Temporal profile of potassium channel dysfunction in 
cerebrovascular smooth muscle after experimental subarachnoid haemorrhage. 
Neuroscience letters 440:81-6.  
Jan M, Buchheit F, Tremoulet M (1988) Therapeutic trial of intravenous nimodipine in 
patients with established cerebral vasospasm after rupture of intracranial 
aneurysms. Neurosurgery 23:154-7.  
Jenkins JS, Ang VT, Hawthorn J, Rossor MN, Iversen LL (1984) Vasopressin, oxytocin 
and neurophysins in the human brain and spinal cord. Brain Research 291:111-7.  
Jentsch TJ (2000) Neuronal KCNQ potassium channels: physiology and role in disease. 
Nat Rev Neurosci 1:21-30.  
Jeon H, Ai J, Sabri M, Tariq A, Shang X, Chen G, Macdonald RL (2009) Neurological 
and neurobehavioral assessment of experimental subarachnoid hemorrhage. BMC 
neuroscience 10:103.  
Jepps TA, Greenwood IA, Moffatt JD, Sanders KM, Ohya S (2009) Molecular and 
functional characterization of Kv7 K+ channel in murine gastrointestinal smooth 
muscles. American journal of physiology 297:G107-15.  
Jespersen T, Grunnet M, Olesen S (2005) The KCNQ1 Potassium Channel: From Gene 
to Physiological Function. Physiology 20:408-416.  
Jia Q, Jia Z, Zhao Z, Liu B, Liang H, Zhang H (2007) Activation of epidermal growth 
factor receptor inhibits KCNQ2/3 current through two distinct pathways: membrane 
180 
 
PtdIns(4,5)P2 hydrolysis and channel phosphorylation. Journal of Neuroscience 
27:2503-12.  
Jia Z, Bei J, Rodat-Despoix L, Liu B, Jia Q, Delmas P, Zhang H (2008) NGF Inhibits 
M/KCNQ Currents and Selectively Alters Neuronal Excitability in Subsets of 
Sympathetic Neurons Depending on their M/KCNQ Current Background. Journal 
of General Physiology 131:575-587.  
Jiang F, Li CG, Rand MJ (1998) Role of potassium channels in the nitrergic nerve 
stimulation-induced vasodilatation in the guinea-pig isolated basilar artery. British 
journal of pharmacology 123:106-12.  
Jiang JY, Lyeth BG, Kapasi MZ, Jenkins LW, Povlishock JT (1992) Moderate 
hypothermia reduces blood-brain barrier disruption following traumatic brain injury 
in the rat. Acta neuropathologica 84:495-500.  
Jones SW (1985) Muscarinic and peptidergic excitation of bull-frog sympathetic 
neurones. The Journal of physiology 366:63-87.  
Joshi S, Balan P, Gurney AM (2006) Pulmonary vasoconstrictor action of KCNQ 
potassium channel blockers. Respiratory Research 7:31.  
Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM (2009) KCNQ Modulators Reveal a 
Key Role for KCNQ Potassium Channels in Regulating the Tone of Rat Pulmonary 
Artery Smooth Muscle. Journal of Pharmacology and Experimental Therapeutics 
329:368-376.  
Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of 
cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021-9.  
Juvela S (2000) Plasma endothelin concentrations after aneurysmal subarachnoid 
hemorrhage. Journal of neurosurgery 92:390-400.  
Kamiya K, Kuyama H, Symon L (1983) An experimental study of the acute stage of 
subarachnoid hemorrhage. Journal of neurosurgery 59:917-24.  
Kannel WB (2000a) Fifty years of Framingham Study contributions to understanding 
hypertension. Journal of human hypertension 14:83-90.  
Kannel WB (2000b) Risk stratification in hypertension: new insights from the 
Framingham Study. American journal of hypertension 13:3S-10S.  
Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH (2005) 
Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-
181 
 
inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's 
lymphoma in vitro and in vivo. Cancer Biol Ther 4:571-82.  
Kassell NF, Sasaki T, Colohan AR, Nazar G (1985) Cerebral vasospasm following 
aneurysmal subarachnoid hemorrhage. Stroke 16:562-572.  
Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP (1982) 
Treatment of ischemic deficits from vasospasm with intravascular volume 
expansion and induced arterial hypertension. Neurosurgery 11:337-43.  
Katori E, Ohta T, Nakazato Y, Ito S (2001) Vasopressin-induced contraction in the rat 
basilar artery in vitro. Eur J Pharmacol. 416:113-21.  
Kazda S, Towart R (1982) Nimodipine: a new calcium antagonistic drug with a 
preferential cerebrovascular action. Acta neurochirurgica 63:259-65.  
Keef KD, Hume JR, Zhong J (2001) Regulation of cardiac and smooth muscle Ca(2+) 
channels (Ca(V)1.2a,b) by protein kinases. Am J Physiol Cell Physiol 281:C1743-
56.  
Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as 
targets of the intracellular signalling network: benefits of PDE inhibitors in various 
diseases and perspectives for future therapeutic developments. Br J Pharmacol 
165:1288-1305.  
Kessler IM, Pacheco YG, Lozzi SP, S. dAA,Jr, Onishi FJ, de Mello PA (2005) 
Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral 
vasospasm after aneurysmal subarachnoid hemorrhage. Surgical neurology 64 
Suppl 1:S1:2-5; discussion S1:5.  
Keyrouz SG, Diringer MN (2007) Clinical review: Prevention and therapy of vasospasm 
in subarachnoid hemorrhage. Crit Care 11:220.  
Khajavi K, Ayzman I, Shearer D, Jones SC, Levy JH, Prayson RA, Skibinski CI, Hahn 
JF, Chyatte D (1997) Prevention of chronic cerebral vasospasm in dogs with 
milrinone. Neurosurgery 40:354-62; discussion 362-3.  
Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, Petit C, Jentsch 
TJ (2000) KCNQ4, a K+ channel mutated in a form of dominant deafness, is 
expressed in the inner ear and the central auditory pathway. Proceedings of the 
National Academy of Sciences of the United States of America 97:4333-8.  
182 
 
Kim P, Yoshimoto Y, Iino M, Tomio S, Kirino T, Nonomura Y (1996) Impaired calcium 
regulation of smooth muscle during chronic vasospasm following subarachnoid 
hemorrhage. J Cereb Blood Flow Metab 16:334-41.  
King JTJ (1997) Epidemiology of aneurysmal subarachnoid hemorrhage. Neuroimaging 
clinics of North America 7:659-68.  
Kitazono T, Ibayashi S, Nagao T, Fujii K, Fujishima M (1997) Role of Ca(2+)-activated 
K+ channels in acetylcholine-induced dilatation of the basilar artery in vivo. British 
journal of pharmacology 120:102-6.  
Klauck TM, Faux MC, Labudda K, Langeberg LK, Jaken S, Scott JD (1996) 
Coordination of three signaling enzymes by AKAP79, a mammalian scaffold 
protein. Science (New York, N Y 271:1589-92.  
Klein C (2002) Nitric oxide and the other cyclic nucleotide. Cellular signalling 14:493-8.  
Klein T, Eltze M, Grebe T, Hatzelmann A, Komhoff M (2007) Celecoxib dilates guinea-
pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 
inhibition. Cardiovascular Research 75:390-397.  
Kloner RA (2004) Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors 
approved for the treatment of erectile dysfunction. Circulation 110:3149-55.  
Knudsen JF, Carlsson U, Hammarstrom P, Sokol GH, Cantilena LR (2004) The 
cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic 
anhydrase II. Inflammation 28:285-90.  
Kobayashi H, Hayashi M, Kobayashi S, Kabuto M, Handa Y, Kawano H, Ide H (1991) 
Cerebral vasospasm and vasoconstriction caused by endothelin. Neurosurgery 
28:673-8; discussion 678-9.  
Kobayashi H, Hayashi M, Kobayashi S, Kabuto M, Handa Y, Kawano H (1990) Effect of 
endothelin on the canine basilar artery. Neurosurgery 27:357-61.  
Kobayashi H, Libet B (1968) Generation of slow postsynaptic potentials without 
increases in ionic conductance. Proceedings of the National Academy of Sciences 
of the United States of America 60:1304-11.  
Kochegarov AA (2003) Pharmacological modulators of voltage-gated calcium channels 
and their therapeutical application. Cell calcium 33:145-62.  
Koide M, Penar PL, Tranmer BI, Wellman GC (2007) Heparin-binding EGF-like growth 
factor mediates oxyhemoglobin-induced suppression of voltage-dependent 
183 
 
potassium channels in rabbit cerebral artery myocytes. Am J Physiol Heart Circ 
Physiol. 293:H1750-9. Epub 2007 Jun 8.  
Kolias AG, Sen J, Belli A (2009) Pathogenesis of cerebral vasospasm following 
aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. 
Journal of neuroscience research 87:1-11.  
Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG (1999) Flupirtine shows 
functional NMDA receptor antagonism by enhancing Mg2+ block via activation of 
voltage independent potassium channels. Rapid communication. J Neural Transm 
106:857-67.  
Korsgaard MPG, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR (2005) 
Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of 
Neuronal Kv7 Channels. Journal of Pharmacology & Experimental Therapeutics 
314:282-292.  
Kramer A, Fletcher J (2009) Do endothelin-receptor antagonists prevent delayed 
neurological deficits and poor outcomes after aneurysmal subarachnoid 
hemorrhage?: a meta-analysis. Stroke; a journal of cerebral circulation 40:3403-6.  
Kramer SP (1912) On the Function of the Circle of Willis. The Journal of experimental 
medicine 15:348-64.  
Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Stern Y, 
Connolly ES, Mayer SA (2002) Predictors of cognitive dysfunction after 
subarachnoid hemorrhage. Stroke; a journal of cerebral circulation 33:200-8.  
Kristensen LV, Sandager-Nielsen K, Hansen HH (2011) Kv7 (KCNQ) channel openers 
induce hypothermia in the mouse. Neuroscience Letters 488:178-182.  
Krnjevic K, Pumain R, Renaud L (1971) The mechanism of excitation by acetylcholine 
in the cerebral cortex. The Journal of physiology 215:247-68.  
Kuba K, Koketsu K (1976) Analysis of the slow excitatory postsynaptic potential in 
bullfrog sympathetic ganglion cells. The Japanese journal of physiology 26:651-69.  
Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El-Amraoui A, Marlin S, Petit C, 
Jentsch TJ (1999) KCNQ4, a novel potassium channel expressed in sensory outer 
hair cells, is mutated in dominant deafness. Cell 96:437-46.  
Kurasako T, Zhao L, Pulsinelli WA, S. NT,Jr (2007) Transient cooling during early 
reperfusion attenuates delayed edema and infarct progression in the Spontaneously 
Hypertensive Rat. Distribution and time course of regional brain temperature 
184 
 
change in a model of postischemic hypothermic protection. J Cereb Blood Flow 
Metab 27:1919-30.  
Kwan AL, Lin CL, Wu CS, Chen EF, Howng SL, Kassell NF, Lee KS (2000) Delayed 
administration of the K+ channel activator cromakalim attenuates cerebral 
vasospasm after experimental subarachnoid hemorrhage. Acta neurochirurgica 
142:193-7.  
Kwan AL, Lin CL, Yanamoto H, Howng SL, Kassell NF, Lee KS (1998) Systemic 
administration of the potassium channel activator cromakalim attenuates cerebral 
vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 42:347-50; 
discussion 350-1.  
Lacinova L (2005) Voltage-dependent calcium channels. General physiology and 
biophysics 24 Suppl 1:1-78.  
Laher I, Zhang JH (2001) Protein kinase C and cerebral vasospasm. J Cereb Blood Flow 
Metab 21:887-906.  
Laher I, Thompson LP, Gagne L (1990) Protein kinase C as a modulator of response 
amplification in vascular smooth muscle. Blood vessels 27:333-40.  
Laher I, Vorkapic P, Dowd AL, Bevan JA (1989) Protein kinase C potentiates stretch-
induced cerebral artery tone by increasing intracellular sensitivity to Ca2+. 
Biochemical and biophysical research communications 165:312-8.  
Lamont C, Wier WG (2002) Evoked and spontaneous purinergic junctional Ca2+ 
transients (jCaTs) in rat small arteries. Circ Res 91:454-456.  
Lang EW, Diehl RR, Mehdorn HM (2001) Cerebral autoregulation testing after 
aneurysmal subarachnoid hemorrhage: the phase relationship between arterial blood 
pressure and cerebral blood flow velocity. Critical care medicine 29:158-63.  
Laskowitz DT, Kolls BJ (2010) Neuroprotection in subarachnoid hemorrhage. Stroke; a 
journal of cerebral circulation 41:S79-84.  
Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ (2011) Clinical 
relevance of cortical spreading depression in neurological disorders: migraine, 
malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain 
injury. J Cereb Blood Flow Metab 31:17-35.  
Leao A (1944) Spreading depression of activity in cerebral cortex. Journal of 
neurophysiology 7:359-90.  
185 
 
Lee KH, Lukovits T, Friedman JA (2006) "Triple-H" therapy for cerebral vasospasm 
following subarachnoid hemorrhage. Neurocritical care 4:68-76.  
Lee SM, Zhao H, Maier CM, Steinberg GK (2009) The protective effect of early 
hypothermia on PTEN phosphorylation correlates with free radical inhibition in rat 
stroke. J Cereb Blood Flow Metab 29:1589-600.  
Leng LZ, Fink ME, Iadecola C (2011) Spreading depolarization: a possible new culprit in 
the delayed cerebral ischemia of subarachnoid hemorrhage. Archives of neurology 
68:31-6.  
Leung FP, Yung LM, Yao X, Laher I, Huang Y (2008) Store-operated calcium entry in 
vascular smooth muscle. Br J Pharmacol 153:846-857.  
Li Y, Gamper N, Hilgemann DW, Shapiro MS (2005) Regulation of Kv7 (KCNQ) K+ 
channel open probability by phosphatidylinositol 4,5-bisphosphate. Journal of 
Neuroscience 25:9825-35.  
Li Y, Langlais P, Gamper N, Liu F, Shapiro MS (2004a) Dual phosphorylations underlie 
modulation of unitary KCNQ K(+) channels by Src tyrosine kinase. Journal of 
Biological Chemistry 279:45399-407.  
Li Y, Gamper N, Shapiro MS (2004b) Single-Channel Analysis of KCNQ K+ Channels 
Reveals the Mechanism of Augmentation by a Cysteine-Modifying Reagent. 
Journal of Neuroscience 24:5079-5090.  
Linares G, Mayer SA (2009) Hypothermia for the treatment of ischemic and hemorrhagic 
stroke. Critical care medicine 37:S243-9.  
Link TE, Murakami K, Beem-Miller M, Tranmer BI, Wellman GC (2008) 
Oxyhemoglobin-Induced Expression of R-Type Ca2+ Channels in Cerebral 
Arteries. Stroke; a journal of cerebral circulation.  
Liu JK, Couldwell WT (2005) Intra-arterial papaverine infusions for the treatment of 
cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocritical 
care 2:124-32.  
Lopatin AN, Makhina EN, Nichols CG (1994) Potassium channel block by cytoplasmic 
polyamines as the mechanism of intrinsic rectification. Nature 372:366-9.  
Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, 
Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N (2011) Clazosentan, an 
endothelin receptor antagonist, in patients with aneurysmal subarachnoid 
186 
 
haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-
controlled phase 3 trial (CONSCIOUS-2). Lancet neurology 10:618-25.  
Macdonald RL, Pluta RM, Zhang JH (2007) Cerebral vasospasm after subarachnoid 
hemorrhage: the emerging revolution. Nature clinical practice 3:256-63.  
Macdonald RL, Weir BK (1991) A review of hemoglobin and the pathogenesis of 
cerebral vasospasm. Stroke; a journal of cerebral circulation 22:971-82.  
Macías A, Moreno C, Moral-Sanz J, Cogolludo A, David M, Alemanni M, Pérez-
Vizcaíno F, Zaza A, Valenzuela C, González T (2010) Celecoxib blocks cardiac 
Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels. Effects on cardiac action potentials. 
Journal of Molecular and Cellular Cardiology 49:984-992.  
Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, Byron 
KL (2008) Vascular KCNQ potassium channels as novel targets for the control of 
mesenteric artery constriction by vasopressin, based on studies in single cells, 
pressurized arteries, and in vivo measurements of mesenteric vascular resistance. 
Journal of Pharmacology and Experimental Therapeutics 325:475-83.  
Mackie AR, Byron KL (2008) Cardiovascular KCNQ (Kv7) Potassium Channels: 
Physiological Regulators and New Targets for Therapeutic Intervention. Mol 
Pharmacol 74:1171-1179.  
Maekawa T, Tateishi A, Sadamitsu D, Kuroda Y, Soejima Y, Kashiwagi S, Yamashita T, 
Ito H (1994) Clinical application of mild hypothermia in neurological disorders. 
Minerva anestesiologica 60:537-40.  
Mani BK, Brueggemann LI, Cribbs LL, Byron KL (2009) Opposite regulation of 
KCNQ5 and TRPC6 channels contributes to vasopressin-stimulated calcium 
spiking responses in A7r5 vascular smooth muscle cells. Cell Calcium 45:400-11.  
Marbacher S, Fandino J, Kitchen N (2011) Characteristics of in vivo animal models of 
delayed cerebral vasospasm. Acta neurochirurgica 110:173-5.  
Marin J (1988) Vascular effects of calcium antagonists. Uses in some cerebrovascular 
disorders. General pharmacology 19:295-306.  
Marrion NV (1997) Control of M-current. Annual review of physiology 59:483-504.  
Martire M, Castaldo P, D'Amico M, Preziosi P, Annunziato L, Taglialatela M (2004) M 
channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and 
GABA release from hippocampal nerve terminals. J Neurosci 24:592-7.  
187 
 
Maruyama Y, Nakanishi Y, Walsh EJ, Wilson DP, Welsh DG, Cole WC (2006) 
Heteromultimeric TRPC6-TRPC7 channels contribute to arginine vasopressin-
induced cation current of A7r5 vascular smooth muscle cells. Circulation research 
98:1520-7.  
Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K (1989) Raised plasma 
endothelin in aneurysmal subarachnoid haemorrhage. Lancet 2:1402.  
Mather HM, Ang V, Jenkins JS (1981) Vasopressin in plasma and CSF of patients with 
subarachnoid haemorrhage. Journal of neurology, neurosurgery, and psychiatry 
44:216-9.  
Matsui T, Sugawa M, Johshita H, Takuwa Y, Asano T (1991a) Activation of the protein 
kinase C-mediated contractile system in canine basilar artery undergoing chronic 
vasospasm. Stroke; a journal of cerebral circulation 22:1183-7.  
Matsui T, Takuwa Y, Johshita H, Yamashita K, Asano T (1991b) Possible role of protein 
kinase C-dependent smooth muscle contraction in the pathogenesis of chronic 
cerebral vasospasm. J Cereb Blood Flow Metab 11:143-9.  
Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, 
Elbatarny HS, Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, 
expression, and targeting in cells of the cardiovascular system. Molecular 
pharmacology 64:533-46.  
Mayberg MR, Batjer HH, Dacey R, Diringer M, Haley EC, Heros RC, Sternau LL, 
Torner J, Adams HP,Jr, Feinberg W (1994) Guidelines for the management of 
aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals 
from a special writing group of the Stroke Council, American Heart Association. 
Stroke 25:2315-2328.  
Mayhan WG (1998) Constrictor responses of the rat basilar artery during diabetes 
mellitus. Brain Research 783:326-331.  
Mazarati A, Wu J, Shin D, Kwon YS, Sankar R (2008) Antiepileptogenic and 
antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic 
study. Epilepsia 49:1777-1786.  
McCallum LA, Pierce SL, England SK, Greenwood IA, Tribe RM (2011) The 
contribution of Kv7 channels to pregnant mouse and human myometrial 
contractility. Journal of cellular and molecular medicine 15:577-86.  
188 
 
McGettigan P, Henry D (2006) Cardiovascular Risk and Inhibition of Cyclooxygenase: A 
Systematic Review of the Observational Studies of Selective and Nonselective 
Inhibitors of Cyclooxygenase 2. JAMA 296:1633-1644.  
McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz DT, Pelligrino DA, 
Warner DS (2002) Simvastatin increases endothelial nitric oxide synthase and 
ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke; a 
journal of cerebral circulation 33:2950-6.  
Megyesi JF, Vollrath B, Cook DA, Findlay JM (2000) In vivo animal models of cerebral 
vasospasm: a review. Neurosurgery 46:448-60; discussion 460-1.  
Mendelow AD, McCalden TA, Hattingh J, Coull A, Rosendorff C, Eidelman BH (1981) 
Cerebrovascular reactivity and metabolism after subarachnoid hemorrhage in 
baboons. Stroke; a journal of cerebral circulation 12:58-65.  
Miceli F, Soldovieri MV, Martire M, Taglialatela M (2008) Molecular pharmacology and 
therapeutic potential of neuronal Kv7-modulating drugs. Current Opinion in 
Pharmacology 8:65-74.  
Minami K, Fukuzawa K, Nakaya Y (1993) Protein kinase C inhibits the Ca(2+)-activated 
K+ channel of cultured porcine coronary artery smooth muscle cells. Biochemical 
and biophysical research communications 190:263-9.  
Miyoshi H, Yamaoka K, Garfield RE, Ohama K (2004) Identification of a non-selective 
cation channel current in myometrial cells isolated from pregnant rats. Pflugers 
Arch 447:457-64.  
Moore SD, Madamba SG, Schweitzer P, Siggins GR (1994) Voltage-dependent effects of 
opioid peptides on hippocampal CA3 pyramidal neurons in vitro. Journal of 
Neuroscience 14:809-820.  
Mucha M, Ooi L, Linley JE, Mordaka P, Dalle C, Robertson B, Gamper N, Wood IC 
(2010) Transcriptional Control of KCNQ Channel Genes and the Regulation of 
Neuronal Excitability. J. Neurosci. 30:13235-13245.  
Mufti RE, Brett SE, Tran CH, Abd El-Rahman R, Anfinogenova Y, El-Yazbi A, Cole 
WC, Jones PP, Chen SR, Welsh DG (2010) Intravascular pressure augments 
cerebral arterial constriction by inducing voltage-insensitive Ca2+ waves. J Physiol 
588:3983-4005.  
Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with 
selective COX-2 inhibitors. JAMA 286:954-959.  
189 
 
Munro G, Dalby-Brown W (2007) K(v)7 (KCNQ) Channel Modulators and Neuropathic 
Pain. Journal of Medicinal Chemistry 50:2576-82.  
Murray MA, Faraci FM, Heistad DD (1992a) Effect of protein kinase C inhibitors on 
endothelin- and vasopressin-induced constriction of the rat basilar artery. Am J 
Physiol. 263:H1643-9.  
Murray MA, Faraci FM, Heistad DD (1992b) Role of protein kinase C in constrictor 
responses of the rat basilar artery in vivo. The Journal of physiology 445:169-79.  
Nagao S, Irie K, Kawai N, Nakamura T, Kunishio K, Matsumoto Y (2003) The use of 
mild hypothermia for patients with severe vasospasm: a preliminary report. J Clin 
Neurosci 10:208-12.  
Nagao S, Irie K, Kawai N, Kunishio K, Ogawa T, Nakamura T, Okauchi M (2000) 
Protective effect of mild hypothermia on symptomatic vasospasm: a preliminary 
report. Acta neurochirurgica 76:547-50.  
Nakagomi T, Kassell NF, Sasaki T, Fujiwara S, Lehman RM, Johshita H, Nazar GB, 
Torner JC (1987) Effect of subarachnoid hemorrhage on endothelium-dependent 
vasodilation. Journal of neurosurgery 66:915-23.  
Nakajo K, Kubo Y (2005) Protein kinase C shifts the voltage dependence of KCNQ/M 
channels expressed in Xenopus oocytes. J Physiol 569:59-74.  
Navarro-Gonzalez MF, Grayson TH, Meaney KR, Cribbs LL, Hill CE (2009) Non-L-
type voltage-dependent calcium channels control vascular tone of the rat basilar 
artery. Clinical and experimental pharmacology & physiology 36:55-66.  
Negro A, Dodge-Kafka K, Kapiloff MS (2008) Signalosomes as Therapeutic Targets. 
Progress in pediatric cardiology 25:51-56.  
Nelson MT, Quayle JM (1995) Physiological roles and properties of potassium channels 
in arterial smooth muscle. Am J Physiol. 268:C799-822.  
Nelson MT, Patlak JB, Worley JF, Standen NB (1990) Calcium channels, potassium 
channels, and voltage dependence of arterial smooth muscle tone. The American 
journal of physiology 259:C3-18.  
Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, Faure S, Gary F, 
Coumel P, Petit C, Schwartz K, Guicheney P (1997) A novel mutation in the 
potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen 
cardioauditory syndrome. Nature genetics 15:186-9.  
190 
 
Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A, Reddy M, Melville D, 
Nardi A, Khong TK, Greenwood IA (2011) Expression and function of the K+ 
channel KCNQ genes in human arteries. Br J Pharmacol 162:42-53; 42.  
Nichols DE, Nichols CD (2008) Serotonin receptors. Chemical reviews 108:1614-41.  
Nickolson VJ, Tam SW, Myers MJ, Cook L (1990) DuP 996 (3,3-bis(4-
pyrindinylmethyl)-1-phenylindolin-2-one) enhances the stimulus-induced release of 
acetylcholine from rat brain in vitro and in vivo. Drug Development Research 
19:285-300; 285.  
Nikaido H, Tsunoda H, Nishimura Y, Kirino T, Tanaka T (2004) Potential role for heat 
shock protein 72 in antagonizing cerebral vasospasm after rat subarachnoid 
hemorrhage. Circulation 110:1839-46.  
Nikitina E, Kawashima A, Takahashi M, Zhang ZD, Shang X, Ai J, Macdonald RL 
(2010) Alteration in voltage-dependent calcium channels in dog basilar artery after 
subarachnoid hemorrhage. Laboratory investigation. Journal of neurosurgery 
113:870-80.  
Nikitina E, Zhang ZD, Kawashima A, Jahromi BS, Bouryi VA, Takahashi M, Xie A, 
Macdonald RL (2007) Voltage-dependent calcium channels of dog basilar artery. 
The Journal of physiology 580:523-41.  
Nishiguchi M, Ono S, Iseda K, Manabe H, Hishikawa T, Date I (2010) Effect of 
vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries 
after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal 
injection of milrinone. Neurosurgery 66:158-64; discussion 164.  
Nishihashi T, Trandafir CC, Wang A, Ji X, Kurahashi K (2005) Enhanced reactivity to 
vasopressin in rat basilar arteries during vasospasm after subarachnoid hemorrhage. 
European Journal of Pharmacology 513:93-100.  
Nishimura Y (1996) Characterization of 5-hydroxytryptamine receptors mediating 
contractions in basilar arteries from stroke-prone spontaneously hypertensive rats. 
British journal of pharmacology 117:1325-1333.  
Nishizawa S, Obara K, Nakayama K, Koide M, Yokoyama T, Yokota N, Ohta S (2001) 
Which protein kinase C isoforms are involved in the development of vasospasm 
after subarachnoid haemorrhage? Acta neurochirurgica 77:21-4.  
Nishizawa S, Obara K, Nakayama K, Koide M, Yokoyama T, Yokota N, Ohta S (2000) 
Protein kinase cdelta and alpha are involved in the development of vasospasm after 
subarachnoid hemorrhage. European journal of pharmacology 398:113-9.  
191 
 
Nishizawa S, Yamamoto S, Yokoyama T, Ryu H, Uemura K (1995) Chronological 
changes of arterial diameter, cGMP, and protein kinase C in the development of 
vasospasm. Stroke; a journal of cerebral circulation 26:1916-20; discussion 1920-1.  
Nishizawa S, Nezu N, Uemura K (1992) Direct evidence for a key role of protein kinase 
C in the development of vasospasm after subarachnoid hemorrhage. Journal of 
neurosurgery 76:635-9.  
Nystoriak MA, O'Connor KP, Sonkusare SK, Brayden JE, Nelson MT, Wellman GC 
(2010) Fundamental increase in pressure-dependent constriction of brain 
parenchymal arterioles from subarachnoid hemorrhage model rats due to membrane 
depolarization. American journal of physiology 300:H803-12.  
O'Byrne PM, Gauvreau G (2009) Phosphodiesterase-4 inhibition in COPD. Lancet 
374:665-7.  
Ohya S, Sergeant GP, Greenwood IA, Horowitz B (2003) Molecular variants of KCNQ 
channels expressed in murine portal vein myocytes: a role in delayed rectifier 
current. Circulation Research 92:1016-23.  
Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y (2002) Molecular and 
functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach 
smooth muscle. Am J Physiol Gastrointest Liver Physiol. 282:G277-87.  
Okabe K, Kitamura K, Kuriyama H (1987) Features of 4-aminopyridine sensitive 
outward current observed in single smooth muscle cells from the rabbit pulmonary 
artery. Pflugers Arch 409:561-8.  
Okada M, Zhu G, Hirose S, Ito KI, Murakami T, Wakui M, Kaneko S (2003) Age-
dependent modulation of hippocampal excitability by KCNQ-channels. Epilepsy 
research 53:81-94.  
Oliveira-Filho J, Ezzeddine MA, Segal AZ, Buonanno FS, Chang Y, Ogilvy CS, Rordorf 
G, Schwamm LH, Koroshetz WJ, McDonald CT (2001) Fever in subarachnoid 
hemorrhage: relationship to vasospasm and outcome. Neurology 56:1299-304.  
Oliver JJ, Melville VP, Webb DJ (2006) Effect of regular phosphodiesterase type 5 
inhibition in hypertension. Hypertension 48:622-627.  
Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circulation research 
100:309-27.  
192 
 
Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T, 
Kurose H (2006) TRPC3 and TRPC6 are essential for angiotensin II-induced 
cardiac hypertrophy. EMBO Journal 25:5305-16. Epub 2006 Nov 2.  
Osuka K, Watanabe Y, Yamauchi K, Nakazawa A, Usuda N, Tokuda M, Yoshida J 
(2006) Activation of the JAK-STAT signaling pathway in the rat basilar artery after 
subarachnoid hemorrhage. Brain research 1072:1-7.  
Osuka K, Suzuki Y, Watanabe Y, Takayasu M, Yoshida J (1998) Inducible 
cyclooxygenase expression in canine basilar artery after experimental subarachnoid 
hemorrhage. Stroke; a journal of cerebral circulation 29:1219-22.  
Padilla K, Wickenden AD, Gerlach AC, McCormack K (2009) The KCNQ2/3 selective 
channel opener ICA-27243 binds to a novel voltage-sensor domain site. 
Neuroscience Letters 465:138-142.  
Passmore G, Delmas P (2011) Does cure for pain REST on Kv7 channels? Pain 152:709-
10.  
Passmore GM, Selyanko AA, Mistry M, Al-Qatari M, Marsh SJ, Matthews EA, 
Dickenson AH, Brown TA, Burbidge SA, Main M, Brown DA (2003) KCNQ/M 
Currents in Sensory Neurons: Significance for Pain Therapy. Journal of 
Neuroscience 23:7227-7236.  
Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn 
JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG (2000) 
Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in 
rats. Drug Metab Dispos 28:514-521.  
Peng H, Matchkov V, Ivarsen A, Aalkjaer C, Nilsson H (2001) Hypothesis for the 
initiation of vasomotion. Circulation research 88:810-5.  
Peretz A, Degani-Katzav N, Talmon M, Danieli E, Gopin A, Malka E, Nachman R, Raz 
A, Shabat D, Attali B (2007) A tale of switched functions: from cyclooxygenase 
inhibition to M-channel modulation in new diphenylamine derivatives. PLoS ONE. 
2:e1332.  
Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B (2005) 
Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium 
Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant 
Properties. Molecular Pharmacology 67:1053-1066.  
193 
 
Perez GJ, Bonev AD, Patlak JB, Nelson MT (1999) Functional coupling of ryanodine 
receptors to KCa channels in smooth muscle cells from rat cerebral arteries. The 
Journal of general physiology 113:229-38.  
Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium 
channels. Physiological reviews 83:117-61.  
Peterson EC, Wang Z, Britz G (2011) Regulation of cerebral blood flow. International 
journal of vascular medicine 2011:823525.  
Pfizer Canada I (2007) CELEBREX, Product Monograph.  
Pluta RM (2006) Dysfunction of nitric oxide synthases as a cause and therapeutic target 
in delayed cerebral vasospasm after SAH. Neurological research 28:730-7.  
Pluta RM, Thompson BG, Dawson TM, Snyder SH, Boock RJ, Oldfield EH (1996) Loss 
of nitric oxide synthase immunoreactivity in cerebral vasospasm. Journal of 
neurosurgery 84:648-54.  
Polson JB, Strada SJ (1996) Cyclic nucleotide phosphodiesterases and vascular smooth 
muscle. Annual review of pharmacology and toxicology 36:403-27.  
Porchet F, Chiolero R, de Tribolet N (1995) Hypotensive effect of nimodipine during 
treatment for aneurysmal subarachnoid haemorrhage. Acta neurochirurgica 137:62-
9.  
Prieto D, Rivera L, Benedito S, Recio P, Villalba N, Hernandez M, Garcia-Sacristan A 
(2006) Ca2+-activated K+ (KCa) channels are involved in the relaxations elicited 
by sildenafil in penile resistance arteries. European journal of pharmacology 
531:232-7.  
Psaty BM, Furberg CD (2005) COX-2 inhibitors--lessons in drug safety. N Engl J Med 
352:1133-1135.  
Quayle JM, Nelson MT, Standen NB (1997) ATP-sensitive and inwardly rectifying 
potassium channels in smooth muscle. Physiological reviews 77:1165-232.  
Quayle JM, Bonev AD, Brayden JE, Nelson MT (1994) Calcitonin gene-related peptide 
activated ATP-sensitive K+ currents in rabbit arterial smooth muscle via protein 
kinase A. The Journal of physiology 475:9-13.  
Rasmussen G, Hauerberg J, Waldemar G, Gjerris F, Juhler M (1992) Cerebral blood flow 
autoregulation in experimental subarachnoid haemorrhage in rat. Acta 
neurochirurgica 119:128-33.  
194 
 
Raymond DR, Carter RL, Ward CA, Maurice DH (2009) Distinct phosphodiesterase-4D 
variants integrate into protein kinase A-based signaling complexes in cardiac and 
vascular myocytes. Am J Physiol Heart Circ Physiol 296:H263-71.  
Reffelmann T, Kloner RA (2005) Pharmacotherapy of erectile dysfunction: focus on 
cardiovascular safety. Expert opinion on drug safety 4:531-40.  
Rembold CM (1992) Regulation of contraction and relaxation in arterial smooth muscle. 
Hypertension 20:129-37.  
Robbins J, Marsh SJ, Brown DA (2006) Probing the regulation of M (Kv7) potassium 
channels in intact neurons with membrane-targeted peptides. J Neurosci. 26:7950-
61.  
Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology, and 
pharmacology. Pharmacology and Therapeutics 90:1-19.  
Rode F, Svalo J, Sheykhzade M, Ronn LC (2010) Functional effects of the KCNQ 
modulators retigabine and XE991 in the rat urinary bladder. European journal of 
pharmacology 638:121-7.  
Rose K, Ooi L, Dalle C, Robertson B, Wood IC, Gamper N (2011) Transcriptional 
repression of the M channel subunit Kv7.2 in chronic nerve injury. Pain 152:742-
54.  
Rose RJ, Liu H, Palmer D, Maurice DH (1997) Cyclic AMP-mediated regulation of 
vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J 
Pharmacol 122:233-240.  
Rosenblum WI (2003) ATP-sensitive potassium channels in the cerebral circulation. 
Stroke; a journal of cerebral circulation 34:1547-52.  
Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, 
Loscher W, Honack D, White HS, Wolf HH (1996) D-23129: a new anticonvulsant 
with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 
23:211-223.  
Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M 
(1997) Ro 61-1790, a new hydrosoluble endothelin antagonist: general 
pharmacology and effects on experimental cerebral vasospasm. The Journal of 
pharmacology and experimental therapeutics 283:1110-8.  
Ruehlmann DO, Lee CH, Poburko D, van Breemen C (2000) Asynchronous Ca(2+) 
waves in intact venous smooth muscle. Circ Res 86:E72-9.  
195 
 
Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases 
and regulation of smooth muscle function. Circulation research 93:280-91.  
Sabri M, Ai J, Macdonald RL (2010) Dissociation of vasospasm and secondary effects of 
experimental subarachnoid hemorrhage by clazosentan. Stroke; a journal of cerebral 
circulation 42:1454-60.  
Sako M, Nishihara J, Ohta S, Wang J, Sakaki S (1993) Role of protein kinase C in the 
pathogenesis of cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood 
Flow Metab 13:247-54.  
Salom JB, Castello-Ruiz M, Burguete MC, Guzman C, Jover-Mengual T, Torregrosa G, 
Jover R, Lizasoain I, Alborch E (2008) Role of K+ and Ca2+ fluxes in the 
cerebroarterial vasoactive effects of sildenafil. European journal of pharmacology 
581:138-47.  
Sanders KM (2001) Invited review: mechanisms of calcium handling in smooth muscles. 
J Appl Physiol 91:1438-49.  
Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E (2007) PDE5 inhibitors beyond 
erectile dysfunction. International journal of impotence research 19:533-43.  
Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT 
(1996) Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) 
potassium channel. Nature 384:80-3.  
Satake N, Shibata S (1997) Potentiation of the relaxing action of isoproterenol by 
forskolin in rabbit aortic rings: the involvement of beta 2-adrenoceptors. Gen 
Pharmacol 28:753-756.  
Sato M, Tani E, Matsumoto T, Fujikawa H, Imajoh-Ohmi S (1997) Generation of the 
catalytic fragment of protein kinase C alpha in spastic canine basilar artery. Journal 
of neurosurgery 87:752-6.  
Satoh M, Perkins E, Kimura H, Tang J, Chun Y, Heistad DD, Zhang JH (2002) 
Posttreatment with adenovirus-mediated gene transfer of calcitonin gene-related 
peptide to reverse cerebral vasospasm in dogs. Journal of neurosurgery 97:136-42.  
Satoh S, Suzuki Y, Harada T, Ikegaki I, Asano T, Shibuya M, Sugita K, Saito A (1991) 
The role of platelets in the development of cerebral vasospasm. Brain research 
bulletin 27:663-8.  
196 
 
Scheel P, Ruge C, Petruch UR, Schoning M (2000) Color duplex measurement of 
cerebral blood flow volume in healthy adults. Stroke; a journal of cerebral 
circulation 31:147-50.  
Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J, Schwake M (2005) 
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the 
anticonvulsant retigabine. Journal of Neuroscience 25:5051-60.  
Schnee ME, Brown BS (1998) Selectivity of linopirdine (DuP 996), a neurotransmitter 
release enhancer, in blocking voltage-dependent and calcium-activated potassium 
currents in hippocampal neurons. Journal of Pharmacology & Experimental 
Therapeutics 286:709-17.  
Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic control of vasopressin 
release. The American journal of physiology 236:F321-32.  
Schrøder RL, Jespersen T, Christophersen P, Strøbæk D, Jensen BS, Olesen S (2001) 
KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 
40:888-898.  
Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ (2000a) KCNQ5, a 
novel potassium channel broadly expressed in brain, mediates M-type currents. 
Journal of Biological Chemistry 275:24089-95.  
Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, Jentsch TJ (2000b) A 
constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 
403:196-9.  
Schroeder BC, Kubisch C, Stein V, Jentsch TJ (1998) Moderate loss of function of 
cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy. Nature 
396:687-690.  
Schubert GA, Poli S, Schilling L, Heiland S, Thome C (2008) Hypothermia reduces 
cytotoxic edema and metabolic alterations during the acute phase of massive SAH: 
a diffusion-weighted imaging and spectroscopy study in rats. Journal of 
neurotrauma 25:841-52.  
Schwake M, Jentsch TJ, Friedrich T (2003) A carboxy-terminal domain determines the 
subunit specificity of KCNQ K+ channel assembly. EMBO Rep. 4:76-81.  
Sehba FA, Pluta RM, Zhang JH (2011) Metamorphosis of subarachnoid hemorrhage 
research: from delayed vasospasm to early brain injury. Mol Neurobiol 43:27-40.  
197 
 
Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D (1995) Endothelin 
concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation 
with cerebral vasospasm, delayed ischemic neurological deficits, and volume of 
hematoma. Journal of neurosurgery 82:55-62.  
Selyanko AA, Brown DA (1996) Intracellular calcium directly inhibits potassium M 
channels in excised membrane patches from rat sympathetic neurons. Neuron 
16:151-62.  
Sen J, Belli A, Albon H, Morgan L, Petzold A, Kitchen N (2003) Triple-H therapy in the 
management of aneurysmal subarachnoid haemorrhage. Lancet neurology 2:614-21.  
Setoguchi M, Ohya Y, Abe I, Fujishima M (1997) Stretch-activated whole-cell currents 
in smooth muscle cells from mesenteric resistance artery of guinea-pig. The Journal 
of physiology 501 ( Pt 2):343-53.  
Seule MA, Muroi C, Mink S, Yonekawa Y, Keller E (2009) Therapeutic hypothermia in 
patients with aneurysmal subarachnoid hemorrhage, refractory intracranial 
hypertension, or cerebral vasospasm. Neurosurgery 64:86-92; discussion 92-3.  
Seyfried J, Evert BO, Rundfeldt C, Schulz JB, Kovar KA, Klockgether T, Wullner U 
(2000) Flupirtine and retigabine prevent L-glutamate toxicity in rat 
pheochromocytoma PC 12 cells. European journal of pharmacology 400:155-66.  
Shankar JJ, dos Santos MP, Deus-Silva L, Lum C (2011) Angiographic evaluation of the 
effect of intra-arterial milrinone therapy in patients with vasospasm from 
aneurysmal subarachnoid hemorrhage. Neuroradiology 53:123-8.  
Shapiro MS, Wollmuth LP, Hille B (1994) Angiotensin II inhibits calcium and M current 
channels in rat sympathetic neurons via G proteins. Neuron 12:1319-29.  
Shearman MS, Sekiguchi K, Nishizuka Y (1989) Modulation of ion channel activity: a 
key function of the protein kinase C enzyme family. Pharmacological reviews 
41:211-37.  
Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, 
Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Peiffer A, 
Anderson VE, Leppert M (1998) A novel potassium channel gene, KCNQ2, is 
mutated in an inherited epilepsy of newborns. Nature Genetics 18:25-29.  
Smith SL, Hall ED (1996) Mild pre- and posttraumatic hypothermia attenuates blood-
brain barrier damage following controlled cortical impact injury in the rat. Journal 
of neurotrauma 13:1-9.  
198 
 
Sobey CG, Quan L (1999) Impaired cerebral vasodilator responses to NO and PDE V 
inhibition after subarachnoid hemorrhage. The American journal of physiology 
277:H1718-24.  
Sobey CG, Heistad DD, Faraci FM (1996) Effect of subarachnoid hemorrhage on 
dilatation of rat basilar artery in vivo. The American journal of physiology 
271:H126-32.  
Soboloff J, Spassova M, Xu W, He LP, Cuesta N, Gill DL (2005) Role of endogenous 
TRPC6 channels in Ca2+ signal generation in A7r5 smooth muscle cells. Journal of 
Biological Chemistry 280:39786-94.  
Soehle M, Czosnyka M, Pickard JD, Kirkpatrick PJ (2004) Continuous assessment of 
cerebral autoregulation in subarachnoid hemorrhage. Anesthesia and analgesia 
98:1133-9, table of contents.  
Solenski NJ, C. HE,Jr, Kassell NF, Kongable G, Germanson T, Truskowski L, Torner JC 
(1995) Medical complications of aneurysmal subarachnoid hemorrhage: a report of 
the multicenter, cooperative aneurysm study. Participants of the Multicenter 
Cooperative Aneurysm Study. Critical care medicine 23:1007-17.  
Somlyo AP, Somlyo AV (2003) Ca2+ sensitivity of smooth muscle and nonmuscle 
myosin II: modulated by G proteins, kinases, and myosin phosphatase. 
Physiological reviews 83:1325-58.  
Sorensen PS (1986) Studies of vasopressin in the human cerebrospinal fluid. Acta 
neurologica Scandinavica 74:81-102.  
Spinelli W, Follmer C, Parsons R, Colatsky T (1990) Effects of cromakalim, pinacidil 
and nicorandil on cardiac refractoriness and arterial pressure in open-chest dogs. 
European journal of pharmacology 179:243-52.  
Stafstrom CE, Grippon S, Kirkpatrick P (2011) Ezogabine (retigabine). Nature reviews 
10:729-30.  
Standen NB, Quayle JM (1998) K+ channel modulation in arterial smooth muscle. Acta 
Physiologica Scandinavica 164:549-57.  
Stull JT, Lin PJ, Krueger JK, Trewhella J, Zhi G (1998) Myosin light chain kinase: 
functional domains and structural motifs. Acta physiologica Scandinavica 164:471-
82.  
Stull JT, Gallagher PJ, Herring BP, Kamm KE (1991) Vascular smooth muscle 
contractile elements. Cellular regulation. Hypertension 17:723-32.  
199 
 
Suarez JI (2011) Magnesium sulfate administration in subarachnoid hemorrhage. 
Neurocrit Care 15:302-307.  
Sugai K, Yaganisawa T, Motohashi O, Suzuki M, Yoshimoto T (1999) Levcromakalim 
decreases cytoplasmic Ca2+ and vascular tone in basilar artery of SAH model dogs. 
Journal of cardiovascular pharmacology 33:868-75.  
Suh BC, Hille B (2007) Regulation of KCNQ channels by manipulation of 
phosphoinositides. J Physiol. 582:911-6. Epub 2007 Apr 5.  
Suh BC, Hille B (2006) Does diacylglycerol regulate KCNQ channels? Pflugers Arch 
453:293-301.  
Suh BC, Hille B (2002) Recovery from muscarinic modulation of M current channels 
requires phosphatidylinositol 4,5-bisphosphate synthesis. Neuron. 35:507-20.  
Sun BL, Shen FP, Wu QJ, Chi SM, Yang MF, Yuan H, Xie FM, Zhang YB, Chen J, 
Zhang F (2010) Intranasal delivery of calcitonin gene-related peptide reduces 
cerebral vasospasm in rats. Frontiers in bioscience (Elite edition) 2:1502-13.  
Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T (2000) Endothelin-1 
concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by 
subarachnoid hemorrhage. Surgical neurology 53:131-5.  
Svendgaard NA, Edvinsson L, Owman C, Sahlin C (1977) Increased sensitivity of the 
basilar artery to norepinephrine and 5-hydroxytryptamine following experimental 
subarachnoid hemorrhage. Surgical neurology 8:191-5.  
Sweeney M, Yu Y, Platoshyn O, Zhang S, McDaniel SS, Yuan JX (2002) Inhibition of 
endogenous TRP1 decreases capacitative Ca2+ entry and attenuates pulmonary 
artery smooth muscle cell proliferation. American journal of physiology 283:L144-
55.  
Takahashi Y, Watanabe H, Murakami M, Ono K, Munehisa Y, Koyama T, Nobori K, 
Iijima T, Ito H (2007) Functional role of stromal interaction molecule 1 (STIM1) in 
vascular smooth muscle cells. Biochem Biophys Res Commun 361:934-940.  
Takeuchi H, Handa Y, Kobayashi H, Kawano H, Hayashi M (1991) Impairment of 
cerebral autoregulation during the development of chronic cerebral vasospasm after 
subarachnoid hemorrhage in primates. Neurosurgery 28:41-8.  
Tani E, Matsumoto T (2004) Continuous elevation of intracellular Ca2+ is essential for 
the development of cerebral vasospasm. Current vascular pharmacology 2:13-21.  
200 
 
Tani E (2002) Molecular mechanisms involved in development of cerebral vasospasm. 
Neurosurgical focus 12:ECP1.  
Tatulian L, Brown DA (2003) Effect of the KCNQ potassium channel opener retigabine 
on single KCNQ2/3 channels expressed in CHO cells. The Journal of physiology 
549:57-63.  
Tatulian L, Delmas P, Abogadie FC, Brown DA (2001) Activation of expressed KCNQ 
potassium currents and native neuronal M-type potassium currents by the anti-
convulsant drug retigabine. J Neurosci. 21:5535-45.  
Tilley DG, Maurice DH (2002) Vascular smooth muscle cell phosphodiesterase (PDE) 3 
and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 
62:497-506.  
Titova E, Ostrowski RP, Zhang JH, Tang J (2009) Experimental models of subarachnoid 
hemorrhage for studies of cerebral vasospasm. Neurological research 31:568-81.  
Torok E, Klopotowski M, Trabold R, Thal SC, Plesnila N, Scholler K (2009) Mild 
hypothermia (33 degrees C) reduces intracranial hypertension and improves 
functional outcome after subarachnoid hemorrhage in rats. Neurosurgery 65:352-9; 
discussion 359.  
Toyoda K, Faraci FM, Russo AF, Davidson BL, Heistad DD (2000a) Gene transfer of 
calcitonin gene-related peptide to cerebral arteries. American journal of physiology 
278:H586-94.  
Toyoda K, Faraci FM, Watanabe Y, Ueda T, Andresen JJ, Chu Y, Otake S, Heistad DD 
(2000b) Gene transfer of calcitonin gene-related peptide prevents vasoconstriction 
after subarachnoid hemorrhage. Circulation research 87:818-24.  
Tran Dinh YR, Jomaa A, Callebert J, Reynier-Rebuffel AM, Tedgui A, Savarit A, 
Sercombe R (2001) Overexpression of cyclooxygenase-2 in rabbit basilar artery 
endothelial cells after subarachnoid hemorrhage. Neurosurgery 48:626-33; 
discussion 633-5.  
Trandafir CC, Nishihashi T, Wang A, Murakami S, Ji X, Kurahashi K (2004) 
Participation of vasopressin in the development of cerebral vasospasm in a rat 
model of subarachnoid haemorrhage. Clinical and Experimental Pharmacology and 
Physiology 31:261-6.  
Treggiari MM, Deem S (2009) Which H is the most important in triple-H therapy for 
cerebral vasospasm? Current opinion in critical care 15:83-6.  
201 
 
Tunquist BJ, Hoshi N, Guire ES, Zhang F, Mullendorff K, Langeberg LK, Raber J, Scott 
JD (2008) Loss of AKAP150 perturbs distinct neuronal processes in mice. 
Proceedings of the National Academy of Sciences of the United States of America 
105:12557-62.  
Ueberall MA, Mueller-Schwefe GH, Terhaag B (2011) Efficacy and tolerability of 
flupirtine in subacute/ chronic musculoskeletal pain - results of a patient level, 
pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin 
Pharmacol Ther 49:637-647.  
Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P 
(2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in 
the prevention of cerebral vasospasm following severe aneurysmal subarachnoid 
hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter 
phase IIa study. Journal of neurosurgery 103:9-17.  
Vale FL, Bradley EL, Fisher WS,3rd (1997) The relationship of subarachnoid 
hemorrhage and the need for postoperative shunting. Journal of neurosurgery 
86:462-6.  
Varnai P, Hunyady L, Balla T (2009) STIM and Orai: the long-awaited constituents of 
store-operated calcium entry. Trends Pharmacol Sci 30:118-128.  
Vatter H, Konczalla J, Seifert V (2011) Endothelin related pathophysiology in cerebral 
vasospasm: what happens to the cerebral vessels? Acta neurochirurgica 110:177-80.  
Vatter H, Konczalla J, Weidauer S, Preibisch C, Zimmermann M, Raabe A, Seifert V 
(2007) Effect of delayed cerebral vasospasm on cerebrovascular endothelin A 
receptor expression and function. Journal of neurosurgery 107:121-7.  
Velat GJ, Kimball MM, Mocco JD, Hoh BL (2011) Vasospasm after aneurysmal 
subarachnoid hemorrhage: review of randomized controlled trials and meta-
analyses in the literature. World Neurosurg 76:446-454.  
Vergouwen MD (2009) Effect of endothelin-receptor antagonists on delayed cerebral 
ischemia after aneurysmal subarachnoid hemorrhage remains unclear. Stroke; a 
journal of cerebral circulation 40:e714; author reply e715-6.  
Voldby B, Enevoldsen EM, Jensen FT (1985) Cerebrovascular reactivity in patients with 
ruptured intracranial aneurysms. Journal of neurosurgery 62:59-67.  
Voldby B, Engbaek F, Enevoldsen EM (1982) CSF serotonin concentrations and cerebral 
arterial spasm in patients with ruptured intracranial aneurysm. Stroke; a journal of 
cerebral circulation 13:184-9.  
202 
 
Wanebo JE, Arthur AS, Louis HG, West K, Kassell NF, Lee KS, Helm GA (1998) 
Systemic administration of the endothelin-A receptor antagonist TBC 11251 
attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose 
study and review of endothelin-based therapies in the literature on cerebral 
vasospasm. Neurosurgery 43:1409-17; discussion 1417-8.  
Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D 
(1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of 
the M-channel. Science. 282:1890-3.  
Waters A, Harder DR (1985) Altered membrane properties of cerebral vascular smooth 
muscle following subarachnoid hemorrhage: an electrophysiological study. I. 
Changes in resting membrane potential (Em) and effect on the electrogenic pump 
potential contribution to Em. Stroke; a journal of cerebral circulation 16:990-7.  
Webb DJ, Freestone S, Allen MJ, Muirhead GJ (1999) Sildenafil citrate and blood-
pressure-lowering drugs: results of drug interaction studies with an organic nitrate 
and a calcium antagonist. The American journal of cardiology 83:21C-28C.  
Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G (2004) 
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective 
celecoxib: new pharmacological opportunities due to related binding site 
recognition. Journal of medicinal chemistry 47:550-7.  
Weber YG, Geiger J, Kampchen K, Landwehrmeyer B, Sommer C, Lerche H (2006) 
Immunohistochemical analysis of KCNQ2 potassium channels in adult and 
developing mouse brain. Brain research 1077:1-6.  
Weight FF, Votava J (1970) Slow synaptic excitation in sympathetic ganglion cells: 
evidence for synaptic inactivation of potassium conductance. Science (New York, 
N Y 170:755-8.  
Wellman GC (2006) Ion channels and calcium signaling in cerebral arteries following 
subarachnoid hemorrhage. Neurol Res. 28:690-702.  
Wellman GC, Nelson MT (2003) Signaling between SR and plasmalemma in smooth 
muscle: sparks and the activation of Ca2+-sensitive ion channels. Cell calcium 
34:211-29.  
Wellman GC, Nathan DJ, Saundry CM, Perez G, Bonev AD, Penar PL, Tranmer BI, 
Nelson MT (2002) Ca2+ sparks and their function in human cerebral arteries. 
Stroke; a journal of cerebral circulation 33:802-8.  
203 
 
Wen H, Levitan IB (2002) Calmodulin is an auxiliary subunit of KCNQ2/3 potassium 
channels. J Neurosci 22:7991-8001.  
Weyer GW, Jahromi BS, Aihara Y, Agbaje-Williams M, Nikitina E, Zhang ZD, 
Macdonald RL (2006a) Expression and function of inwardly rectifying potassium 
channels after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab 
26:382-91.  
Weyer GW, Nolan CP, Macdonald RL (2006b) Evidence-based cerebral vasospasm 
management. Neurosurgical focus 21:E8.  
Whelton A, White WB, Bello AE, Puma JA, Fort JG (2002) Effects of celecoxib and 
rofecoxib on blood pressure and edema in patients > or =65 years of age with 
systemic hypertension and osteoarthritis. The American journal of cardiology 
90:959-63.  
Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM (2001) 
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, 
controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis 
patients. American journal of therapeutics 8:85-95.  
White JA, McAlpine PJ, Antonarakis S, Cann H, Eppig JT, Frazer K, Frezal J, Lancet D, 
Nahmias J, Pearson P, Peters J, Scott A, Scott H, Spurr N, C. T,Jr, Povey S (1997) 
Guidelines for human gene nomenclature (1997). HUGO Nomenclature Committee. 
Genomics 45:468-71.  
Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, Roeloffs 
R, McNaughton-Smith G, Rigdon GC (2008) N-(6-chloro-pyridin-3-yl)-3,4-
difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel 
activator. Molecular Pharmacology 73:977-986.  
Wickenden AD, Roeloffs R, McNaughton-Smith G, Rigdon GC (2004) KCNQ potassium 
channels: drug targets for the treatment of epilepsy and pain. Expert Opinion on 
Therapeutic Patents 14:457-469; 469.  
Wickenden AD, Zou A, Wagoner PK, Jegla T (2001) Characterization of KCNQ5/Q3 
potassium channels expressed in mammalian cells. British Journal of Pharmacology 
132:381-4.  
Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, 
Palmisano J, F. KJ,Jr, Morrow JD, Vita JA (2003) Short- and Long-Term COX-2 
Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension. 
Hypertension 42:310-315.  
204 
 
Willoughby DA, Moore AR, Colville-Nash PR (2000) COX-1, COX-2, and COX-3 and 
the future treatment of chronic inflammatory disease. Lancet 355:646-8.  
Winks JS, Hughes S, Filippov AK, Tatulian L, Abogadie FC, Brown DA, Marsh SJ 
(2005) Relationship between membrane phosphatidylinositol-4,5-bisphosphate and 
receptor-mediated inhibition of native neuronal M channels. Journal of 
Neuroscience 25:3400-13.  
Wladyka CL, Kunze DL (2006) KCNQ/M-currents contribute to the resting membrane 
potential in rat visceral sensory neurons. J Physiol 575:175-189.  
Wong GK, Chan MT, Gin T, Poon WS (2011) Intravenous magnesium sulfate after 
aneurysmal subarachnoid hemorrhage: current status. Acta Neurochir Suppl 
110:169-173.  
Worley JF, Quayle JM, Standen NB, Nelson MT (1991) Regulation of single calcium 
channels in cerebral arteries by voltage, serotonin, and dihydropyridines. Am J 
Physiol 261:H1951-60.  
Wu YJ, Boissard CG, Greco C, Gribkoff VK, Harden DG, He H, L'Heureux A, Kang SH, 
Kinney GG, Knox RJ, Natale J, Newton AE, Lehtinen-Oboma S, Sinz MW, Sivarao 
DV, E. SJ,Jr, Sun LQ, Tertyshnikova S, Thompson MW, Weaver D, Wong HS, 
Zhang L, Dworetzky SI (2003) (S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-
phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in 
a cortical spreading depression model of migraine. Journal of medicinal chemistry 
46:3197-200.  
Wulff H, Castle NA, Pardo LA (2009) Voltage-gated potassium channels as therapeutic 
targets. Nature reviews 8:982-1001.  
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a 
mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA 
splicing. Proceedings of the National Academy of Sciences of the United States of 
America 88:2692-6.  
Xiong Q, Gao Z, Wang W, Li M (2008) Activation of Kv7 (KCNQ) voltage-gated 
potassium channels by synthetic compounds. Trends in Pharmacological Sciences 
29:99-107.  
Xu SZ, Beech DJ (2001) TrpC1 is a membrane-spanning subunit of store-operated 
Ca(2+) channels in native vascular smooth muscle cells. Circulation research 88:84-
7.  
205 
 
Yamada T, Tanaka Y, Fujimoto K, Nakahara N, Shinoda S, Masuzawa T (1994) 
Relationship between cytosolic Ca2+ level and contractile tension in canine basilar 
artery of chronic vasospasm. Neurosurgery 34:496-503; discussion 503-4.  
Yamaura I, Tani E, Maeda Y, Minami N, Shindo H (1992) Endothelin-1 of canine basilar 
artery in vasospasm. Journal of neurosurgery 76:99-105.  
Yang L, Liu G, Zakharov SI, Bellinger AM, Mongillo M, Marx SO (2007) Protein kinase 
G phosphorylates Cav1.2 alpha1c and beta2 subunits. Circ Res 101:465-474.  
Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, Schwake M, Ohya S, Greenwood IA 
(2007) Molecular expression and pharmacological identification of a role for K(v)7 
channels in murine vascular reactivity. British Journal of Pharmacology 151:758-
770; 758.  
Yeung SY, Greenwood IA (2005) Electrophysiological and functional effects of the 
KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. British 
Journal of Pharmacology 146:585-95.  
Young RC, Schumann R, Zhang P (2001) Intracellular calcium gradients in cultured 
human uterine smooth muscle: a functionally important subplasmalemmal space. 
Cell calcium 29:183-9.  
Yus-Najera E, Santana-Castro I, Villarroel A (2002) The identification and 
characterization of a noncontinuous calmodulin-binding site in noninactivating 
voltage-dependent KCNQ potassium channels. Journal of Biological Chemistry 
277:28545-53.  
Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, 
Rominger DH, Earl RA (1998) Two new potent neurotransmitter release enhancers, 
10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-
pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. The Journal of 
pharmacology and experimental therapeutics 285:724-30.  
Zaritsky JJ, Eckman DM, Wellman GC, Nelson MT, Schwarz TL (2000) Targeted 
disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly 
rectifying K(+) current in K(+)-mediated vasodilation. Circulation research 87:160-
6.  
Zhang H, Craciun LC, Mirshahi T, Rohacs T, Lopes CM, Jin T, Logothetis DE (2003) 
PIP(2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated 
inhibition of M currents. Neuron. 37:963-75.  
206 
 
Zhang J, Bal M, Bierbower S, Zaika O, Shapiro MS (2011) AKAP79/150 signal 
complexes in G-protein modulation of neuronal ion channels. J Neurosci 31:7199-
211.  
Zhang J, Ding EL, Song Y (2006) Adverse effects of cyclooxygenase 2 inhibitors on 
renal and arrhythmia events: meta-analysis of randomized trials. Jama 296:1619-32.  
Zhang L, Bonev AD, Mawe GM, Nelson MT (1994) Protein kinase A mediates activation 
of ATP-sensitive K+ currents by CGRP in gallbladder smooth muscle. The 
American journal of physiology 267:G494-9.  
Zhang YH, Youm JB, Sung HK, Lee SH, Ryu SY, Ho WK, Earm YE (2000) Stretch-
activated and background non-selective cation channels in rat atrial myocytes. The 
Journal of physiology 523 Pt 3:607-19.  
Zhang Y, Tao J, Huang H, Ding G, Cheng Y, Sun W (2007) Effects of celecoxib on 
voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. 
Pharmacological Research 56:267-274.  
Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, Greenwood IA (2010) 
Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral 
arterial diameter. The Journal of Physiology 588:3277-3293.  
Zimmermann M, Seifert V (1998) Endothelin and subarachnoid hemorrhage: an 
overview. Neurosurgery 43:863-75; discussion 875-6.  
Zubkov AY, Rabinstein AA (2009) Medical management of cerebral vasospasm: present 
and future. Neurol Res 31:626-631.  
Zuccarello M, Boccaletti R, Tosun M, Rapoport RM (1996a) Role of extracellular Ca2+ 
in subarachnoid hemorrhage-induced spasm of the rabbit basilar artery. Stroke; a 
journal of cerebral circulation 27:1896-902.  
Zuccarello M, Bonasso CL, Lewis AI, Sperelakis N, Rapoport RM (1996b) Relaxation of 
subarachnoid hemorrhage-induced spasm of rabbit basilar artery by the K+ channel 
activator cromakalim. Stroke; a journal of cerebral circulation 27:311-6.  
Zusman RM, Morales A, Glasser DB, Osterloh IH (1999) Overall cardiovascular profile 
of sildenafil citrate. Am J Cardiol 83:35C-44C.  
 
 207 
VITA 
 
Bharath Mani was born on April 02, 1978 in Namakkal, a small town in the 
southern state of Tamil Nadu, India to Subraya Gounder Mani and Rajeswari Mani. After 
completing his grade school education in 1995, Bharath entered the Bachelor of 
Veterinary Sciences program at Veterinary College and Research Institute located in his 
hometown. After graduating in 2001, he moved to Chennai, India to pursue a Master’s 
degree, majoring in pharmacology. During his Master’s program he worked on a thesis 
project investigating the effects of ionophores on ruminant digestion. In 2004, he joined 
the cardiovascular drug discovery program at Torrent Research Centre, Ahmedabad, 
India, where he was involved in conducting pre-clinical efficacy and toxicity studies of 
new chemical entities. 
In July of 2006, Bharath moved to Chicago and enrolled in the pharmacology 
graduate program at Loyola University Medical Center. After his research rotations, 
Bharath joined the laboratory of Dr. Kenneth Byron in the fall of 2007. Bharath has since 
been working to understand the regulation of vascular tone by ion channels in smooth 
muscle cells. Bharath’s dissertation research was funded by American Heart Association 
(2009-2011) and Arthur J. Schmitt Foundation (2011-2012).  
Bharath is married since 2007 to Thejashree and they have a lovely daughter, 
Aditi.  
